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Summary
The lysine-dependent, activation-resistant, conformation of glu-plasminogen is
converted to an activation susceptible conformation after binding to cell-surface
lysine residues. These lysine-dependent interactions of glu-plasminogen are mediated
by its lysine binding sites (LBS's). Thus, it is hypothesised that lysine residues from
the cell surface plasminogen receptors compete with lysine residues from gluplasminogen for occupation of its LBS's, thereby inducing a conformational change
to glu-plasminogen. Previously, an a-enolase-related molecule was identified as a cell
surface plasminogen receptor. Hence, the plasminogen binding characteristics of
recombinant human a-enolase (r-a-enolase) were assessed.
R-a-enolase bound glu-plasminogen in a lysine-dependent manner with an
apparent Kd of 1.9 pM. This interaction [1] was dependent on the C-terminal lysine
residue of r-a-enolase, [2] enhanced the activation rate of glu-plasminogen and [3]
blocked a2-antiplasmin from binding glu-plasminogen.
BIACORE kinetic analysis of the interaction suggested that the dissociation of
glu-plasminogen from r-a-enolase was mediated by at least two components with
-2 -1 -3 -1
apparent dissociation rate constants of kdl=4.7xl0 s

andkd2=l-6xl0 s .Global

analysis of the interaction suggested that it was a two-state conformational change
reaction, mediated by a concentration-dependent increase in the initial association
rate. Intrinsic fluorescence spectroscopy confirmed that r-a-enolase induced a more
open conformation of glu-plasminogen. Thus, the gene product of human ENOl
encoded an authentic plasminogen binding protein and the binding of gluplasminogen to a-enolase is mediated by an initial lysine-dependent competition
reaction that results in a conformational change to the zymogen.

XV

The binding of glu-plasminogen to the metastatic breast cancer cell line
MDA-MB-231 in this study was: [1] lysine-dependent [2] low affinity (Kd = 1.8
UM), but high capacity (5.0xl07 sites/cells) and [3] dependent on the viability status
of the cells. Multiple plasminogen binding proteins may be responsible for localising
glu-plasminogen to the cell surface. The MDA-MB-231 cells were capable of
generating large amounts of plasmin compared to the non-metastatic breast cancer
cell lines which did not have a high plasminogen binding capacity.
Therefore, glu-plasminogen binds to the cell surface by a lysine-competitive,
two-step binding event that results in a more open, activation-susceptible
conformation. This competitive-lysine reaction mechanism of glu-plasminogen
explains the relationship between binding, conformation and activation of gluplasminogen.

Chapter 1 .-Biology of plasminogen binding, conformation and activation
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Chapter 1

Plasminogen binding: a fundamental event, essential to
the plasminogen activation cascade
The plasminogen activation system is a serine protease mediated cascade that
results in the formation of plasmin, a broad spectrum, trypsin-like, serine-protease.
This system is responsible for mediating several important physiological (e.g.
fibrinolysis, cell migration) and pathological (e.g. inflammation, local tumour
invasion, and metastasis) processes. Physiologically, the control of plasminogen
activation is multi-fascitated and involves both spatial and temporal regulatory
mechanisms. Since glu-plasminogen is the central constituent of the plasminogen
activation system (figure 1.1) detailed knowledge of its structure is essential for
understanding the physiology and pathology of the plasminogen activation cascade.
An important biological process that must be considered in the activation of
plasminogen is the relationship between the conformation of glu-plasminogen and its
activation rate. Glu-plasminogen changes from an activation-resistant to an
activation-susceptible conformation after binding small lysine analogues. This is
referred to as a lysine-dependent conformational change. This same type of
conformational change is also hypothesised to occur when glu-plasminogen binds in a
lysine-dependent manner to the plasminogen binding proteins such as fibrin and aenolase. Lysine-dependent binding of glu-plasminogen to these proteins also targets
the proteolytic activity of plasmin to specific sites within the body, thereby adding a
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Figure 1.1: Solution-phase plasminogen activation:
Plasminogen is activated by either single-chain or twin-chain, urokinase plasminogen activator (sc-uPA, tcu P A ) and by either single-chain or twin-chain tissue plasminogen activator (sc-tPA, tc-tPA). Once formed
the serine protease plasmin can degrade fibrin clots, and extracellular matrix ( E C M ) either directly or
indirectly via the activation of metalloproteases. The serpins PAI-1 and PAI-2 are physiological inhibitors of
the plasminogen activators. Solution phase plasmin is inhibited by the serpin a2-antiplasmin (oc2-AP) in a
lysine-dependent manner. A n activation event is represented by ••% whereas —» represents an inhibition
event.

further dimension of regulation to the cascade. Hence, the lysine-dependent binding
of glu-plasminogen to fibrin and protein receptors is hypothesised to induce
conformational changes in glu-plasminogen promoting activation, as well as targeting
plasmin activity to a specific tissue. If plasminogen binding proteins induce a lysinedependent conformational change to glu-plasminogen upon binding, then this may be
considered fundamental for the correct physiological outcomes of the plasminogen
activation cascade. Furthermore, aberrations of the lysine-dependent plasminogen

binding capacity of a tissue may result in, or contribute to pathologies associated with
plasmin-induced proteolytic damage.
This chapter will provide an overview of the plasminogen activation cascade,
focussing on the relationship between the lysine-dependent conformation of gluplasminogen and its activation. Secondly, the consequences of lysine-dependent gluplasminogen binding on the rate of fibrinolysis will be discussed and compared to
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glu-plasminogen binding and activation at the cell surface. Finally, aberrations of th
plasminogen activation cascade associated with breast cancer cell invasion and
metastasis will be reviewed, highlighting the lack of research into the expression of
plasminogen binding potential of both benign and metastatic breast cancer cells.

1.1 Plasminogen Activation Cascade Components
1.1.1 Glu-Plasminogen.
Plasminogen (EC 3.4.21.7), a broad spectrum serine endopeptidase zymogen,
is a single chain 790 amino acid glycoprotein that has a molecular weight of 92 k D a
(Wiman, 1977; Sottrup-Jensen et. al., 1978). It is a ^-globulin (Miyashita et. al,
1988) consisting of seven compact co-operative structural domains (Novokhatny et.
al, 1984). Plasminogen is composed of both a heavy chain (approximately 65 kDa),
containing an N-terminal acidic domain with a basic hinge region (NTP; amino acids
1-77) (Forsgren et. al, 1987), as well as five triple-disulfide-bonded kringle (K)
structures on which the lysine binding site (LBS) motifs are located, and a light chain
(25 kDa) or protease domain chain (Sottrup-Jensen et. al, 1978) (figure 1.2). The
chromosomal location of the plasminogen gene is 6q26 of the human genome (Murry
et. al, 1987). The liver is the primary plasminogen producing site of the body (Raum
et. al, 1980), however, other tissues such as microglia cells of the brain (Nakajima et.
al, 1992a,b). W h e n synthesised, plasminogen has 809 amino acids. The 19 amino
acid signal peptide of plasminogen (figure 1.2) is removed during the secretion
process resulting in mature, glu-plasminogen (790 amino acids). The concentration of
glu-plasminogen in the blood is approximately 2 u M (Rabiner et. al, 1969; R a u m et.

Hum
symb
amini
and t
site c

plasmino
.the 19 a

ino acids i
the heavy
dof plasm
iplic ated a
rkriiigle d

S § B* e. S

ifferent typ
f domains of glu-p
mino acids
he mature protein (l
fined by 41 e glycosylation site
minants in the NTP
K2andK 3 into a
rmational d
bond linki

sminog
) and ff
as well
dentifie
uper kt

e repiesente
itease domai
e plasminog#.T he phc
" arerepres

CL

by di:
light i
activ
ihoryl
ted b

ft oo ft 3
3 -a 3

H^

B

CJ

w.
3 O

C

65

5
5'

©

oprotein composed of 7 amino
ignal peptide •, the ami acids o
S motifs 0. The amino ds of th
arrows. The lysine resid s (Lys50
j by 0. The cystine re: ues that

rt g

d- Q. p

3 ft

3

3

.

ST r*. O

S

3" _? 1
"-•00
C5

O

p -"' 3

ft 3

#Thec

2 kDa
secret
softh
entifie
) is de

a
a
a
o
5
aST
"2.
»• c s 3 ^> a
S"
a ri 2. o o ce
©

3 r^Z "
01
s^£.
s o ^dS
o
5' "1". ET. e

5.
So f
a.
3 o.
"
f
t O
t GJ

ft

* -. « O p

«< p p g, s
5" o S. g"

"^M*!*
2
rt
e
3
g °*" OOQ re
g o- r 3 c^ rt
rt

)—
l^|0|0|«|^|^|-n|^|^|^|^

<
<
m

a.
CA

rt

3 v>
ft
3
ft
'35 p
*
*
R ;£ -1
^ ft 3
-—-a,~1 "CL

TO
B
rt
., ft *-'> P
5?> *° ^ ct o
O 3 2
ffs'
3 C L & ft C L
5

3
o
65

3 OP
3. 32
3
o —•
CO
p VO
Q.
o P

ft ft O
3n
c
3,Cf
C
ft
ft

min cut s
ilasminog

•o

s

/

H
io eo ft ,

\f3 •a

n

ft •

3

S ol r- £*K>

—

Br
rt
»5'

i

- JJ* aOQ •H-

-£«
17

T3

ore'
c
;

>
a

Chapter 1 .-Biology of plasminogen binding, conformation and activation

5

1980).
1.1.1.1 Plasmino gen-like growth factor family of proteins
Plasminogen is a member of the family of proteins known as the plasminogenlike growth factors. Other proteins of this family include: hepatocyte growth
factor/scatter factor (HGF/SF) (Nakamura et. al, 1989; Weidner et. al, 1991) and
hepatocyte growth factor-like/macrophage stimulating factor (HGFL/MSF) (Degen et.
al, 1991; Han et. al, 1991; Yoshimura et. al, 1993), both of which have
approximately 50% sequence similarity to human plasminogen (BLAST database).
These growth factors typically contain an N-terminal peptide (NTP) domain, four
kringle (K) domains, an inactive protease-like domain and a plasminogen activation
site. Donate et. al, (1994) has suggested that this family of proteins have evolved
from a common ancestral gene that consisted of an N-terminal domain corresponding
to the NTP of plasminogen, three copies of the kringle domain and a serine protease
domain. The precursor forms of these plasminogen-like growth factors are probably
substrates for plasminogen activators. For example, urokinase plasminogen activator
(uPA) activates pro-HGF by cleavage of its Arg494-Val495 peptide bond (Naldini et. al,
1992), which is homologous to the Arg560-Val561 activation bond of plasminogen.
These growth factors do not have proteolytic activity but have been implicated in
various physiological processes such as angiogenesis (Grant et. al, 1993) and
organogenesis (Sonnenberg et. al, 1993).
1.1.1.2 Glu- and lys-plasminogen- secondary and tertiary structures.
Three distinct types of domains exist within secreted plasminogen (figure 1.2).
Firstly, the NTP domain, which is responsible for maintaining the conformation of the
molecule. The second type of domain within plasminogen are the kringle domains
which contain the LBS motifs of the protein that are responsible for regulating the
conformation and tissue specific interactions of plasminogen. The final domain is the
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trypsin-like protease domain located at the C-terminal end of plasminogen. As
discussed in detail below, the combination of these domains confers unique properties
on plasminogen that facilitates its biological activity (i.e. activation of plasminogen
and the tissue specificity of plasmin).
There are two in vivo species of plasminogen namely glu-plasminogen and
lys-plasminogen. The apparent half lives of iodinated glu- and lys-plasminogen in the
circulation are 2.2 and 0.8 days, respectively (Collen and Verstraete, 1975). Gluplasminogen, (native plasminogen) designated as such because the N-terminal amino
acid of the NTP is glutamate (Wiman and Wallen, 1975). The crystal structure of gluplasminogen has not been solved. However, a combination of low-resolution physical
techniques as well as biochemical studies have advanced the hypothesis that gluplasminogen exists in a closed right-handed spiral conformation. Electron microscopy
of glu-plasminogen demonstrates that it has a right-handed spiral conformation with a
diameter of 9-11 nm (Tranqui, et. al, 1979; Weisel et. al, 1994). Small angle,
electron scattering experiments also suggest that the structure of glu-plasminogen in
solution is compact. Glu-plasminogen has a radius of gyration of 3.05 nm and a
maximum intramolecular distance of 9.1 nm (Ponting, et. al, 1992), which is
comparable to the electron microscopy data of Tranqui, et. al, (1979) and Weisel et.
al, (1994). However, the precise dimensions of the zymogen remain controversial
since Mangel et. al, (1990), using neutron scattering techniques, describes gluplasminogen as a prolate ellipsoid with radius of gyration and the maximum
intramolecular distance of 3.39 and 15 nm respectively. Chemical cross-linking
analysis of glu-plasminogen demonstrates that Lys2o4 of K2 and Tyr672 of the Cterminal protease domain are approximately 3 A from each other in the protein
(Banyai and Patthy, 1984, 1985). Taken together these studies suggest that gluplasminogen exists in a tight right hand spiral, known as the closed conformation.
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Lys-plasminogen (Lys78-Asn790), in which the NTP (GlurLys77) is absent, has a
more open conformation than glu-plasminogen. Electron microscopy of lysplasminogen demonstrates that it exists in a U-shaped conformation with approximate
dimensions of 14 nm x 7 nm (Wiesel et. al, 1994). This open conformation has also
been described as a Debye random coil with a radius of gyration of 56 A
(Ramakrishnan et. al, 1991). The N-terminal fragment of lys-plasminogen (Kl-3) is
described equally well by either a Debye random coil or an elongated, prolate
ellipsoid, shapes with a radius of gyration of 29 A (Ramakrishnan et. al, 1991). This
more open conformation of lys-plasminogen is also associated with an increase in the
intrinsic fluorescence of the protein (Markus et. al, 1979). The secondary structure of
both glu- and lys-plasminogen are very similar (Sjoholm et. al, 1973; Misselwitz et.
al, 1994), suggesting that a negligible change in secondary structure is associated
with a large tertiary conformational change. Thus, the spatial relationship of the
individual domains with each other is different between the closed to the open
conformations of glu-plasminogen, whilst the structures of the domains themselves
remains constant. Taken together, these studies suggest that the NTP domain may act
as a conformational determinant of glu-plasminogen.
The NTP domain of glu-plasminogen contains two disulfide bonds, Cys30Cys54 and Cys34-Cys42 and is predicted to have a loop-in-loop topology (Donate et. al,
1994). The solution phase tertiary structure for the GlurSer57 fragment of the NTP,
determined by 'H-NMR, demonstrates that this fragment has very low secondary
structure content (about 10% a-helix) (An et. al, 1998a). Similarly, the tertiary
structure of the hairpin loop containing domain of HGF (Gly31-Asn127), which has
approximately 27% sequence similarity to the NTP domain of glu-plasminogen, has
been solved by 'H-NMR and also contains approximately 10% a-helix secondary
structure (Zhou et. al, 1998).
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Site-directed mutagenesis of the basic amino acid hinge region of the NTP
domain (Cys54-Val79) demonstrates that this plasmin susceptible region is directly
involved in maintaining the conformation of glu-plasminogen (Horrevoets et. al,
1995; figure 1.2). Plasmin catalysed proteolysis of glu-plasminogen at Arg68-Met69,
Lys77-Lys78 or Lys78-Val79 (figure 1.2) results in the autocatalytic removal of the 8
kDa NTP of the protein and the formation of lys-plasminogen (Wiman, 1973;
Summaria et. al, 1973; Gonzalez-Gronow et. al, 1977). The conformational change
from glu- to lys-plasminogen, mediated by the removal of the NTP domain, is
reversible since addition of the isolated NTP back to lys-plasminogen restores the
native lysine-dependent conformation of glu-plasminogen (Sjoholm et. al, 1973).
This suggests that the conformation of glu-plasminogen is regulated by non-covalent,
lysine-dependent interactions between the NTP of glu-plasminogen and the LBS
motifs of the kringle domains of the protein (Wiman and Wallen, 1975; Violand et.
al, 1975). This further implicates the NTP domain of glu-plasminogen as a lysinedependent conformational determinant of the protein.
Lys-plasminogen is more readily activated by the plasminogen activators
(Claeys and Vermylen, 1974), and has a higher specific activity when converted to
plasmin (Lucas et. al, 1983) than glu-plasminogen. Thus, the lysine-dependent
interactions between the kringle domains and NTP of glu-plasminogen may modulate
the biological role of glu-plasminogen by regulating the conformation of the protein.
Therefore, detailed structural knowledge of the NTP and the kringle domains of
plasminogen is required to understand the conformational regulation of gluplasminogen and hence, biological activity of the protein.
1.1.1.3 The kringle domains of plasminogen.
The L B S motifs of glu-plasminogen are contained within the five kringle
domains (figures 1.2 and 1.3) of the heavy chain of the zymogen. These motifs
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mediate the lysine-dependent binding of glu-plasminogen to various proteins such as
fibrin (Sottrup-Jensen et. al, 1978). The kringles contain approximately 80 amino
acids each (figures 1.2 and 1.3A) and are homologous to kringle domains of several
other proteins, including: tissue plasminogen activator (tPA), urokinase plasminogen
activator (uPA), prothrombin, factor XII (reviewed by Patthy, 1985) and
apolipoprotein(a) (McClean et. al, 1987; Tomlinson et. al, 1989). Structurally,
kringles are triple disulfide bonded domains characterised by three short
perpendicular antiparallel (3-strands (figure 1.3B).
All of the plasminogen kringle domains have been isolated and individually
characterised with respect to their affinities for the lysine analogues that structurally
resemble either the N-terminal, C-terminal or internal lysine residues of proteins. The
binding of lysine analogues, such as £-amino caproic acid (e-ACA), to Kl-3 or
isolated KI, K4 and K5 thermodynamically stabilise the native structures of these
kringles (Menhart et. al, 1991; Menhart et. al, 1993; Castellino et. al, 1981).
Furthermore, both the enthalpy (AH) and entropy (AS) of the interactions are the
driving forces for the binding of e-ACA and other analogues to kringles such as K4
(Sehl and Castellino, 1990). Thus, the binding of lysine analogues to isolated,
functional kringle domains of plasminogen is energetically favourable and results in
the stabilisation of these domains.

Figure 1.3: T h e tertiary structures of the kringle domains of plasminogen.
(A) Sequence alignment of the laringle domains of glu-plasminogen. Amino acids of the anionic,
cationic loci and the hydrophobic clefts (red, blue and green respectively). (B) The tertiary structures of
K I (Matthews et. al, 1996), K 2 (Marti et. al, 1999), K 4 ( W u et. al, 1991) and K 5 (Chang et. al, 1998)
of glu-plasminogen complexed with either s-ACA or T A (pink). Note, K 2 tertiary structure was
resolved using 1 H - N M R , whereas K I , K 4 and K 5 tertiary structures were derived using x-ray
crystallography. (C) The anionic loci (-1.80; red), cationic loci (+1.80; blue) separated by the
hydrophobic clefts (green) of the kringle domains.
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KI contains the high affinity LBS for co-amino carboxylic acid ligands such as
e-ACA and some cyclic analogues such as trans-4(aminomethyl)cyclohexanecarboxylic acid (t-AMCHA; table 1.1). The LBS motif of
isolated KI displays a preference for C-terminal lysine analogues as opposed to
internal lysine residue analogues (table 1.1). Furthermore, the LBS motif of KI binds
in a lysine-dependent manner to the plasmin inhibitory serpin a2-antiplasmin (Wiman
et. al, 1979) and the plasma plasminogen binding protein, histidine rich glycoprotein
(Lijenen et. al, 1980).
The lysine binding characteristics of K2 and K3 of human plasminogen are
not as well characterised as KI, K4 and K5 possibly due to the presence of an interkringle disulfide bond between Cys169-Cys297 (figure 1.2) (Cys4 of K2 to Cys43 of K3,
kringle numbering convention). This disulfide bridge permits the generation of a K2K3 "supermodule". Recombinant K2 (r-K2) and r-K3 were engineered to remove the
inter-kringle disulfide bond so the individual lysine binding characteristics could be
studied. The LBS motif of K2 is designated as the lowest affinity LBS within
plasminogen for all the classes of lysine analogues examined (table 1.1). Furthermore,
it exhibits weak binding to lysine-Bio-Gel (Marti et, al, 1994). Isolated K2 binds to
the C-terminal lysine analogue Afa-acetyl-L-lysine with an affinity approximately 40fold lower than the LBS motifs of KI and K4 (table 1.1; Marti et. al, 1997). Despite
its very low affinity for small lysine analogues, r-K2 as opposed to r-Kl and r-K3,
binds to an internal sequence of the streptococcal surface plasminogen binding
protein PAM with an apparent Ka of 4.5xl07 M"1 (Wistedt et. al, 1998), which
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suggests an important biological function. In contrast, r-K3 is devoid of a binding
affinity for co- aminocarboxylic acids (Marti et, al, 1994). The binding of e-ACA to
K2 is not inhibited by the presence of K3 in the isolated kringle supermodule
conformation (Sohndel et. al, 1996).
Several studies have determined that isolated K4 of plasminogen has slightly
lower affinity for e-ACA than KI (table 1.1; deMarco et. al, 1987; Lerch, et. al,
1980; Sehl and Castellino, 1987). The surface availability of the LBS motif of K4
within glu-plg may be limited due to the positioning of the Kl-3 domains in the
parent molecule (Vali and Patthy, 1982). K4 also binds to the plasminogen-K4
binding protein tetranectin (Clemmensen et. al, 1986; Kluft et. al, 1989b).
The LBS motif of K5 displays low affinity for all classes of lysine analogues
(table 1.1). It has also been termed the amino-hexyl (AH) site of plasminogen since it
preferentially interacts with the AH but not the carboxylate function of lysine residues
(table 1.1; Christensen, 1984). The preference of the K5 LBS motif for the AH side
chain of lysine residues is further demonstrated by its higher affinites for Na-acetylL-lysine methoxyester, a lysine analogue that resembles an internal lysine residue of
proteins (table 1.1). However, K5 also binds N- and C-terminal lysine residue

analogues with a similar affinity (table 1.1). It is predicted that due to this low affin
but broad binding specificity, that LBS motif of K5 may bind internal lysine residues
of a protein (Ponting et. al, 1992), such as Lys50 or Lys62 of the NTP of gluplasminogen (Cockrell et. al, 1998). In contrast to the other plasminogen kringle LBS
motifs, K5 displays selective affinity for both benzamidine and benzylamine (table
1.1; Thewes et. al, 1987; Varadi and Patthy, 1981). Hence, these small cyclic
molecules may be used to discern the contribution of K5 to the physiological
functions of glu-plasminogen.
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Within plasminogen there are four classes of LBS motifs with respect to their
affinities for the co-aminocarboxylic acid analogues: K1>K4>K5>K2. Furthermore,
KI and K4 preferentially bind C-terminal analogues whilst K5 displays a preference
for internal lysine analogues. Therefore, each of the kringle LBS motifs may play a

slightly different role due to: [1] their differential affinities for the three classes
lysine residues within proteins, and [2] their position in the A-chain of glu-

plasminogen. The differential affinities of the kringle LBS motifs for lysine analogues
that mimic N-terminal, C-terminal and internal lysine residues of proteins may be due
to slight structural differences of the individual LBS motifs of the kringle domains.
1.1.1.4 The Architecture of the LBS motif
The structural characteristics of the L B S motifs located within the isolated
kringle domains of plasminogen have been determined using chemical modification
studies (Vali and Patthy, 1984; Trexler et. al, 1982; Trexler et. al, 1985), sitedirected mutagenesis (Nielsen et. al, 1993; McCance and Castellino, 1995), NMR
spectroscopy (Hochschwender et. al, 1983; Llinas et. al, 1983; Trexler et. al, 1983;
Ramesh et. al, 1987; DeMarco et. al, 1987; DeMarco et. al, 1985; Motta et. al,
1986; Motta et. al, 1987; Thewes et. al, 1987; Petros et. al, 1989; Rejante and
Llinas, 1994) and x-ray crystallography (Matthews et. al, 1996; Wu et. al, 1991;
Chang et. al, 1998). The crystal structures of KI (Matthews et. al, 1996), K4 (Wu et.
al, 1991; Mulichak et. al, 1991) and K5 (Chang et. al, 1998) demonstrate that the
kringle LBS motifs are: (1) preformed and localised to the surfaces of these domains
(figure 1.3B, C), and (2) that the kringle domains do not change conformation upon
ligand binding (Wu et. al, 1991; Mulichak et. al, 1991; Matthews et. al, 1996).
Water probably occupies the apo (unligated) LBS motifs of the kringle domains of
glu-plasminogen (Chang et. al, 1998). 'H-NMR of isolated KI (DeMarco et. al,
1982), K4 (Hochschwender et. al, 1983; Llinas et. al, 1983; Ramesh et. al, 1987;
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Trexler et. al, 1983) and K5 (Thewes et. al, 1987) suggest that these domains exist as
compact globular structures in solution.
Each of the plasminogen kringle LBS motifs has a slightly different
architecture that may account for the different affinities observed for individual lysine
analogues (table 1.1). The basic structural elements required for a functional, high
affinity, LBS are anionic and cationic loci separated by a hydrophobic cleft, optimised
for the specific electrostatic, hydrophobic and steric requirements of lysine residues
(figure 1.3).
The e-amino group of a bound lysine ligand is stabilised by an ionic
interaction with the carboxylate functions of the aspartate residues of the anionic
locus (figure 1.3). The aspartate anionic locus is present in all functional lysine
binding kringle domains of plasminogen, for example, Asp55 and Asp57 are rigorously
conserved in KI, K4 and K5 of plasminogen (figure 1.3A). This is not unexpected,
since the e-amino group is part of the R group of L-lysine and therefore is common to
all classes of lysine residues within proteins. K2 of plasminogen, which has very low
affinity for lysine analogues (table 1.1), has a glutamate residue at position 57 (figure
1.3). This may reduce the electrostatic attraction between the anionic locus of K2 and
the e-amino group of the lysine ligand. Thus, the apparent low affinity of K2 for all
classes of lysine analogues (table 1.1) may be partially due to this aspartate/glutamate
substitution. K3 of plasminogen, which does not bind lysine analogues, has a lysine
residue (opposite charge) at position 57 (figure 1.3A). This would sufficiently perturb
the charge of the anionic locus of kringle 3 thereby destroying its ability to bind the eamino group of a lysine ligand. Substitution of Asp57 with alanine or asparagine
eliminates the lysine binding capacities of KI, K4 and K5 (Nielsen et. al, 1993;
McCance and Castellino, 1995). Thus, the anionic locus of a kringle is fundamental to
its lysine binding ability.
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The amino acids of the cationic locus, which stabilise the carboxyl group of a
lysine analogue, are more ambiguous to define than those of the anionic locus.
Positively charged amino acids such as either lysine and arginine at positions 34 or 35
and arginine at position 71 define the cationic locus of the kringle LBS (figure 1.3).
The x-ray crystal structure for human plasminogen KI suggests that both Arg34 and
Arg71 may contribute to the cationic locus (figure 1.3; Matthews et. al, 1996). In
contrast to human plasminogen KI, mouse plasminogen KI does not contain a basic
residue at a position homologous to Arg34 of human plasminogen KI (Degan et.
al, 1990). Nevertheless, mouse plasminogen KI has an affinity for e-ACA
comparable to human plasminogen KI (Castellino, 1995). Furthermore, the

orientation of Arg34 the cationic loci in the solution structure of KI varies significantl
from the crystal structure of KI (figure 1.4; Rejante and Llinas, 1994; Matthews et.
al, 1996). In contrast, the orientation of the anionic loci of the solution and crystal
structures of KI are comparable (figure 1.4; Rejante and Llinas, 1994; Matthews et.
al, 1996). Therefore, Arg34 may not be a member of the cationic locus of KI of
soluble plasminogen.
Chemical modification of isolated K4 suggests that Arg71 is critical for lysinedependent binding (figure 1.3). In contrast, Lys35 may not be an important member of
the cationic locus in solution phase K4 (Nielsen et. al, 1993). Thus, Arg71 may be the
sole constituent of the cationic locus of soluble KI and K4. In K5 of plasminogen
Arg71 is replaced by Leu71 (neutral R-group) (figure 1.3). Replacement of Leu71 with an
arginine residue by site-directed mutagenesis increases the affinity of mutant K5 for
e-ACA to levels comparable to KI and K4 (Chang et. al, 1998). Thus, a single
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Figure 1.4:Comparison of the tertiary structure of solution-phase and crystallised plasminogen K I .
(A) Alignment of solution-phase (green; Rejante and Llinas, 1994) and crystallised (pink; Matthews et. al,
1996) of plasminogen K I . The relative positions of the anionic and cationic loci of both the solution-phase
(green) and crystal-phase (red) are shown. (B) Comparison of the anionic (red), cationic (light blue) and
hydrophobic (green) components of the L B S of the solution-phase and crystal-phase complexed to e - A C A
(pink).
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basic amino acid at position 71 may be sufficient for the stablisation of the ligand
carboxyl group by the cationic locus.
The anionic and cationic loci of the kringle LBS motifs are separated by a
series of aromatic amino acids, namely Phe36/Tyr36, Trp62, Phe64/TyrM and Tyr72/Trp72,
organised into a hydrophobic cleft approximately 7.33 A in length (Marti et.
al, 1997). The hydrophobic cleft of all plasminogen kringles contains Trp62 and
Tyr72/Trp72 residues. However, only functional, lysine-binding kringles of
plasminogen contain Phe64/Tyr64 residues, in contrast to the non-functional K3, which
has a histidine at position 64 (figure 1.3A). Furthermore, of the lysine binding
functional kringles, only K4 does not have a phenylalanine or tyrosine at position 36
(figure 1.3A). The binding of e-ACA to the hydrophobic clefts of KI, K4 and K5
results in a negative change in the standard heat of capacity (AC ) for this interaction
of -81, -37 and -40 cal K'mol"1 respectively (Menhart and Castellino, 1995). The
absence of Phe36/Tyr36 in K4 may contribute to its reduced ligand affinity when
compared to ligand affinity of KI, since K4 had the highest AC for e-ACA binding.
This suggests that the aromatic amino acid side chains of the hydrophobic clefts are
important for stabilising the interaction of e-ACA with these kringles (Menhart and
Castellino, 1995).
The LBS motifs of KI and K4 of plasminogen preferentially bind C-terminal
lysine residue analogues (table 1.1). Physiologically, the carboxylate function of
lysine is only present on free lysine and C-terminal lysine residues of proteins. Thus,
the presence of a cationic locus within the LBS motifs of KI and K4 may confer Cterminal lysine residue specificity to these kringles, as opposed to the internal lysine
residue specificity of the K5 LBS, which does not contain a cationic locus (figure
1.3). Hence, the ubiquitous presence of the anionic locus in all functional
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plasminogen kringle LBS motifs, facilitates lysine-dependent binding, whilst the
cationic locus confers lysine residue-type specificity.
1.1.1.5 Lysine-dependent conformational changes of glu-plasminogen
The lysine-dependent conformations of glu-plasminogen have been defined
using small lysine analogues. For example, incubation of glu-plasminogen with Llysine, e-ACA, or tranexamic acid induces the fully open, but reversible change in the
conformation of glu-plasminogen (table 1.1; Violand et. al, 1978; Brockway and
Castellino, 1972; Castellino et. al, 1973; Markus et. al, 1978; Markus et. al, 1979)
from a tight right hand spiral to a U-shaped conformation (Weisel et. al, 1994)
thereby shifting the conformational equilibrium of the protein (figure 1.5; table 1.1).
Glu-Plasminogen Lys-Plasminogen

Plasmin Jfl Bk >^\ ^-^ J

«
Closed, right-hand spiral Open U-shaped
conformation

•fj 3 _i_

^\f^^\<\

conformation

•

Lysine analogues

Open conformation

Figure 1.5: Schematic representations of the conformations of glu- and lys-plasminogen.
Glu-plasminogen exists a closed right hand spiral conformation. Plasmin mediated cleavage of the N T P (•)
from the A-chain of glu-plasminogen results in the formation of lys-plasminogen (in an open U-shaped
conformation). The functional L B S motifs are represented by
within the kringle domains %.

In an manner similar to lys-plasminogen, this lysine-dependent conversion of
glu-plasminogen from the closed to the open isomer is not accompanied by a change
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in the secondary structure of the molecule (Sjoholm et. al, 1973; Vuk-Pavlovic and
Gafni, 1979; Ramakrishnan et. al, 1991). Hence, the closed conformation is a product
of the interactions between the different domains of glu-plasminogen. Moreover,
under acidic conditions the kringle domain and protease domain of miniplasminogen
(K5-protease domain) have significant structural and motional independence (Teuten
et. al, 1991). Similarly, glu-plasminogen under the same conditions also exhibits
domain independence (Teuten et. al, 1991) thereby re-enforcing the notion that the
interdomain linker sequences of glu-plasminogen are flexible. Although gluplasminogen exists predominantly in the closed conformation, regions of the molecule
may oscillate ("breath") between the closed and open conformations of the protein.
For example the LBS motif(s) responsible for the lysine-induced conformational
changes of glu-plasminogen, are estimated to spend between 20% and 40% of their
time in the open conformation (Markus et. al, 1978; Markus et. al, 1979; Weisel et.
al, 1994). Nevertheless, in the absence of exogenous lysine, the conformational
equilibrium of glu-plasminogen exists in favour of the closed isomer.
The LBS motifs of the kringle domains maintain the closed conformation of
glu-plasminogen by binding to internal lysine residues of plasminogen. Site-directed
mutagenesis experiments that eliminated the lysine binding function of individual
kringles within glu-plasminogen, demonstrated that both the high affinity KI LBS
and the lower affinity LBS of K4 (both of which preferentially bind C-terminal lysine
analogues (table 1.1)), are responsible for mediating large conformational changes to
glu-plasminogen (McCance and Castellino, 1995). In contrast, K5 is responsible for
minor (or partial) conformational changes of glu-plasminogen (McCance and
Castellino, 1995). Thus, the closed conformation of glu-plasminogen is maintained by
the lysine-dependent interactions of KI, K4 and K5 with lysine residues from other
regions of glu-plasminogen. The presence of this intramolecular lysine-binding
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network suggests that the LBS motifs of glu-plasminogen are occupied by the internal
lysine residues of the protein.
The NTP domain contributes to the closed, lysine-dependent conformation of
glu-plasminogen by providing some of the internal lysine residues that bind to the
kringle domains. Christensen (1984) first suggested that the closed conformation of
glu-plasminogen might be mediated by a lysine-dependent interaction between the
Lys50 of the NTP and the LBS motif of kringle 5. Incubation of glu-plasminogen with
an exogenous peptide containing the Ala44-Lys50 residues of the NTP domain induces
a conformational change in the molecule (Takada et. al, 1993). Furthermore, isolated
K4 binds to this peptide thereby supporting the notion that LBS motifs can bind to the
NTP of glu-plasminogen (Ramesh et. al, 1995). However, within this peptide Lys50
has a C-terminal configuration and hence does not accurately reflect the chemical
properties of Lys50 in the NTP of glu-plasminogen. Site-directed mutagenesis studies
that eliminated the lysine-binding activity of K5, as well as substituting Lys50or Lys62
of the NTP with alanine residues, have provided direct evidence that this kringle does
interact with Lys50 or Lys62 of the NTP to maintain the closed conformation of the
protein (Cockrell et. al, 1998). Furthermore, isolated KI, K2, K4 and K5 bind, in a
lysine-dependent manner to the Glu,-Met57 fragment of the NTP of glu-plasminogen
(which contains Lys50 as an internal residue), with affinities ranging from 6.2 mM"1
down to 2.3 mM"1 with K4 having the highest affinity for Lys50 of the NTP (An et.
al, 1998a). The Ala^-Lys^ NTP fragment binds specifically to isolated K4. Thus,
Lys of the NTP of glu-plasminogen has also been suggested as a possible ligand for
K4 (An et. al, 1998b).
The amino acid sequence containing Lys50 in the NTP is highly flexible (An et.
al, 1998a). This flexibility may be important for the interaction of Lys50 with either
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the K4 or K5 LBS. H-NMR and molecular modeling studies have suggested that the
Glu39-Lys50 stretch in the NTP of glu-plasminogen generates an area that complements
both topologically and electrostatically the solvent-exposed K4 LBS surface (An et.
al, 1998b). Homology modeling of the NTP of glu-plasminogen using the NTP of
HGF (designated as 2hgf in the Brookhaven database; figure 1.6) suggests that both
Lys50 and Lys62 are located on opposite sides of the hairpin loop of the NTP of gluplasminogen (approximately 23 A apart). If this model (figure 1.6) were correct, there
would be enough space for a kringle domain to bind to each of these lysine residues
simultaneously (figure 1.6). Therefore, Lys50 and Lys62 of the NTP are implicated as
the conformational determinants of glu-plasminogen. However, other lysine residues,
acting a conformational determinants may exist since KI has been shown by
mutagenesis to be an important conformational determinant of glu-plasminogen
(McCance and Castellino, 1995).
Exogenous lysine analogues, such as e-ACA (table 1.1) induce the open
conformation of glu-plasminogen by disrupting the intramolecular lysine-binding
network of protein. Tranexamic acid (Markus et. al, 1979) and e-ACA (Markus et.
al, 1978) bind to approximately five sites within glu-plasminogen (one high affinity
and four low affinity sites). Marshall et. al, 1994, using different lysine analogues,
has suggested that glu-plasminogen can actually exist in three distinct conformations:
a or closed conformation (in the absence of exogenous lysine analogues); (3 or
partially open conformation (resembling the U-shaped conformation of lysplasminogen); and 7 (fully open, exogenous lysine saturated conformation).
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Figure 1.6: A hypothetical model of the N T P of glu-plasminogen and its possible interactions.
A hypothetical model of the N T P of glu-plasminogen modeled on the structure of the N T P of H G F and
generated using Swiss Pdbviewer (Peitsch and Guex 1997). (A) Ribbon model of K 4 (pink) and K 5 (orange)
binding to lys50 and lys62 of the N T P (white). (B) A n electrostatic surface model showing the charge (red: 1.80; blue: +1.80) distribution of the K5-NTP-K4 complex.
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Incubation of glu-plasminogen a with the K 5 specific ligand, benzamidine (table 1.1;
Thewes et. al, 1990), induces the formation of glu-plasminogen p (figure 1.7;
Marshall et. al, 1994). Lys-plasminogen and glu-plasminogen P have a similar
conformation, thus disruption of the lysine-dependent binding of K5 to a lysine
residue in the NTP for both is responsible for a partial conformational change of gluplasminogen. Subsequent treatment of glu-plasminogen P or lys-plasminogen with eACA induces the fully open (y) conformation of these proteins. This suggests that
multiple kringle lysine-dependent interactions are responsible for inducing the fully
open conformation of glu-plg (Marshall et. al, 1994). Thus, the conformational status
of glu-plasminogen is the result of a series of competition reactions between the
internal lysine residues of glu-plasminogen and exogenous lysine analogues that
disrupt the intramolecular lysine-binding network of glu-plasminogen.

Figure 1.7: Schematic representation of the lysine-dependent conformational changes of gluplasminogen.
The interaction of multiple L B S motifs with exogenous lysine residues is hypothesised to be required for the
complete conformational change of glu-plasminogen to the open, activation-susceptible conformation.
Kringle domains (#), N T P (•), protease domain (*) and the L B S motifs ( ).
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The interaction of multiple L B S motifs with exogenous lysine analogues is
responsible for disrupting the closed conformation of glu-plasminogen (table 1.1).
The total lysine-dependent conformational change of glu-plasminogen (i.e. a -» y)
involves both the high affinity and multiple, low affinity, kringle LBS motifs over a
wide range of lysine analogue concentrations (Markus et. al, 1978; Markus et. al,
1979). Strong binding of the first lysine analogue to glu-plasminogen causes little
change in the conformation of the protein. In contrast, saturation of the weak LBS
motifs of glu-plasminogen with tranexamic acid or e-ACA induces most of the lysinedependent conformational change of the protein (Markus et. al, 1978; Markus et. al,
1979). Similarly, Christensen and Molgaard, 1991 demonstrated that a rapid
conformational change of glu-plasminogen (t1/2 = 0.01 s) is mediated by the
cooperative binding of the LBS of K5 and K4 to e-ACA (Christensen and Molgaard,
1992). However, the interaction of KI with e-ACA does not mediate a conformational
change to glu-plasminogen (Christensen and Molgaard, 1992). Both C-terminal and
internal lysine analogues are capable of inducing this conformational change to gluplasminogen (Christensen and Molgaard, 1992). The apparent e-ACA-induced
conformational change rate constants for glu-plasminogen are k, = 69 sand k2 = 3 s"1
(Christensen and Molgaard, 1991), suggesting that exogenous e-ACA locks gluplasminogen in the open conformation. Thus, the lysine-dependent conformational
changes of glu-plasminogen are mediated by its multiple kringle domains.
1.1.1.6 Plasminogen activation and conformation
The lysine-dependent conformation of glu-plasminogen regulates its activation
rate. Both the conformations (Weisel et. al, 1994; Sjoholm et. al, 1973) and
activation rates (table 1.2; Markus et. al, 1978; Violand et. al, 1978; Peltz et. al,
1982; Lijnen et. al, 1984) of glu-plasminogen in the presence of lysine analogues,
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and lys-plasminogen are comparable. This suggests that the lysine-dependent, open
conformation of glu-plasminogen increases the catalytic efficiency (kca/KJ of the
activation reaction (table 1.2). This lysine-dependent increase in the activation rate is
due to both a concomitant decrease and increase in the Km and kcat of the reaction,
respectively (table 1.2).
The lysine-dependent increase in the activation rate of glu-plasminogen is
partially driven by a decrease in the Km of the reaction. Crosslinking of Lys203 of K2 to
Tyr671 of the protease domain prevents an increase in activation rate of gluplasminogen, induced by e-ACA, by impeding the lysine-dependent conformational
change of the protein (Banyai and Patthy, 1985; table 1.2). The heavy chain of gluplasminogen, when the protein is in its lysine-dependent, closed conformation may
hinder the access of the plasminogen activators to the Arg560-Val561 activation bond of
glu-plasminogen. The Km for unbound, soluble, glu-plasminogen is approximately 10
fold above the physiological plasma concentration of glu-plasminogen. Thus, the
plasminogen activators require approximately 10-fold more unbound, soluble, gluplasminogen than is physiologically available for efficient activation of gluplasminogen. In contrast, the Km of glu-plasminogen in the open conformation is less
than or equal to the physiological concentration of glu-plasminogen suggesting that
when present in this conformation the efficient activation of glu-plasminogen is
facilitated under physiological conditions.
The rate of this lysine-induced glu-plasminogen conformational change (70 s
') (Christensen and Molgaard, 1991) is approximately 20-fold greater than the
catalytic activation rate constant (kcat) for the hydrolysis of the plasminogen activation
bond of glu-plasminogen (table 1.2; Christensen, 1977; Hoylaerts et. al, 1982; Peltz
et. al, 1982; Ranby, 1982; Banyai and Patthy, 1985). This indicates that the time
taken for a plasminogen activator to hydrolyse the activation bond of glu-plasminogen
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(table 1.2) is greater than the time taken for glu-plasminogen to undergo the lysinedependent conformational changes. Thus, the open conformation of glu-plasminogen,
as opposed to the time taken for the either the conformational change or the
hydrolysis of the activation bond, is the rate determining factor in activation of gluplasminogen. This suggests that the lysine-dependent binding of glu-plasminogen to
physiologically relevant sites may modulate its conformation and presents gluplasminogen as a better substrate to the activator that rapidly converts it into plasmin.
The net result would be a decrease in the concentration of lysine-bound gluplasminogen required for efficient activation.
Chloride ions, in contrast to lysine molecules, act as negative allosteric
regulators that impede the activation of glu-plasminogen. Chloride ions act by binding
to glu-plasminogen with a K; of 9 mM (Urano et. al, 1988) and may help to maintain
the protein in its closed, activation resistant, conformation in solution (Urano et. al,
1988; Urano et. al, 1987a). Both lysine and chloride ions bind glu-plasminogen
simultaneously, suggesting that their binding sites are separate (Urano et. al, 1987a).
However, the inhibitory effect of chloride ions is negated in the presence of E-ACA
(Urano et. al, 1987b). For example the K^, of urokinase for the activation of the gluplasminogen :C1" complex is 25 uM compared to 2.2 uM for uncomplexed gluplasminogen (Urano et. al, 1987a). In contrast, e-ACA facilitates activation of gluplasminogen by inducing a favourable conformational change in the molecule for
activation by urokinase as indicated by a K^ of 1.8 uM (Urano et. al, 1987a). The
physiological concentrations of chloride ions and L-lysine in plasma ranges between
96-106 mM (Murry et. al, 1990) and 105-207 uM (Diem and Lentner,1970),
respectively. Since the concentration of L-lysine required to produce a half maximal
conformational change in glu-plasminogen is approximately 26 mM (table 1.1;
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Violand et. al., 1978) it is predicted that the majority of soluble plasma gluplasminogen would be in the closed, activation resistant conformation.
1.1.1.7Post-translational modifications of plasminogen.
T w o glycoforms of h u m a n plasminogen (Pig I and Pig II), which differ in both
the composition and extent of their glycosylation have been isolated from plasma
based on their different affinities for lysine sepharose (Hayes and Castellino, 1979a;
Hayes and Castellino, 1979b and Traas et. al, 1984). Both glycoforms are
glycosylated with an o-linked tetrasaccharide at Thr345 whereas glycoform I contains
an additional TV-glycosylation site at Asn289 (Hayes and Castellino, 1979a; Hayes and
Castellino, 1979b; Hayes and Castellino, 1979c; Lijnen et. al, 1981). Moreover, the
N-linked glycosylation of glu-plasminogen increases its activation rate by urokinase
(Takada and Takada, 1983). Lower concentrations of lysine analogues are required to
induce a conformational change in glycoform I than glycoform II. The lysinedependent transition of both glu-plasminogen glycoforms from the closed to open
conformation I (Sugawara, et. al, 1984) resulted in an increase in the activation rates
of the molecules by urokinase (Takada et. al, 1984). However, glycosylation at
Asn289 (glycoform I) stabilises glu-plasminogen in the open conformation after a
lysine-dependent interaction has occurred by significantly decreasing the rate of the
reverse conformational change (i.e. the closing of the molecule via the removal of
lysine) (Molgaard et. al, 1997). This stablisation of the lysine-dependent, open
conformation glu-plasminogen I would facilitate an increase in the activation rate of
the molecule by allowing the plasminogen activators access to Arg560-Val561
activation bond. Thus, glycosylation of glu-plasminogen affects both the stability and
affinity of the protein to interact with lysine moieties as well as its subsequent
activation rate.
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Both neonatal glycoforms of glu-plasminogen have significantly more
mannose and sialic acid than the adult glycoforms. This difference in the carbohydrate
composition may be responsible for the decreased binding and activation rate
observed for neonatal glu-plasminogen compared to adult glu-plasminogen (Edelberg
et. al, 1990). Hence, not only is the site of glu-plasminogen glycosylation important
for the binding and activation of the molecule, but the composition of the
carbohydrate moieties also impacts on the biology of glu-plasminogen.
Finally, circulating human plasminogen is a serine/threonine and tyrosine
phospho-protein (Wang et. al, 1997). Ser578 , located within the protease domain of
the protein (figure 1.2), is a major phosphorylation site on circulating gluplasminogen (Wang et. al, 1997). Since Ser578 is present in the protease domain,
phosphorylation at this site may affect plasmin activity. However, the role
phosphorylation plays in plasminogen biology remains unknown.
1.1.1.8 Plasmin
The C-terminal 230 amino acids of the plasminogen comprise the protease
domain (figure 1.2) containing the catalytic triad of plasmin (His602, Asp645 and
Ser740). When activated by the mammalian plasminogen activators, uPA and tPA
(Vassalli et. al, 1992), plasminogen is cleaved at Arg56Q-Val56i (Figure 1.2) and
converted into twin-chain plasminogen (i.e. plasmin) thereby facilitating the
formation of the trypsin-like protease catalytic triad (Robbins et. al, 1967). The
heavy and light chains of plasmin are covalently joined by two disulfide-bridges,
between Cys548 of the heavy chain and Cys666 of the light chain, and between Cys558 of
the heavy chain and Cys566 of the light chain (figure 1.2). Sedimentation coefficients
indicate that the lys-plasmin has a more open conformation comparable to lysplasminogen (Robbins et. al, 1975). The binding of lysine analogues such as e-ACA
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and TA to the kringle domains of plasmin stabilises the structure of the protease
domain and preserve the enzymatic activity of plasmin (Ueshima et. al, 1996).
The physiological activation of glu-plasminogen may occur via two related
pathways. Firstly, glu-plasminogen may be cleaved at Arg -Val by the
560

561

plasminogen activators resulting in the formation of glu-plasmin, which can autocatalytically remove its NTP forming lys-plasmin (i.e. the most active form of
plasmin) (Summaria et. al, 1973). Secondly, lys-plasminogen (formed by the removal
of the NTP of glu-plasminogen by plasmin proteolysis) is cleaved at Arg -Val by
plasminogen activators thereby forming lys-plasmin (Violand and Castellino, 1976).
Proteases, other than the plasminogen activators, such as factor XIa, factor
Xlla, and kallikrein are able to activate glu-plasminogen in vitro. However, uPA is
approximately 20,000 fold more active than kallikrein or factor XIa and 300,000
times more active than (3-factor Xlla (Miles et. al, 1983). Indirect plasminogen
activation may also occur via the actions of both pancreatic and leukocyte elastases on
glu-plasminogen which form val^-plasminogen (lacks the LBS motifs of the parent
molecule; Sottrup-Jensen et. al, 1977), which in the presence of uPA and the
plasmin-specific inhibitor a2-antiplasmin is converted to plasmin (Machovich and
Owen, 1989). This form of plasmin is more resistant to a2-antiplasmin inhibition than
native plasmin possibly due to the absence of the KI LBS motif (Machovich and
Owen, 1989), however the rate of fibrinolysis by val^-plasmin is comparable to lysplasmin (Ney and Pizzo, 1982). Thus, the inhibition of plasmin as opposed to its
fibrinolytic rate is influenced by its LBS motifs.
In the blood vascular system, plasmin is primarily responsible for the
degradation of fibrin polymers (Astrup, 1978) since plasminogen deficient mice are
predisposed to severe thrombosis as well as fibrin depositions in numerous major
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organs including the liver (Bugge et. al, 1995; Ploplis et. al, 1995). The specificity
of plasmin is similar to that of trypsin (Robbins et. al, 1981). Plasmin hydrolyses

peptide bonds with exposed lysine or arginine residues in position Pl (Keil, 1992) (i.e
on the C-terminal side of lysine or arginine residues; [K,R]vl>X). Plasmin cleaves 11
out of 73 arginine residues and 20 out of 98 lysine residues of human fibrinogen
(Henschen and Lottspeich, 1980). The cleaved residues are present in clusters within
the Ace, B(3 and y chains of human fibrinogen (Henschen and Lottspeich, 1980)
(figure 1.8).
Plasmin is also able to degrade several extracellular matrix (ECM) basement
membrane components such as fibronectin, laminin, vitronectin, and proteoglycans
(Richardson et. al, 1988; reviewed by Werb, 1997). However, plasmin alone is not
sufficient for the complete degradation of the ECM. A significant proportion of the
plasmin catalysed ECM degradation, is indirect and brought about by the plasminmediated activation of matrix pro-metalloproteases (pro-MMP's) such as pro-MMPl,
-3, -9 and -14 (reviewed by Werb, 1997; Gordon et. al, 1993). Thus, plasmin has
been effectively used for the detachment and disaggregation of cells in tissue culture
(Muranova et. al, 1998).
Other substrates of plasmin include: the complement components Cl, C3 and
C5 (reviewed by Werb, 1997), tenascin-C (Gundersen et. al, 1997) and aggrecan (Poe
et. al, 1992). Plasmin is also responsible for the activation and release of growth
factors such as transforming growth factor P (TGF-P; reviewed by Werb, 1997).
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1.1.1.9 Plasminogen summary
In summary, glu-plasminogen is a multi-domain protein. The heavy chain of
glu-plasminogen is composed of the NTP and five kringle domains, which contain the
LBS motifs of the protein. The NTP and the kringle LBS motifs of glu-plasminogen
regulate the lysine-dependent conformation of zymogen and thus regulate its
activation. The tertiary conformation of glu-plasminogen is very dynamic and
dependent upon the interaction of lysine with the LBS motifs of the protein and Cl".
The interaction of lysine residues with the kringle domains of glu-plasminogen
stabilises their structures. The majority of the time glu-plasminogen exists in vivo in
the closed activation resistant conformation. The interaction of glu-plasminogen with
exogenous lysine residues via its LBS motifs increases the activation of gluplasminogen by changing the conformation of the protein thereby converting it into a
better substrate for the mammalian plasminogen activators. This results in the
formation of the active protease plasmin. The closed "activation resistant"
conformation

of

glu-plasminogen

is physiologically

beneficial, since this

conformation retards the formation of broad-spectrum protease plasmin at
inappropriate sites or times. Thus, the lysine-dependent binding of glu-plasminogen to
either the cell-surface, or the fibrin clot may modulate the biological activity of this
protease by inducing the above mentioned conformational changes in the molecule. In
addition to modulating the conformation and activation of glu-plasminogen, the heavy
chain of glu-plasminogen targets the trypsin-like proteolytic activity of the protease
domain (light chain) to correct physiological substrates such as thrombi.

1.1.2 The Plasminogen Activators
Four major enzymes are responsible for the activation of plasminogen. These
include two mammalian proteins: uPA and tPA, as well as the two bacterial
plasminogen activators: streptokinase and staphylokinase. The mammalian
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plasminogen activators will be reviewed briefly here. The mammalian plasminogen
activators, uPA and tPA share approximately 40% amino acid sequence homology
(Degen et. al, 1986). Both of the mammalian plasminogen activators share the
following functional domains: [1] an N-terminal growth factor-like domain, which is
homologous to the receptor-binding regions of epidermal growth factor (EGF) and
transforming growth factor alpha (TGF-a) (Gunzler et. al, 1982; Derynck et. al,
1984; Komoriya et. al, 1984), [2] a single kringle structure and, [3] the C-terminal
serine protease catalytic domain of the molecules (Strassburger et. al, 1983). In
addition, tPA has a second kringle domain, which is homologous to kringle 4 of
plasminogen that it uses to bind to fibrin (Verheijen et. al, 1986; Ichinose et. al,
1986) as well as an additional 43 N-terminal amino acids.
1.1.2.1 Urokinase-type plasminogen activator.
The u P A gene is located on chromosome 8 (Rajput et. al, 1985). Urokinase is
synthesised and secreted as single chain zymogen termed sc-uPA and has a half-life in
the plasma of approximately 10 minutes (Fletcher et. al, 1965). Similarly,
recombinant sc-uPA has a short half-life of only 3.5 min in vivo (Collen et. al, 1984).
Plasmin, (Wun et. al, 1982; Blasi et. al, 1987), kallikrein (Eaton et. al, 1984),
trypsin (Ichinose et. al, 1986), factor XII (Wun et. al, 1982) and human lung mast
cell tryptase (Stack and Johnson, 1994) catalyse the activation of sc-uPA by cleaving
its Lys158-Ile159 activation bond (Marcotte et. al, 1992). However, plasmin appears to
be the most efficient (Wun et. al, 1982; Andreasen et. al, 1986). The light-chain (24
kDa) and heavy-chain (30 kDa) of activated twin chain-uPA (tc-uPA) are connected
by a single disulfide bond. The proteolytic activity of tc-uPA is meditated by the
catalytic triad of Asp275, His224 and Ser276 (Pollenen et. al, 1991). Further cleavage of
tc-uPA by plasmin results in the active 33 kDa protein that lacks the growth factorlike domain (Barlow et. al, 1981).
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It is commonly accepted that tc-uPA is the active conformation of the enzyme
since, it has the ability to hydrolyze small synthetic chromogenic substrates,
incorporate diisopropylfluorophosphate (DFP) and react with physiological inhibitors
(Andreasen et. al, 1986; W u n and Reich, 1987; W u n et. al, 1982; Nielsen et. al,
1982). In contrast, sc-uPA is accepted as the zymogenic form of u P A since it does not
significantly interact with the small chromogenic substrates ( W u n et. al, 1982), it
does not bind D F P ( W u n et. al, 1982; Nielsen et. al, 1982) and it does not interact
with the physiological inhibitors of the plasminogen activators ( W u n and Reich,
1987; Andreasen et. al, 1986). However, evidence is emerging that sc-uPA m a y also
catalyse the activation of glu-plasminogen under certain physiological conditions,
even though the catalytic efficiency (kca/Km) of tc-uPA is 200-1000 fold higher for
plasminogen than sc-uPA (Gurewich, 1988a, 1988b). This intrinsic activity of sc-uPA
and is substantially higher than other protease zymogens (Gertler et. al, 191 A; Pannell
and Gurewich, 1987). Lysine-dependent binding of sc-uPA to glu-plasminogen m a y
be essential for the activation of glu-plasminogen by

sc-uPA. e-ACA, at

concentrations that induce the open conformation of glu-plasminogen, facilitates the
activation of glu-plasminogen by sc-uPA (Urano et. al, 1988). In contrast,
physiological levels of Cl", which maintain glu-plasminogen in a closed conformation,
inhibit the activation of glu-plasminogen by sc-uPA (Urano et. al, 1988). Thus, the
open conformation of glu-plasminogen m a y be a pre-requisite for its activation by scuPA.
Single chain-uPA has no enzymatic activity when assayed by a low molecular
weight peptide substrate, however, it does catalyse the activation of glu-plasminogen
(Ellis et .al, 1987). This suggests that elements, other than the activation bond of gluplasminogen, m a y be required for the catalytic activity of sc-uPA. Thus, gluplasminogen m a y act as both an effector and as a substrate for sc-uPA (Ellis et. al,
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1987). Glu-plasminogen can bind to sc-uPA, in a lysine-dependent manner, with an
apparent Kd of 50 nM (Ellis et. al, 1999). This lysine-dependent binding of gluplasminogen to sc-uPA may induce a conformational change in glu-plasminogen
necessary for the activation of glu-plasminogen by sc-uPA. The activation of gluplasminogen by sc-uPA is mediated by three distinct phases based on the activation
rate of glu-plasminogen (Liu et. al, 1992). A slow, initial activation phase followed
by an intermediate, rapid activation phase (most rapid phase) and the finally a less
rapid activation phase (Liu et. al, 1992). Taken together, these studies suggest that
the activation of glu-plasminogen by sc-uPA may be dependent on both the lysinedependent conformation of glu-plasminogen as well as the transition of uPA from
single chain to twin chain. Thus, the activation of glu-plasminogen by sc-uPA under
normal physiological condition may be dependent on a lysine-binding event that
facilitates the open, activation-susceptible conformation glu-plasminogen. Single
chain uPA may catalyse the initial activation of lysine-bound glu-plasminogen. Newly
generated plasmin, is thought to act in a positive feedback amplification loop by
activating sc-uPA thereby forming tc-uPA which, in turn, can activate more lysinebound glu-plasminogen (figure 1.1).
At low sc-uPA concentrations, plasmin activates sc-uPA in vitro via a nonstandard Michaelis-Menton model (Longstaff et. al, 1992). The model predicts that
plasmin may exist in two distinct conformations, firstly, a lower activity conformation
where a LBS motif of plasmin is unoccupied or a higher activity conformation
induced by the binding of sc-uPA to a LBS motif of plasmin (Longstaff et. al, 1992).
Thus, lysine-bound plasmin is more efficient at converting sc-uPA to tc-uPA.
Once formed plasmin, converts sc-uPA into the more catalytically active
isomer tc-uPA by cleavage of the Lys158-Ile159 activation bond of sc-uPA (Marcotte et.
al, 1992) resulting in lys158 becoming the C-terminal lysine residue of the A-chain of
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uPA (lys-uPA). However, uPA, isolated from the urine has phenylalanine as the Achain C-terminal residue (phe-uPA). There is a 1.6 fold decrease in the K for the in
m

vitro activation of glu-plasminogen by lys-uPA compared to phe-uPA (Table 1.2;
Lenich et. al, 1991). This suggests that the binding of glu-plasminogen to the Cterminal lysine residue of tc-uPA induces a lysine-dependent conformational change
to glu-plasminogen, which transforms it into a better substrate for activation. The
lysine-dependent interactions of glu-plasminogen, which influences its conformation,
modulate its activation by both sc-uPA, tc-uPA as well as the activation of uPA by
plasmin.
1.1.2.2 Tissue-type plasminogen activator
Tissue-type plasminogen activator is a 68 k D a serine protease that displays
high substrate specificity for plasminogen (Bachmann and Kruithof, 1984). The gene
that encodes tPA is located on chromosome 10 (Rajput et. al, 1985). Endothelial cells
are the primary source of tPA and release the molecule into the blood where it is
maintained at a concentration between 5-50 ng/ml (Rijken et. al, 1984; Nilsson et.
al, 1985). Once secreted into the blood tPA has a half-life of approximately 2 mins
(Matsuo, 1982; Fuchs et. al, 1985; Emeis et. al, 1985; Nilsson et. al, 1985).
In a similar manner to uPA, tPA exists as both a single chain (sc-tPA) and a
twin chain (tc-tPA) isomer. Plasmin cleavage of the Arg275-Ile276 peptide bond of sctPA concerts sc-tPA into tc-tPA. Other proteases such as factor Xa and tissue
kallikrein can also convert sc-tPA into tc-tPA (Ichinose et. al, 1984). In contrast to
uPA, the catalytic efficiency of sc-tPA is only 5-10 fold lower than the catalytic
efficiency tc-tPA (Tachias and Madison, 1996). Furthermore, sc-tPA is able to bind
DFP and is active when assayed with synthetic tripeptide substrates (Wallen et. al,
1983). Both sc-tPA and tc-tPA, in the absence of fibrin, display Michalis-Menton
kinetics for the activation of glu-plasminogen, although tc-tPA possesses the greater
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activity (table 1.2; Ranby, 1982; Bauchmann and Kruitof, 1984). However, at low
glu-plasminogen substrate concentrations and in the absence of fibrin tc-tPA activates
glu-plasminogen

via

non-linear

(non-Michalis-Menton)

activation

kinetics

(Nieuwenhuizen et. al, 1988; Geppert and Binder, 1992). This suggests that gluplasminogen m a y be modulating the enzymatic activity of sc-tPA. Glu-plasminogen
may act as a modifying binding to the A-chain of tc-tPA via a single site with an
apparent K d of 0.1 u M (Geppert and Binder, 1992). This interaction between tPA and
glu-plasminogen m a y be mediated by the lysine-dependent interaction of K 5 since
mini-plasminogen has comparable affinity for the A-chain of tPA (Geppert and
Binder, 1992).
The contributions of both the single and twin-chain isoforms of the
plasminogen activators m a y be important for the in vivo activation of gluplasminogen, even though the involvement of the single-chain isomers remains
controversial. Nevertheless, it is conceivable that both sc-PA m a y initially convert a
small percentage of glu-plasminogen to plasmin resulting in an amplification
feedback loop, especially when glu-plasminogen is in an activation-susceptible
conformation.
1.1.3 The Plasmin Serine Protease Inhibitor (SERPIN): o2-Antiplasmin
al-Antiplasmin (67 kDa) is the primary serine protease inhibitor (SERPIN)
which inhibits plasmin (Mori and Aoki, 1976; W i m a n and Collen, 1977). It has a
circulating plasma concentration of approximately 1 u M (Mori and Aoki, 1976; Plow
and Collen, 1991). al-Antiplasmin contains 452 amino acids as determined by
protein and D N A sequencing with the PI-PI' bond corresponding to Arg 364 -Met 365
(Wiman and Collen, 1979; Holmes et. al, 1987; Hirosawa et. al, 1988; Sumi et. al,
1989). The a2-antiplasmin gene located on chromosome 17pl3 is 16 kb and contains
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10 exons and 9 introns (Hirosawa et. al, 1988; Kato et. al, 1993). There are four
potential glycosylation sites at Asp87, Asp256, Asp270 and Asp277 and two disulfide
bonds Cys64-Cys104 and Cys31-Cys113 (Holmes et. al, 1987). Circular dichorism studies
of a2-antiplasmin in the far UV region suggests that it is composed of 16% a-helix,
18% P-structure and 66% random coil (Nilsson et. al, 1982). A higher molecular
weight a2-antiplasmin with an additional 12 amino acids at the N-terminal end of the
molecule has been isolated from plasma and this may represent the full-length form of
oc2-antiplasmin (Sumi et. al, 1989; Bangert et. al, 1993; Enghild et. al, 1993). a2-

Antiplasmin has three domains that are important for its function as a regulator of th

plasminogen activation cascade: [1] the plasminogen binding site, [2] the fibrin crosslinking site and [3] the reactive centre loop (RCL).
The inhibition of plasmin by a2-antiplasmin is a two-step process that
involves lysine-dependent binding followed by classic serpin inhibition of the
protease. In the initial interaction, a2-antiplasmin binds to plasmin in a rapid,
reversible, lysine-dependent, second-order reaction mechanism. The second step of
the inhibition reaction involves the slower irreversible first-order reaction between
reactive centre loop (RCL) of oc2-antiplasmin and the active site of plasmin (Wiman
and Collen, 1978).
The initial lysine-dependent inhibition step of plasmin by a2-antiplasmin is
mediated by the LBS of KI binding to the C-terminal lysine residue (i.e. Lys491) of
a2-antiplasmin (Wiman et. al, 1979). For example, incubation of a fibrin clot with
glu-plasminogen, a2-antiplasmin, Kl-3 and either uPA or tPA decreases the plasminmediated lysis time of the fibrin clot by competitively inhibiting the interaction
between oc2-antiplasmin and plasmin (Sugiyama et. al, 1987). In contrast, incubation

of the fibrin clot with plasminogen, oc2-antiplasmin, either uPA or tPA in the presence
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of K4 does not decrease fibrin clot lysis time (Sugiyama et. al, 1987). Thus, oc2antiplasmin competitively inhibits the Kl-3, lysine-dependent binding of gluplasminogen binding to fibrin thereby delaying the onset of plasmin-mediated
proteolysis (Aoki et. al, 1978; Rakozi et. al, 1978). This suggests that the KI LBS
plasminogen mediates the binding of plasminogen to cc2-antiplasmin. However, K4
and K5 domains of plasminogen also bind to a2-antiplasmin with apparent Kd of 0.18
and 9 |iM respectively (Wiman et. al, 1979). In addition, Lys475 (internal lysine
residue) and the C-terminal lysine residue of a2-antiplasmin both appear to be
involved in the lysine-dependent binding of serpin to plasmin (Sugiyama et. al,
1988). This suggests that the lysine-dependent interaction of oc2-antiplasmin may not
be attributed to just a single LBS of plasmin(ogen). Using midiplasmin (plasmin
lacking Kl-3), Christensen et. al, (1995) has suggested that the lysine-dependent
binding inhibition phase of bovine plasmin by bovine a2-antiplasmin may be
mediated by both K4 and K5. Consequently, oc2-antiplasmin appears to bind to
plasmin(ogen) at the same sites as fibrin, ECM or cell-surface plasminogen binding
proteins (Plow et. al, 1986; Sugiyama et. al, 1988; Hortin et. al, 1989).
The inhibition rate of plasmin by oc2-antiplasmin is modulated 10-fold by the
lysine-dependent interaction of plasmin with oc2-antiplasmin. The reversible lysinedependent a2-antiplasmin inhibition constant of plasmin is 5xl0"10 M (Edelberg and
Pizzo, 1992). However, under conditions where the plasmin kringle-cc2-antiplasmin

interaction is blocked, the reversible oc2-antiplasmin inhibition constant is increase
from 5xl0"10 to 5xl0"9 M (Edelberg and Pizzo, 1992). Thus, lysine-dependent
interactions of glu-plasminogen are important not only for the activation of gluplasminogen but also for its inhibition.
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1.1.4 Plasminogen Activator Inhibitor-type 1 and 2.
The plasminogen activator inhibitor serpins, PAI-1 and PAI-2, add a further
dimension of control to the plasminogen activation system by specifically inhibiting
the plasminogen activators uPA and tPA. PAI-1 is the predominant inhibitor of uPA
and tPA which function in both fibrinolysis and tissue remodeling (Carmeliet et. al,
1993a,b). It is a 52 kDa molecular weight glycoprotein (Colman et. al, 1982;
Loskutoff et. al. 1983; van Mourik et. al, 1984) that has three potential N-linked
glycosylation sites but no disulfide bonds. The reactive centre PI-PI' bond is Arg346Met347 (Ginsberg et. al, 1986; Ny et. al, 1986; Pannekoek et. al, 1986; Andreasen et.
al, 1986).
The PAI-1 gene has been localised to chromosome 7q21.3-q22 (Ginsburg et.
al, 1986) and the protein is synthesised and secreted by endothelial cells, platelets,
megakaryocytes and heptatocytes (Schleef and Loskutoff, 1984). The plasma
concentrations of PAI-1 are approximately 20 ng/ml, but may be enhanced at sites of
vascular damage by the release of the inhibitor from platelets (Erikson et. al, 1984;
Booth et. al, 1988; Juhan-Vague et. al, 1984). PAI-1 is able to inhibit sc-tPA, tc-tPA
and tc-uPA, however, it cannot inhibit sc-uPA (figure 1.1; Kruithof et. al, 1986).
PAI-1 inhibit tc-tPA by only interacting with the protease domain of tPA (Bjorquist
et. al, 1994).
The PAI-2 gene is located on chromosome 18q21.3 and encodes a 415 amino
acid protein with a characteristic SERPIN reactive centre (Pl-Pl') bond formed by
Are -Thr (Kruithof et. al, 1986; Schleuning et. al, 1987; Ye et. al, 1987; Antalis
O380
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et. al, 1988; Kiso et. al, 1988). Physiologically, PAI-2 is synthesised by numerous
tissues including the placenta (reviewed by Kruitoff et. al, 1995). Hence, the
distribution of PAI-2 is widespread under normal physiological conditions. PAI-2
exists in two distinct molecular forms; an extracellular glycosylated 60 kDa protein
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and the more abundant intracellular non-glycosylated 47 kDa protein (Genton et. al,
1987; Christensen et. al, 1982; Mikus et. al, 1993). Both forms of PAI-2 efficiently
inhibit the activity of tc-uPA (Mikus et. al, 1993; Kruithof, 1988; Kruithof et.
al, 1995). PAI-2 rapidly inhibits both tc-uPA and tc-tPA by forming S D S stable 1:1
protease/inhibitor complexes (figure 1.1; Kruithof et. al, 1986). In contrast, PAI-2
reversibly inhibits solution-phase sc-uPA in a concentration-dependent, non-SDSstable manner (figure 1.1; Schwartz, 1994).
1.1.5 Urokinase-type plasminogen activator receptor (uPAR)
Urokinase interacts at a single, saturable, specific site on the surfaces of
numerous nucleated cell types (Vassille et. al, 1985; Neilson et. al, 1988; Chapman
et. al, 1990; Stoppelli et. al, 1985; Bajpai and Baker, 1985; Plow et. al, 1986; Boyd
et. al, 1988). The urokinase plasminogen activator receptor (uPAR) binds both scu P A and tc-uPA with apparent high affinity (Kj 10"10-10"9 M ; Cubellis et. al, 1986).
The human 23 kb u P A R gene has been isolated to chromosome 19ql3 (Borglum et.
al, 1992). The gene is transcribed into a 1.4 K b m R N A which encodes a 313 amino
acid polypeptide (Roldan et. al, 1990). The 50-60 k D a highly glycosylated, single
chain, cell-surface u P A R molecule (Neilson et. al, 1988; Behrendt et. al, 1990) is a
glycosyl-phosphatidyl-inositol (GPI) linked glycoprotein that consists of three distinct
functional domains. Post-translational modification of u P A R involves removal of 30
amino acids from the C-terminal of the molecule in the endoplasmic reticulum as well
as the addition of the G P I moiety on residues 282, 283 or 284 (Plough et. al, 1991).
This hydrophobic G P I moiety is responsible for anchoring u P A R to the extracellular
surface of the plasma membrane (Plough et. al, 1991). A n alternatively spliced
variant of h u m a n u P A R m R N A (designated u P A R 2 ) has been isolated from H T 1 0 8 0
cells which is devoid of G P I anchor domain and thus can not bind to cell surfaces
(Pyke et. al, 1993).
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Secreted sc-uPA binds to its receptor via its growth factor domain (GFD)
(residues 4-43), which is contained within the amino terminal fragment of uPA (ATF)
(residues 1-135) in an autocrine manner where it can be activated by plasmin
(Cubellis et. al., 1986; Stoppelli et. al, 1985; Stoppelli et. al, 1986; Appella et. al,
1987). The binding of uPA via its ATF to uPAR does not influence the activity of
bound uPA (Ellis and Dano, 1991) since the ATF, kringle and protease domains
display a high degree of independence (Bogusty et. al, 1989; Oswald et. al, 1989).
Thus, the protease domain of receptor-bound uPA functions independently at the cell
surface. However, the binding of sc-uPA to uPAR enhances the activation rate of the
molecule by plasmin (Ellis et. al, 1989). Oleic acid, which is the most abundant free
fatty acid in plasma, inhibits the binding of sc-uPA to u P A R under physiological
concentrations of oleic acid (Higazi et. al, 1996).
Receptor-bound, active, tc-uPA is prone to inactivation by PAI-1 and PAI-2
(Andreasen et. al, 1990; Baker et. al, 1990; Ellis et. al, 1990). In contrast, receptorbound sc-uPA (which has low enzyme activity) is refractory to inhibition by PAI-2,
whereas, solution-phase sc-uPA is susceptible to inhibition by PAI-2 (Schwartz,
1994). Therefore, the initial activation of glu-plasminogen by cell-surface sc-uPA
may occur in a PAI-2 rich pericellular environment. Thus, cells that express surface
uPAR have a mechanism whereby they can selectively capture sc-uPA, activate and
inhibit the proteolytic activity of tc-uPA within a pericellular environment.

1.2 Plasminogen binding.
As

described previously

(section

1.1), the relationship between the

conformation of glu-plasminogen and its activation rate has been established in vitro
using small lysine analogues. Whilst lysine analogues provide good models that
describe the type of lysine residues within proteins responsible for the binding and
activation of glu-plasminogen, they do not provide information about the spatial
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relationships of lysine residues within a protein required to facilitate the lysinedependent conformational changes in glu-plasminogen. Physiologically, the lysine
residues responsible for binding glu-plasminogen are located within proteins such as
fibrin and the cell-surface plasminogen receptors.
Since the occupancy of the LBS motifs by lysine residues of the NTP
maintains the closed conformation of solution-phase glu-plasminogen (section
1.1.1.5) the lysine-dependent binding of glu-plasminogen to proteins is hypothesised
to involve a competition reaction between the lysine residues of these proteins and the
lysine residues of the NTP of glu-plasminogen for the LBS motifs of the kringle
domains of glu-plasminogen. Thus, the lysine-dependent binding of glu-plasminogen
to the plasminogen binding proteins may result in disruption of the intramolecular
lysine-binding network glu-plasminogen leading to an increase in its activation rate.
Proteins that bind glu-plasminogen in a lysine-dependent manner may be
classified into two groups based on the types of lysine residues pre-existing within the
protein. Group 1 plasminogen binding proteins possess a pre-existing C-terminal
lysine residue, whilst group 2 plasminogen binding proteins do not have a pre-existing
C-terminal lysine residue (e.g. intact fibrin). Whilst many ECM proteins are able to
bind glu-plasminogen in a lysine-dependent manner, the following section will be
limited to a detailed discussion of the plasma plasminogen binding proteins fibrin,
tetranectin and histidine-rich glycoprotein as well as the cellular plasminogen
receptors such as a-enolase. Each of these plasminogen binding proteins typically
have low affinity for glu-plasminogen (Kd between 1-2 uM).

1.2.1 Fibrin
Fibrinogen (factor I; 330 k D a ) is a soluble plasma glycoprotein present at 3
mg/ml and consisting of three non-identical pairs of polypeptide chains designated as
Aa, Bp and y covalently linked by 29 disulfide bonds (reviewed by Doolittle, 1981;
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Doolittle, 1984). The N-terminal regions of fibrinogen polypeptides are held in close
proximity to each other by interchain disulfide bonds (central domain), whilst the Cterminal domains (terminal domains) of the fibrinogen polypeptide chains are
separated by a distance of approximately 47.5 nm (figure 1.9). Thus, fibrinogen has
an asymmetrical elongated structure. The N-terminal regions of the Aa and BP chains
of fibrinogen are designated as fibrinopeptides A (FPA) and B (FPB), respectively,
and are released after fibrinogen is cleaved by thrombin (reviewed by Doolittle,
1984). Removal of the FPA and FPB domains of fibrinogen by thrombin exposes
fibrin binding sites that induce the spontaneous aggregation of fibrin monomers into a
regularly staggered array forming the fibrin clot (reviewed by Doolittle, 1984).

60/
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150 A

Terminal
Domain
(67.2 kDa)

Central Domain
(32.6 kDa)

Terminal
Domain
(67.2 kDa)
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50 A
Plg/tPA Binding (Lys157)

Plg/tPA Binding (Lys157)

A a chain

COO
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Figure 1.9: A schematic representation of fibrinogen.
A schematic representation of fibrinogen (not drawn to scale) showing pairs of A a , B P and y chains linked
by disulfide bonds. Fibrinopeptide A (FPA) andfibrinopeptideB (FPB) are cleaved from fibrinogen by
thrombin (Th) from the A a and B P chains respectively. Plg/tPA and a2-AP denotes the plasminogen/tPA
binding site of Lys 157 and the Glu322 transglutamination site of the A a chain respectively (modified from
Murry et. al, 1990).
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Glu-plasminogen binds with low affinity to intact fibrin in vitro in a lysinedependent manner with an apparent Kd of either 45 or 24 uM (Suenson and Thorsen,
1981). Both small lysine analogues and proteolytic fragments of plasminogen (Kl-3,
K4, K5-protease domain (mini-plasminogen) and protease domain (microplasminogen), have been used to identify the kringles domains of plasminogen
responsible for binding intact fibrin (Thorsen et. al, 1981; Suenson and Thorsen,
1981; Wu et. al, 1990). The LBS of K4 does not significantly bind to either intact
fibrin (Thorsen et. al, 1981) or CNBr fragments derived from fibrin (Wu et. al,
1990) and therefore probably does not mediate the initial interaction of glu- or lysplasminogen with fibrin. The two lysine-dependent fibrin binding sites located in Kl3 and mini-plasminogen bind to intact fibrin (Thorsen et. al, 1981; Suenson and
Thorsen, 1981; Wu et. al, 1990). However, mini-plasminogen binds with high
affinity to both intact (Thorsen et. al, 1981; Suenson and Thorsen 1981) and CNBr
fragments of fibrin (Wu et. al, 1990). Furthermore, mini-plasminogen inhibits the
binding of glu- or lys-plasminogen to fibrin (Wu et. al, 1990). Thus, K5 of
plasminogen may represent the major LBS responsible for localising glu-plasminogen
to intact fibrin. The Kl-3 fragment of plasminogen binds with low affinity to both
intact and CNBr fragments of fibrin. However, Kl-3 did not effectively inhibit the
binding of glu- or lys-plasminogen to fibrin (Wu et. al, 1990). These studies suggest
that Kl-3 and K5 mediate the binding of glu-plasminogen to fibrin, with the K5 LBS
contributing the most to the lysine-dependent interaction of glu-plasminogen to intact
fibrin.
The Aa, BP and y chains of intact fibrin/fibrinogen do not contain C-terminal
lysine residues (Henchen and Lottspeich, 1980) and as such may be catagorised as
group 2 plasminogen binding proteins. The LBS of K5 displays a preference for small
lysine analogues that mimic internal lysine residues of proteins and, as suggested

Chapter 1: Biology of plasminogen binding, conformation and activation

49

above, may be responsible for the initial interaction of glu-plasminogen with fibrin

via an internal lysine residue (table 1.1; Christensen, 1984; Ponting et. al, 1991). Ly
plasminogen and active site inhibited glu-plasmin and lys-plasmin, in which the K5
LBS motifs are unoccupied and available (Marshall et. al, 1994), all have higher
lysine-dependent affinity for fibrin than glu-plasminogen (Lucas et. al, 1983;
Suenson and Thorsen, 1981).
At least two sites on polymeric fibrin are involved in the enhancement of gluplasminogen activation, a site on the Aa-chain between amino acids 148-160 and a
site on the 7-chain between amino acids 311-379 (Nieuwenhuizen, 1994). These sites
are not accessible in fibrinogen but are exposed upon conversion of fibrinogen into
fibrin (Nieuwenhuizen, 1994). The presence of Lys157 of the Aa chain of fibrin
enhances the tPA mediated glu-plasminogen activation rate (Voskuilen et. al, 1987).
Thus, Lys157 of the Aa of fibrin may represent an internal lysine residue candidate
responsible for the initial interaction of glu-plasminogen via K5 or the lysine-

dependent binding of tPA to intact fibrin (Voskuilen et. al, 1987; figures 1.8 and 1.9
Thus, the low affinity LBS of K5 is probably responsible for the initial lysinedependent interaction of glu-plasminogen with fibrin.
The lysine-dependent binding of glu-plasminogen to fibrin is complicated by
the fact that partial plasmin degradation of fibrin creates new C-terminal lysine
binding sites for glu-plasminogen. The fibrin fragments released by plasmin digestion
of intact fibrinogen (340 kDa) have been determined by SDS-PAGE analysis (figure
1.10). Fragment X (250 kDa) is the first fragment observed, further digestion in the
coil-coil region of fragment X induces the removal of a 10 kDa fragment and results
in the production of fragment Y (150 kDa) and fragment D (90 kDa). Continued
plasmin digestion of the coil-coil region of fragment Y results in the formation of
another fragment D (90 kDa) and the 50 kDa E fragment (figure 1.10 Doolittle, 1984;
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Budzynski and Marder, 1977). Thus, the end-products of this asymmetric plasmin
degradation pathway is the formation of two fragments of D and one fragment of E
molecules from each molecule of fibrinogen.
A detailed map of the plasmin cut sites of fibrinogen has been developed by
comparing the plasmin digestion products of fibrinogen characterised by N-terminal
amino acid sequencing from numerous studies to the sequences of the Aa, BP and y
chains of intact fibrinogen (Henschen and Lottspeich, 1980; figure 1.8). Due to the

Figure 1.10: The plasmin cleavage fragments offibrin(ogen).Reproduced from Doolittle, 1981.

coil-coil structure of fibrinogen, clusters of multiple plasmin digestions are required
for the fragmentation of fibrinogen. The early plasmin cleavages of the Aa, Bp and ychains of fibrin(ogen) result in the formation of new C-terminal lysine residues within
the protein but may not result in the fragmentation of fibrin(ogen). Thus, plasmin
cleavages, insufficient for the fragmentation of fibrin(ogen) would create new C-
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terminal lysine residues that may bind the LBS motifs of glu-plasminogen which
display a preference for C-terminal lysine analogues such as KI. These newly formed
C-terminal lysine residues are essential for the high affinity binding of gluplasminogen to partially plasmin-degraded fibrin (Christensen, 1985). Plasmin
digestion of fibrin decreases the apparent Kd of glu-plasminogen binding whilst
increasing the total number of plasminogen binding sites on fibrin (Fleury and
Angles-Cano, 1991). Furthermore, both tPA and uPA induce an increase in the
binding capacity of fibrin that was dependent upon the incubation time as well as the
concentrations of glu-plasminogen and the plasminogen activators (Harpel et. al,
1985) suggesting that the plasminogen activators indirectly regulate the binding of
glu-plasminogen via glu-plasminogen activation. Therefore partially degraded fibrin
has a higher affinity for glu-plasminogen than intact fibrin. The overall interaction of
glu-plasminogen with fibrin may be a two step process. The initial lower affinity
interaction of glu-plasminogen with fibrin may be via K5 binding to an internal lysine
residue of fibrin. Thus, the plasmin creation of C-terminal lysine residues results in
higher affinity interactions of glu-plasminogen. possibly mediated by the LBS of KI.
Plasmin digestion of the central coil-coil region of fibrinogen results in the
formation of fragment E (figures 1.8, 1.9, 1.10). This fragment binds lys-plasminogen
in a lysine-dependent manner (Varadi and Patthy, 1984). Thus, a lysine residue in this
domain is hypothesised to bind plasminogen. However, the thermostable domain
(TSD) of fibrinogen, a fragment consisting of the terminal part of the E fragment
connected to the D fragment of the fibrinogen y-chain (Medved et. al, 1982; Doolitle
et. al, 1978; figures 1.8, 1.9, 1.10) binds the Kl-3 but not the K4 or miniplasminogen fragments of plasminogen (Lezhen et. al, 1986). This suggests that the
Kl-3 LBS of glu-plasminogen binds to a lysine residue within the TSD domain of
fibrin.
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The transition of fibrin from a class 2 plasminogen binding protein (no Cterminal lysine residues) to a class 1 plasminogen binding protein (C-terminal lysine
residues) is associated with an increase in its affinity for glu-plasminogen that induces
an acceleration of its activation rate. Both glu-plasminogen and tPA (via K2) bind to
the fibrin clot in a lysine-dependent manner. In addition, tPA also binds to fibrin via
its fibronectin finger (Pennica et. al, 1983; de Vries et. al, 1989). The lysinedependent binding of glu-plasminogen to fibrinogen or CNBr-fragments of
fibrinogen, in the presence of tc-tPA, increases the activation rate of glu-plasminogen
by increasing the kcat of the reaction (table 1.2; Hoylaerts et. al, 1982; Stack et. al,
1990). Thus, the C-terminal independent binding of glu-plasminogen to fibrinogen
increases the kcat thereby accelerating the activation of the zymogen. In contrast, the
lysine-dependent binding of glu-plasminogen to fibrin decreases the Km of tc-tPA
(table 1.2; Ranby, 1982; Tachias et. al. 1996) induced glu-plasminogen activation and
may be associated with a more complete change to the conformation of gluplasminogen. The magnitude of glu-plasminogen activation rate enhancement is
dependent on the species of fibrinogen present (i.e. fragment D> fragment E> fibrin>
fibrinogen) (Allen and Pepper, 1981; Hoylaerts et. al, 1982; Lucas et. al, 1983). This
suggests that plasmin fragments of fibrin with C-terminal lysine residues present may
induce the fully open, activation-susceptible conformation of glu-plasminogen. The
fundamental reason the fibrin clot acts to stimulate the glu-plasminogen activation
cascade is because it can efficiently co-localise in a lysine-dependent manner both
glu-plasminogen, in an activation susceptible conformation, and tPA. Thus, lysinedependent binding events are essential to the correct physiological outcome of
fibrinolysis.
Glu-Plasmin is probably the major plasmin species present on the fibrin clot
surface as a result of in vivo plasminogen activation. However, Rouy and Angles-
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Cano (1990), using plasminogen-depleted plasma and an artificial system consisting
of tPA and a2-antiplasmin have shown that glu-plasmin is responsible for the lysis of
the clot. Furthermore, complexes of glu-plasmin and a2-antiplasmin are found in the
clot lysis solution (Rouy and Angles-Cano, 1990; Harpel et. al, 1985). Hence, the
presence of a2-antiplasmin in the fibrin clot milieu prevents the plasmin-mediated
over processing of glu-plasmin to lys-plasmin. Harpel et. al, (1985) that gluplasminogen was the molecular form of plasminogen bound to fibrin in plasma.
Similarly, only low levels of lys-plasminogen were consistently detected in the
plasma of patients that were receiving therapeutic doses of tPA (Holvoet et. al,
1985). Thus, under physiological conditions, glu-plasmin is the major fibrinolytic
agent on the fibrin clot surface and lys-plasminogen is not a major physiological
intermediate required for the formation of plasmin at the surface of a blood clot.
1.2.1.1 Inhibitors of fibrinolysis
Agents that modulate fibrinolysis include the serpins a2-antiplasmin, PAI-1
and PAI-2. Plasma and platelets trapped within the blood clot are the primary sources
of PAI-1, a2-antiplasmin and factor XIII available to the thrombus for the inhibition
of fibrinolysis (Reed et. al, 1992). Other agents responsible for modulating
fibrinolysis by inhibiting the binding of glu-plasminogen to fibrin include histidinerich glycoprotein, tetranectin and carboxypeptidases (figure 1.11).
a2-Antiplasmin regulates fibrinolysis by directly inhibiting glu-plasmin in a
lysine-dependent manner since e-ACA significantly reduces the inhibition of plasmin
by a2-antiplasmin (Wiman and Collen, 1978; Longstaff and Gafney, 1992). This
suggests that lysine-dependent binding of plasmin to a substrate decreases the
inhibitory ability of a2-antiplasmin for plasmin. Thus, for the efficient inhibition of
plasmin, a2-antiplasmin must bind in a lysine-dependent manner to the protease.
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Therefore, plasmin bound to fibrin via KI is refractory to inhibition by «2antiplasmin since the a2-antiplasmin LBS motif of plasmin is occupied (Plow et. al,
1986; Sugiyama et. al, 1988; Hortin et. al, 1989). Furthermore, a2-antiplasmin may
also compete with fibrin for the KI LBS motif of plasmin. However, approximately
30% of a2-antiplasmin from plasma does not have the C-terminal lysine residue
required to bind plasminogen/plasmin and m a y represent a pool of enzyme that has

Figure 1.11: T h e blood vascularfibrinolyticcascade.
Both glu-plasminogen (Pig) and tPA are able to bind to the thrombus via thefibrin-associatedlysine residues
of the blood clot (•). The plg-tPA-fibrin ternary complex provides an ideal environment for the activation of
plasmin (Pn). Once formed plasmin readily degrades the fibrin clot which results in the restoration of
vascular integrity. After vascular integrity has been restored,fibrin-dissociatedplasmin is rapidly inhibited
by circulating a2-antiplasmin (a2-AP) in a lysine-dependent manner. The lysine-dependent binding of gluplasminogen to the surface of thefibrinclot shields bound plasmin from inactivation by a2-antiplasmin.
However, a2-antiplasmin m a y be N-terminally transglutaminated to the clot surface by factor X H I and thus
m a y shield the clot from dissolution by plasmin. Lipoprotein (a) (Lp(a)) m a y compete with plasminogen for
lysine residues of the thrombus, thereby reducing the amount of plasminogen bound to the blood clot. Other
modifications to the thrombus that stabilise it against degradation by plasmin include the removal of
thrombus-lysine residues (•) by circulating carboxypeptidases (CPN, C P B , C P U ) . Finally, circulating
plasminogen binding proteins such as histidine-rich glycoprotein ( H R G ) and tetranectin (TN) m a y modulate
fibrinolysis by sequestering plasminogen from the plasma in a lysine-dependent manner.

reduced plasmin inhibitory capacity (Clemmensen et. al, 1981 and Kluft and Los,
1981).
a2-Antiplasmin may also retard fibrinolysis by binding to the fibrin clot and
shielding it from digestion by inhibiting plasmin. Approximately 25% of circulating
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a2-antiplasmin is transglutaminated to Glu322 of the Aa chain of fibrin (figures 1.8,
1.9; LU) by factor XIII (Sakata and Aoki, 1980; Sakata and Aoki, 1982; Tamaki and
Aoki; 1981; Tamaki and Aoki; 1982) via Glu2 residue of the serpin (Ichinose et.
al., 1981). However, Lys303 within the Aa chain of fibrin has been identified as another
a2-antiplasmin transglutamination site (Kimura and Aoki, 1986). In this orientation,
the C-terminal lysine residue of a2-antiplasmin may be able to compete with fibrin
for glu-plasminogen binding. Upon activation, plasmin may be inhibited by clot
localised a2-antiplasmin. Thus, transglutamination of a2-antiplasmin to fibrin may
establish an anti-plasmin protective shield at the clot surface.
PAI-1 decreases the rate of fibrinolysis by inhibiting the plasminogen
activators responsible for activating glu-plasminogen. Fibrin bound sc-tPA is
protected from rapid inhibition by PAI-1 (Chmielewska et. al, 1988). However,
fibrin-bound PAI-1 may inhibit tPA-mediated fibrinolysis (Reilly and Hutzelmann,
1992; Wagner et. al, 1989). Thus, the presence of PAI-1 will inhibit glu-plasminogen
activation by inhibiting the action of tPA.
Another possible mechanism for modulating glu-plasminogen activation
during fibrinolysis is by influencing the amount of glu-plasminogen that is available
to bind the fibrin clot (i.e. the amount of glu-plasminogen that is available for
activation and therefore fibrinolysis). Molecules such as histidine-rich glycoprotein
and tetranectin, which reduce the amount of unbound glu-plasminogen in plasma may
modulate fibrinolysis by influencing the availability of glu-plasminogen for binding
to fibrin. Approximately 60% of the circulating levels of glu-plasminogen is available
for activation in situ. The remainder is bound in a reversible, lysine-dependent
manner to HRG (Lijnen et. al, 1980). The use of the anabolic steroid stanozolol
(Kluft et. al, 1984c) induce a decrease in the circulating levels of HRG, thereby
resulting in an increase in the amount of glu-plasminogen available for activation.
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However, a blood clot is estimated to sequester only about 4% of soluble gluplasminogen from the circulation (Rakoczi et. al, 1978). Due to the small amount of
glu-plasminogen that is sequestered by a thrombus it remains unclear whether the
other blood glu-plasminogen binding proteins influence the fibrinolytic rate of the
thrombus.
Approximately 13-17% of the tetranectin present in human plasma does
associate with the fibrin clot in a calcium dependent manner (Kluft et. al, 1989a).
Furthermore, the binding of tetranectin to the fibrin clot is independent of both gluplasminogen and the transglutaminase, factor XIII (Kluft et. al, 1989). In the
presence of poly-D-lysine, tetranectin enhances the rate of glu-plasminogen activation
by t-PA (Clemmensen et. al, 1986), suggesting that a quaternary complex between
fibrin, tPA, tetranectin and glu-plasminogen mediates this effect. Sequestration of gluplasminogen by soluble blood plasminogen binding proteins effects the rate of
plasminogen activation at the thrombus surface in a manner dependent on the local
milieu concentration of these factors.
Finally, inhibition of the ability of the fibrin clot surface to bind both gluplasminogen and tPA down-regulates the clot associated activation of gluplasminogen. Modification of fibrin by plasma carboxypeptidases decreases the
amount of lysine residues available for glu-plasminogen and tPA binding, thereby
stabilising the thrombus (Felez, 1998). For example, the inactive precursor of
caboxypeptidase U circulates bound to glu-plasminogen in the plasma (Wang et. al,
1994). Once activated by plasmin caboxypeptidase U can degrade C-terminal lysine
residues, however, active carboxypeptidase U is very unstable (Wang et. al, 1994).
The regulation of fibrinolysis is multi-facetted, however, central to the
activation of glu-plasminogen is the formation of a lysine-dependent quaternary
complex between the activator, the zymogen, the inhibitor and the substrate. Factors
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that modulate these binding processes fine tune the amount of plasmin activity
associated with the thrombus, thereby permitting a physiologically appropriate
fibrinolytic rate.
1.2.2 The Cell Surface Plasminogen Receptor Candidates
Because

many

cellular processes

(ovulation, blastocyst implantation,

embryonic development, inflammation, w o u n d healing and angiogenesis) require the
utilisation of plasmin by particular cell-types, another major compartment where
plasminogen activation occurs is the cell-surface.
Plasminogen or plasmin can bind both proteinaceous and non-proteinaceous
moieties in a lysine-dependent manner. Non-proteinaceous molecules that have
plasminogen binding capacity include gangliosides (Miles et. al, 1989) and free fatty
acids (Higazi et. al, 1992). Gangliosides are able to bind glu-plasminogen in a
saturable concentration-dependent manner. However, individual components of the
gangliosides are unable to inhibit plasminogen binding to isolated gangliosides or the
plasma membrane of U 9 3 7 cells (Miles et. al, 1989). This suggests that the
plasminogen binding site of the gangliosides m a y be a combination of the individual
components of the molecule.
Oleic acid increases the activation rate of glu-plasminogen by u P A (Higazi et.
al, 1992) and is able to specifically bind plasmin and increase its amidolytic activity
in a saturable and concentration-dependent manner. However, the plasmin stimulatory
activity of oleic acid can be suppressed by the lysine analogue e - A C A (Higazi et. al,
1992).
The cell-surface plasminogen binding proteins have several properties,
namely; saturablility, low affinity, lysine-dependent binding of plasminogen,
acceleration of glu-plasminogen activation and protection of receptor bound plasmin
from inactivation by a2-antiplasmin. The final criteria these plasminogen binding
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proteins must satisfy to be classified as cellular plasminogen receptors is their
localisation and orientation at the cell-surface such that they can bind extracellular
plasminogen in a form that increases the activation rate of glu-plasminogen by cellsurface-associated plasminogen activators. Because cell-surface plasminogen binding
proteins do modulate the rate of glu-plasminogen activation, it is possible that these
receptors facilitate this by lysine-dependent unfolding in a manner similar to small
lysine analogues.
To date nine, mammalian cellular plasminogen receptors and three bacterial
plasminogen receptors have been identified. However, only the mammalian
plasminogen receptors will be discussed below. They typically have a IQ for gluplasminogen ranging from 0.5 to 1.5 |lM (table 1.4). These receptor candidates are a
diverse group of proteins with the only unifying parameter being that they bind
plasminogen in a lysine-dependent manner. Furthermore, only two of the nine known
plasminogen receptors contain a pre-formed C-terminal lysine residue (i.e. cytokeratin
8 and a-enolase; table 1.4). Many of the plasminogen receptors isolated from the
surfaces of mammalian cells have alternative and often more classical functions (with
the notable exception of tetranectin).
1.2.2.1 Actin
Actin is present in all eukaryotic cells (Korn, 1982) and primarily functions as

a cytoskeletal stress fiber in cells. Actin acts as a both an extracellular and cell-surface
plasminogen binding protein (table 1.4). Extracellular actin has been identified as a
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glu-plasminogen binding protein which is able to decrease the rate of fibrinolysis
possibly by competing with fibrin for the kringle LBS motifs of glu-plasminogen
(Lind and Smith, 1991). Cell-surface actin accounts for approximately 45% and 46%
of the total glu-plasminogen and t-PA binding capacity of endothelial cells,
respectively (Dudani and Ganz, 1996), even though intact actin does not contain a Cterminal lysine residue (table 1.4).
Actin stimulates plasmin formation by lowering the Km for the activation of
glu-plasminogen in a lysine-dependent manner (table 1.4; Lind and Smith, 1991).
Actin has a Kd of 0.55 uM for tPA. Partial plasmin digestion of actin facilitates the
simultaneous binding of both glu-plasminogen and t-PA to the molecule presumably
by creating a C-terminal lysine residue at Lys373 (Lind and Smith, 1993; Mornet and
Ue, 1984). Hence, plasmin treated actin may act as a receptor for both gluplasminogen and t-PA thereby facilitating plasminogen activation in a type of positive
feedback loop. Despite this, actin does not increase the proteolytic activity of t-PA
(Lind and Smith, 1993) during plasminogen activation. Although actin does not bind
to tc-uPA, the presence of actin facilitates the activation of glu-plasminogen by tcuPA. In contrast to glu-plasminogen, actin does not increase the uPA-mediated
activation rate of lys-plasminogen (Lind and Smith, 1993). Therefore it appears that
actin (as with the other plasminogen receptor candidates) facilitates glu-plasminogen
activation by inducing a conformational changes in glu-plasminogen from the
activation resistant to the activation susceptible isomer of the molecule.
1.2.2.2 Amphoterin
Amphoterin is a 30 kDa heparin-binding, sulfoglycolipid-binding (Mohan et.
al, 1992) protein that has multiple biological functions primarily associated with the
nervous system. It is a member of the high mobility group-1 (HMG-1) proteins and is
found throughout the different compartments of cells, including the nucleus and the
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substrate-attached material (Merenmies et. al, 1991). Nuclear amphoterin is involved
in DNA transcription regulation (Maher and Nathans, 1996). In cells that are actively

spreading, amphoterin is localised to the extending filopodia of the advancing plasma
membrane (Merenmies et. al, 1991) of highly motile cells (Parkkinen et. al, 1993).
Amphoterin is also a cell-surface antigen in breast tissue (Salmivirta et. al, 1992).
Amphoterin is localised on the extracellular surface of non-permeabilised
cells (Parkkinen et. al, 1993). Amphoterin and tPA are co-localised on the leading
edge filopodia of the N18 neuroblastoma cell line and to the substrate-attached
material (Parkkinen and Ravala, 1991). In vitro plasminogen binding studies
demonstrate that both tPA and glu-plasminogen bind amphoterin in a lysinedependent manner (Parkkinen and Ravala, 1991). Amphoterin-bound tPA accelerates
the activation rate of glu-plasminogen (Parkkinen and Ravala, 1991). Hence,
amphoterin is a plasminogen binding protein which may be localised to the cellsurface of neural cells and possibly breast tissue.
1.2.2.3 Annexin II
A 40 kDa protein that functions as a plasminogen and tPA receptor on the

surfaces of endothelial cells (Hajjar and Hamel, 1990; Hajjar, 1990) was identified as
annexin II (Hajjar et. al, 1994; Cesarman et. al, 1994). Annexin biology has been
extensively reviewed by Gerke and Moss (1997) and Waisman (1995) and will not be

discussed here in detail. Annexins are a family of calcium binding proteins defined by
a 70 amino acid calcium binding structural motif known as the annexin core
(Donnelly and Moss, 1997). Currently, there are nine proteins within this family.
Since annexin II has been identified as a major plasminogen receptor, the remainder
of the discussion will focus on this member of the family. Annexin II, also known as
lipocortin II and can exist as either a monomer or as a hetrotetramer. The latter is
composed of two annexin II (p36) subunits and two S100A10 (pll) subunits (a
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member of the calcium binding S100 protein family). Monomeric annexin II (36 kDa)
can undergo polymerisation in a calcium-dependent manner forming heterotetrameric
annexin II and is present on the plasma membranes of numerous cell types (Gerke and
Moss 1995; Waisman 1995).
Human tetrameric annexin II is a class 2 plasminogen binding protein since it
does not posses a C-terminal lysine residue and partial degradation of annexin II is
required for maximal plasminogen binding (Hajjar et. al, 1994). The tPA/glu-

plasminogen binding protein annexin II tetramer substantially inhibits the fibrinolyti

activity of plasmin but, it does not inhibit the collagenolytic activity of plasmin (C

et. al, 1998). Thus, the plasmin inhibitory activity of annexin II tetramer is dependen
on the presence of fibrin. Choi et. al, (1998) suggests that the fibrin dependent

plasmin inhibitory activity of annexin II tetramer is due to a ternary complex between
plasmin, annexin II tetramer and fibrin (or possibly a quaternary complex between
glu-plasminogen, annexin II tetramer, tPA and fibrin), since fibrin can also interact
with annexin II tetramer.
1.2.2.4 Cytokeratin 8
Monomeric cytokeratin 8 (55 kDa), a cytoplasmic intermediate filament
protein has been identified as a class 1 plasminogen binding protein found on the
surfaces of hepatocytes (Hembrough et. al, 1985) and MCF-7 breast cancer cells
(Hembrough et. al, 1995, 1996). The binding of glu-plasminogen to cytokeratin 8 is
lysine dependent. However, the physiochemical properties of plasminogen binding to
cytokeratin 8 remain to be characterised.
1.2.2.5 a-Enolase
Enolases (E.C.4.2.1.11) are dimeric, glycolytic, cytoplasmic enzymes with an
apparent molecular weight of approximately 90,000 kDa. They catalyse the
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interconversion of 2-phospho-D-glycerate (2-PGA) and phosphoenolpyruvate (PEP)
in the glycolytic/gluconeogenic pathway. These enzymes have three discrete
isozymes designated a (Mr: 46, 000), p (Mr: 44,000) and y (Mr: 46,000). Five forms
of the enzyme have been found (Rider and Taylor, 1974; Fletcher et. al, 1976;
Marangos et. al, 1978), namely, the three homodimers aa, (3(3 and yy as well as the
two hybrid forms of enolase composed of ay and ap\ The a-enolase isoform (nonneuronal enolase) is known as "liver" enolase and is ubiquitous, occurring in most

adult tissues and probably the sole isoform present during the early stages of fetal
development (Fletcher et. al, 1978; Schmechel et. al, 1980). A second isozyme of
human a-enolase from the lung has been cloned and sequenced. Human lung-specific
a-enolase is devoid of a C-terminal lysine (Verma and Kurl, 1993), and therefore may
not bind plasminogen. The [3 isoform is found predominantly in muscle (muscle-

specific enolase); as opposed to y-enolase which is characteristic of neurons and the
amine-precursor uptake and decarboxylation (APUD) cells (neuronal enolase)
(Schmechel et. al, 1978a, b).
While the primary physiological role of a-enolase involves energy
metabolism via the glycolytic and gluconeogenic pathways of the cell, it has been
shown to have other potential functions. In the lens, a-enolase is identical to xcrystallin, a major lens component of birds and reptiles (Wistow et. al, 1988). The

lens utilises a-enolase as a structural protein since its glycolytic enzyme activity
abrogated.
Secondly, an a-enolase-related molecule (ERM) has been identified as a
candidate cell-surface plasminogen receptor molecule on both the monocytoid cell

line U937 (Miles et. al, 1991; Redlitz et. al, 1995) and rat neuronal cells (Nakajim
et. al, 1994) which is capable of binding plasminogen via its C-terminal lysine
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residue. Purified a-enolase interacts with glu-plasminogen with a Kj of approximate
1.4 uM in a lysine-dependent manner and removal of the C-terminal lysine residue

from a-enolase abrogates its glu-plasminogen binding capacity (Redlitz et. al, 1995
Moreover, the lysine-dependent binding of glu-plasminogen by a-enolase increases
the activation rate of the molecule by tPA and a-enolase competes with a2antiplasmin for the LBS motifs of plasminogen (Redlitz et. al, 1995).
a-Enolase is expressed at high levels in numerous human tumours (Ishiguro
et. al, 1984; Royds et. al, 1982; Oka et. al, 1989; Royds et. al, 1982; Yoneda et.

1987). Although the subcellular location of a-enolase in these tumours has not been
characterised, the high levels of the enzyme may be due to the energy requirements
the tumour cells and thus a-enolase would be associated with the cytoplasm.
Nevertheless, a fraction of a-enolase may be associated with the cell surface
especially in the neurological tumours where it may function as a plasminogen
receptor (Nakajima et. al, 1994)
1.2.2.7 Glycoprotein 330
The autoantigen associated with Heymann nephritis, namely gp330, is also a
cellular plasminogen binding protein. The binding of glu-plasminogen to gp330
induces an increase the activation rate of the zymogen by uPA (Kanalas and Makker,
1988; Kanalas and Makker, 1991; Kanalas, 1992). During active Heymann nephritis,
autoantibodies are produced against both gp330 and plasminogen, with the latter

antibodies capable of blocking the activation of the glu-plasminogen (Kanalas, 1993)
1.2.2.8 Tetranectin
Tetranectin is a homotrimeric C-type lectin (Holtet et. al, 1997) that binds to
K4 of plasminogen in a lysine-dependent manner with an apparent affinity of 0.5 uM
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(Clemmensen et. al, 1986; Kluft et. al, 1989b). It has been isolated from human
plasma (Clemmensen et. al, 1986) and has also been localised to lung, liver, spleen,
kidney and pancreas (Wewer and Albrechtsen, 1992) endothelial cells, numerous
epithelial cells from the intestine, in many of the immune system cells such as mast
cells, macrophages and granulocytes (Cristensen and Clemmensen, 1989) and various
endocrine tissues such as chromophils of the pituitary gland and follicular and
parafollicular cells of the thyroid gland (Christensen et. al, 1987). However, the
biological role of tetranectin remains unknown. Its concentration range in human
plasma is 120-140 nM, and varies slightly with age and sex (Jensen et. al, 1987) and
oral contraceptives (Kluft et. al, 1989c). Each of the non-glycosylated, 20 kDa,
subunits of tetranectin contain three intrachain disulfide bonds (Fuhlendorff et. al,
1987). The crystal structure for human tetranectin has been solved (Nielsen et. al,
1997) and demonstrates that tetranectin is trimeric.
Tetranectin, apart from binding K4 of glu-plasminogen is also able to
specifically interact with sulfated polysaccharides such as chondroitin and heparin
sulfates (Clemmensen, 1989), fibrin in a calcium-dependent manner (Kluft et. al,
1989a) and to the K4 containing protein apo-lipoprotein (a) (Kluft et. al, 1989b). In

the presence of poly-D-lysine, tetranectin enhances the rate of plasminogen activation
by t-PA (Clemmensen et. al, 1986). This suggests that the binding of gluplasminogen to tetranectin via K4 alone is not sufficient to induce the activationsusceptible conformation of glu-plasminogen.
Tissue tetranectin is primarily associated with the ECM of the cells (e.g.
human embryonal fibroblasts) that secrete it and its association with the ECM may be
due to its ability to bind to sulfated carbohydrates (Clemmensen et. al, 1991). Both
normal colon mucosal cells and colonic tumour cells does not express tetranectin,
whereas, tetranectin is expressed and secreted into the ECM by the colonic tumour
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stromal cells where it is co-distributed with plasminogen (Wewer and Albrechtsen,
1992).

1.2.3 Glu-plasminogen and the cell-surface.
M a n y of the plasminogen receptors described above are also able to bind tPA
in a lysine-dependent manner. Thus, glu-plasminogen, its receptor and tPA m a y form
a ternary activation complex that facilitate the formation of plasmin at the cell surface
in a manner comparable to plasminogen activation on a fibrin clot.
T h e ability of plasminogen to interact with the cell surface in a time-,
concentration- and lysine-dependent manner was first demonstrated on the surfaces of
platelets (Miles and Plow, 1985) and subsequently on m a n y nucleated eukaryotic cells
(table 1.5). T h e general properties of plasminogen binding to a cell-surface include:
[1] Saturable, low affinity, lysine-dependent, interactions with a high number of
binding sites/cell (105-107 sites/cell). [2] The facilitation of glu-plasminogen
activation. [3] Protection of cell-surface plasmin from inactivation by a2-antiplasmin
(Plow and Miles, 1990; Hall et. al, 1991). [4] Increased catalytic efficiency of cellsurface plasmin compared to solution-phase plasmin (Gonzalez-Gronow et. al, 1991).

w

5-

X

3

rt
•a

n c

a.
o

<

71

^1

ET

5]

n

rt
<<
0

X
G
•a
05
<
rt M
OF
t
O
ro

|

OV

CU

n

2.

X

rt
0

X
H

C
LO
00
O

vO
LO
^1

3 2

3

ffl

0
CT OCT

0

00

O

13

Br

B

M

—.

2. >o
2. H*

LO

63

a-

OO

ON

v^>

S"

I
5

Cd

2

rt
ca
cn
ca
D.
3
rt
O

>
o
o'

n

g1
0
o.

JO

n

S-

B

B

rt_

JO

2

ffl

ca

0
0
3

3
Q
0.

O
5'
3

-1

0

rt

B

B

3'

JO

2 2

0

3"

51

EL
£L

O

cr
ea

0
3
0

JO
rt
0ca

JO
B>

CT

ea
3 n
>-i

0

0

a

3

O

3
O

3

3

Ca

to

3

9

rt

C/)

re
r
c
•K

JJ
3

g

ca

0o_
"
3.

3
5

3

n'
>O-

05 "

rc
3
O

rt

cr. n

a

3 B
rt a2.
3.
rt BO

0

ca

2"

3 ' c/3
3 pj

r—f

rt

c
3

—. v>
B
H
a
13 Si

2.

c
3.

n

oq

O
ST
B

I

0

rt

re

ca
-1
O

B

a

rs
5"

o^
3

3'

0'

B

-5,
a

i
4^
X

—
0

rt*
4^
X

LO

1

0

-^
>C<
fl

o
VO

T3

k
X>
.-- rt.
oON
( oi
ON

Ln
X
0

,—s

^—v

L(l

~~.
2 Oq"
2 bXo VO
X

0?

2

O

0
1

8 to

IO

o

I

0

00

1

L/i

X
h—*

rt»
0
oi
ON ON

LO

X

00
X

0

O
-O.

ON

VO
X

1
VO

Oq"

^s

}

X

O

'

, bo
X
<1

0

2

s

LO

b
-0.

1

2
2 2 2 2 00^>
tfq* OO* NS
w

LU

LU

VO
'4^
X
X
0
-0 O

2
OQ

2
Oq

O
1

to X

0

x^5

•3

Oq

1

Oq
to
*~~<

2
00*

ON
^1-0 X
0
00

4.

2

4.

Lo.

VO
X

1

w

010

—'

"^
3

2 2
T3

a
ft
a
a
re
/! re

to
to
X

JO

c
to

rt.
to
X
5

LO
tO
X

VO

O 4^

X

C^; o
173

L/i
X
0

ON

.—'

*
d
3,

to

X
0

Oq
VO

VO

bo

O

o

0

bo

LO

X

O
T 4^
to

5

rt.

3

X

X
5

00

X

^

*<*

2

2

Oq"

X
0

OS

LO
ON
X

O

VO
4^ ON Ul X
X
X
X
X
0
0
0
O
0
O
L/l 0
ON -0 ON -P* 4^
ON ON

vO

as
LO

Ln

*.
X

4^

LO

b
X

^

0

X
0^
4^ 4^

-. x
0

W.O

4^-

Z10

w

2 S"
00*
5
a'
X
TO
Lfl

2?

0
§ *>

0

0

ON

LO

O
—

3

CO

X
to

rt

B
C
ft

3
CT"

rt OC
re oo
j^

avo
00

.rt

3"
B

1
0

X
£L
re
^+

3"

re

3
P

vO
vo
ON

VO
00
00

r5"

re N
;-* re
n

vO
VO

VO
VO

O

O

2

0 X

X
B

0
3

1

0

VO

Co
VO

VO
j—•

O

a
0

Ca

5' re
re «••
;-* a

vo
O

O

VO
00
ON

re re
rt
a
r-* a
vo VO
00
ON

00
ON

2

ca"
3
rt
3

vo
00
VO

D
c
>-t
2,
rt'
3
5'
re
rt
rt
N
^*
re _
avo VO vO "
•-* ca
VO
VO
3
ato
to
rt

1

c

; — •

N

C

%
re"
t/i

T3
O*

VO
GO
(Jl

5'
8 g 51
"
B
2
0
'
—

3

00
L»l

VO
00
00

B
y3 &
vo §
n
3vo rt
VO L*i
n>

«
r?
"i

re
3re

Chapter 1: Biology of plasminogen binding, conformation and activation

68

Apart from these four general properties of plasminogen binding and activation at the cell
surface, plasmin may mediate other cellular functions in an agonist, protease-independent
manner (refer to section 1.2.7).
The high number of plasminogen binding sites/cell suggests that more than one

receptor is responsible for localising glu-plasminogen to the cell surface. The amount of g
plasminogen that a-enolase binds on the surface of U-937 cells is approximately 10% of the

total amount of glu-plasrninogen bound by these cell (Redlitz, et. al, 1995). Whereas, acti
accounts for approximately 45% of the plasminogen binding capacity of endothelial cells

(Dudani and Ganz, 1996). These data suggest that it is likely that more than one proteinace
plasminogen receptor candidate and/or non-proteinaceous moiety is responsible for binding
glu-plasminogen at the surface of nucleated cells. The affinity of glu-plasminogen for the

surface and the degree to which the cell binds this protein is dependent upon the variant o
plasminogen investigated and is probably due to differences in the conformations of these

variants. The affinity of glu-plasminogen binding to the cell-surface is approximately 1 |i

(table 1.5). In contrast, lys-plasminogen (Burtin and Fondaneche, 1988; Pollanen, 1989) and

plasmin (Bauer et. al, 1984) bind with higher affinity to cells (table 1.5). This different

affinity of plasminogen variants for the cell surface is probably due to the conformational
differences between glu- and lys-plasminogen in which the latter exists in a more open
conformation with the LBS of K5 uncomplexed and available for binding (Marshall et. al,
1994). Cells may be able to take advantage of the higher affinity that lys-plasminogen has

the cell surface. For example, incubation of glu-plasminogen with either endothelial or U93

cells induces the formation of lys-plasminogen (Hajjar and Nachman, 1988; Silverstein et. a
1988) which has a more open conformation. The authors of these studies suggested that the
pericellular conversion of glu-plasminogen into lys-plasminogen may provide a mechanism

for the increase in plasmin generation at the cell surface. However, physiological pericell
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proteolysis of glu-plasminogen into lys-plasminogen m a y not enhance the capture of
plasminogen by the cell-surface since lys-plasminogen (in the open conformation) would be
in equilibrium with its proteolytically detached pre-activation domain. This equilibrium
dictates that two conformational forms of plasminogen (open and closed) are present in the
pericellular environment due to the lysine-dependent interaction between the NTP and the
kringle LBS motifs of lys-plasminogen (Sjoholm et. al, 1973). A slight modification of this
speculation is that receptor-bound glu-plasminogen may be converted into receptor-bound

lys-plasminogen by cell-surface plasmin. Alternatively, after activation, receptor-bound glu
plasmin may undergo auto-catalysis yielding receptor-bound lys-plasmin plus unbound NTP.
However, the mechanism of pericellular/cellular lys-plasminogen formation remains unclear.
Another parameter that influences cell-surface glu-plasminogen binding is the
glycosylation status of the zymogen. The more heavily glycosylated glu-plasminogen

(glycoform I) binds with a slightly lower affinity than glycoform II (table 1.3) (Hall et. al
1990) possibly due to a glycosylation induced steric hindrance of the LBS motif(s):cellsurface receptor interaction.
Binding studies using elastase fragmented plasminogen identified Kl-3 as a primary
recognition site for plasminogen on stimulated and unstimulated platelets (Miles et. al,
1988). However, lower amounts of isolated K4 and mini-plasminogen (K5-protease domain)
can also bind to stimulated and unstimulated platelets (Miles et. al, 1988). Thus, the LBS
motifs of Kl-3, K4 and K5 have the potential to bind to the cell-surface. Isolation of
plasminogen fragments by elastase digestion would destroy the intramolecular lysine binding
network of glu-plasminogen and thus its conformation. This loss of glu-plasminogen
conformation may confound the importance of which kringle LBS motifs are responsible for
localising glu-plasminogen to the cell surface and the results may simply reflect the higher
affinity LBS motif present in the Kl-3 fragment. Using fragments of plasminogen, £-ACA
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and benzamidine, Burge et. al, (1992) demonstrated that glu-plasminogen binding to basal
cell layers of the epidermis was primarily mediated by the K5 LBS motif as well as by a
second e-ACA-dependent site. This suggested that the binding of glu-plasminogen to cell
surfaces may involve multiple kringle domains.
Many of the cellular plasminogen receptors are proteins that have pre-existing
intracellular biological roles w h e n expressed at locations other than at the cell surface. If the
analysis of the plasminogen binding experimental data does not include a procedure for the
discrimination of the plasminogen bound by viable cells as opposed to binding by non-viable
cells, then the specific number of binding sites per cell m a y be overestimated, since m a n y of
the plasminogen receptors are intracellular proteins. Thus, the viability status of a cell
influence its glu-plasminogen binding capacity.
Finally, the binding of glu-plasminogen to the cell-surface m a y be species specific, for
example, bovine endothelial or smooth muscle cells bind lower amounts of h u m a n gluplasminogen than their human counterparts (Hajjar et.al, 1986).
1.2.4 Cellular plasminogen activation.
The lysine-dependent binding of glu-plasminogen to a cell-surface enhances the
activation rate of glu-plasminogen by the mammalian plasminogen activators (Namiranian et
al, 1995). If the interaction of glu-plasminogen with the cell surface induces a lysinedependent conformational change in glu-plasminogen similar to the change in conformation
the lysine analogues induce, then binding should facilitate the rate of cell-surface plasmin
formation. For example, both the apparent K d (table 1.5; Plow et. al, 1986) for the binding of
glu-plasminogen to U 9 3 7 cells and the apparent K ^ (table 1.2; Felez et. al, 1996) for the

U937 cell-surface bound glu-plasminogen activation are 0.9 uM. This suggests that saturatio

of the cell surface with glu-plasminogen induces the maximal rate of plasminogen activation

Thus, the activation of cell-bound glu-plasminogen by tPA or receptor-bound uPA is due to a
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decrease in the apparent K m of these activators for glu-plasminogen (table 1.2; Hajjar et. al,
1986; Schafer etal, 1989; Ellis et. al, 1991). These apparent decreases in the K m of the
activation reactions suggest that at physiologically relevant concentrations cell-surface-bound
glu-plasminogen acts as better substrate for the plasminogen activators than solution-phase
glu-plasminogen (table 1.2).
Another consequence of plasminogen binding to the cell surface is protection from
inhibition by a2-antiplasmin. In contrast to u P A , plasmin is refractory to inhibition by its
extracellular serpin, a2-antiplasmin when bound in a lysine-dependent manner to its cellsurface receptor (Plow and Miles, 1990; Hall et. al, 1991). Cell-bound plasmin treated with
a2-antiplasmin results in the dissociation of plasmin from the cell surface and the formation
of plamin:a2-antiplasmin complexes (Hall et. al, 1991). This suggests that a2-antiplasmin
can compete with the plasminogen receptors for plasmin. Thus the cell-surface, with respect
to a2-antiplasmin inhibition of plasmin, seems to be homologous to the surface of a fibrin
clot.

1.2.5 Regulation of cell-surface plasminogen binding.
T o date the biochemical pathways and mechanisms responsible for the regulation of
cell-surface plasminogen receptors remains to be characterised. Since there are several
cellular plasminogen receptor molecules there m a y be more than one regulatory pathway
responsible for localising these molecules to the cell-surface. Regulation of plasminogen
binding proteins m a y involve both intracellular and extracellular processes. The extracellular
regulation of the plasminogen binding capacity of a tissue m a y be similar to the regulation of
plasminogen binding of fibrin. D o w n regulation of the plasminogen binding capacity of a cell
m a y result from carboxypeptidase (enzymes that cleave basic carboxyl-terminal residues such
as lysine) proteolysis of cell surface proteins (Plow et. al, 1995; Redlitz et. al, 1995; figure
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1.12). In contrast, cell-surface plasmin m a y cleave pre-existing, cell-surface proteins between

[K,R] X residues thereby exposing cryptic C-terminal lysine residues (figure 1.12; Camach
et. al, 1989 and Gonzalez-Gronow et. al, 1991; Plow et. al, 1995).

Figure 1.12: T h e cell-surface plasminogen activation cascade.
Organisation of the components of the cell-surface plasminogen activation cascade emphasising the role of the
plasminogen receptors. • represents a pre-existing C-terminal lysine residue from a pre-formed or class 1 plasminogen
receptor. O represents a plasmin cleavable lysine residue from a latent or class 2 plasminogen receptor. *Note:
selected plasminogen receptors can bind tPA and plasminogen simultaneously. Solid arrows represent activation
reactions or binding events whereas, broken arrows represent inhibition events.

Therefore, plasmin may act in a positive feedback loop to activate the glu-plasminogen
binding capacity of pre-existing, latent cell-surface plasminogen binding proteins.
A relationship between glu-plasminogen binding and activation capacity and the

apopotic status of a U937 cells has been established (O'Mullane and Baker, 1998, 1999). Glu
plasminogen activation occurs on the surface of these apopotic cells due to a 100-fold
increase in the both their lysine-dependent plasminogen binding capacity and endogenous
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uPA levels in the presence of the protein synthesis inhibitor cycloheximide. Thus, the gluplasminogen binding capacity of monocytes m a y be coupled to the apopotic processes of
these cells (O'Mullane and Baker, 1998).
Another study by Kim et. al, (1996) has suggested that the adhesion of the human
monocytoid cell lines, T H P - 1 and U 9 3 7 , to extracellular matrix proteins promotes an increase
in the expression of cell-surface glu-plasminogen binding (Kim et. al, 1996). The increase in
the binding of plasminogen to the surfaces of these adherent monocytoid cell lines was due to
an increase in the number of binding sites and not an increase in the affinity of the cellsurface for plasminogen (Kim et. al, 1996). This augmentation of the number plasminogen
binding sites was rapid and reversible, involved pre-existing proteins of the cell, promoted
plasminogen activation and dependent upon an interaction between adherent and nonadherent cell populations as well as pi-integrin (Kim et al, 1996). Taken together, these
studies suggest that glu-plasminogen binding does not require n e w protein synthesis.
1.2.6 Physiology of plasminogen binding.
Plasminogen binding plays a central role in the balance between physiological and
pathological consequences of proteolysis. Since the concentration of glu-plasminogen in the
blood is approximately 2 (iM, a proportion of cell-surface plasminogen receptors would be
occupied by glu-plasminogen. This equilibrium m a y result in the compartmetalisation of gluplasminogen into two metabolically distinct pools: firstly, solution-phase, activation-resistant
glu-plasminogen and secondly cell-surface-, E C M -

or fibrin clot-bound, activation-

susceptible, glu-plasminogen. Hence, physiologically inappropriate over-expression of gluplasminogen binding proteins or cellular plasminogen receptors, and thus increased gluplasminogen binding m a y increase the pool of activatable glu-plasminogen resulting in
destructive proteolytic activity. Conversely, inappropriate down-regulation of cellular
plasminogen receptors m a y hamper beneficial proteolytic activity. Within the bound-glu-
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plasminogen metabolic pool there m a y be a specific hierarchy of plasminogen interactions
based on binding protein affinities. The E C M proteins have approximately two orders of
magnitude lower dissociation constants than cell-surface plasminogen receptors (table 1.4;
Stack et. al, 1994; Stack et. al, 1992). This suggests that the binding of glu-plasminogen to
cell-surface receptors (large capacity, low affinity) m a y represent a glu-plasminogen
transportation mechanism that carries the protein from the blood to the tissues under certain
physiological/pathological conditions. For example, Martinez and Santibanez (1994) provided
circumstantial experimental evidence for this transportation process using

WEHI-3B

leukemic cells and collagen I.
1.2.7 Other plasmin-mediated cellular functions
The majority of cell-types associated with the blood vascular system, such as
polymorphonuclear neutrophils (PMN's), platelets, endothelial cells and monocytes bind
plasminogen in a lysine-dependent manner that facilitates the activation of the zymogen and
protection of cell-surface associated plasmin from inactivation. However, some studies have
reported that plasmin m a y also mediate a protease-independent cellular function via the
initiation of intracellular signal transduction cascades within these cells in an agonistdependent manner. (Ryan et. al, 1992; Schafer and Adelman, 1985; Schafer et. al, 1986;
Chang et. al, 1993; Syrovets et. al, 1997). Lysine-dependent binding of plasmin, but not
active-site blocked plasmin or plasminogen induces the synthesis of the intracellular second
messenger molecule cyclic guanosine monophosphate ( c G M P ) in monocytes (Syrovets et. al,
1997). Analogue competitors of c G M P inhibited plasmin-mediated chemotaxis of monocytes
in vitro. This suggests that plasmin, produced at the site of inflammation, m a y act as a
chemoattractant, thereby recruiting monocytes to inflammatory sites within the body
(Syrovets et. al, 1997).
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Another key event in acute inflammation is the adhesion of neutrophils to vascular
endothelial cells during the extravascation of these cells possibly via the neutrophil cellsurface glycoprotein C D 1 8 (Pohlman et. al, 1986; Anderson et. al, 1987). Plasmin m a y also
mediate the adherence of neutrophils to arterial endothelium in a lysine- time- and
concentration-dependent manner and is due to an increase in the functional activity of C D 18
(Lo et. al, 1989). This adhesion event was specific for plasmin, but not dependent on the
proteolytic activity of plasmin. Lys-plasminogen induced less neutrophil adherence than
plasmin, whilst, glu-plasminogen is unable to mediate adherence. Furthermore, the Kl-3 and
K 4 fragments of plasminogen mediate neutrophil adherence, whereas, miniplasminogen has a
minimal effect on neutrophil adherence (Lo et. al, 1989). This induction of neutrophil
adherence m a y be due to a plasmin-induced, lysine-dependent signaling pathway via a cellsurface receptor.

1.3 Normal Breast tissue, carcinogenesis and plasminogen activation
Growth of breast tissue is the result of multiple hormones such as the female sex
hormones (e.g. oestrogen and progesterone) and epidermal growth factors. Breast cancer is an
example of a hormone-dependent malignancy (reviewed by Manni, 1999). T w o well
established antigenic markers of breast tumours are the oestrogen receptor (ER) and the
oncogenes EGFR/c-er^B-2. Approximately 20-30% of all h u m a n breast cancers over-express
two closely related receptor tyrosine kinases, namely epidermal growth factor receptor
(EGFR) and/or c-erbB-1. This phenotype is associated with more aggressive tumour growth
and reduced patient survival (Singleton and Strickler, 1992). In contrast, breast cancer cell
lines that are E R positive and have little or no E G F R , have a non-metastatic phenotype (Lee
etal, 1990).
Breast cancer invasion and metastasis are highly orchestrated pathological processes
involving dynamic but aberrant relationships between the malignant cells and surrounding
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host stromal cells. The co-ordinate expression of molecules of several perturbed biochemical
pathways is required for the adhesion, proteolysis and cell motility of tumour cells. S o m e of
these biochemical pathways include the cell-cell and cell-ECM interactions mediated by the
cadherins and integrins as well as E C M proteolysis (reviewed by Jones and Walker, 1997).
Essentially, two classes of proteases (plasmin and M M P ' s ) have been identified as important
determinants for breast cancer metastasis. The role of the pericellular plasminogen activation
cascade in the process of breast cancer invasion is discussed below.
1.3.1 The plasminogen activation system and breast cancer
The role of the plasminogen activation system in migration, wound healing, tumour
cell invasion and metastasis have recently been reviewed (Plow et. al, 1999; Dano et. al,
1999; Duffy et. al, 1999; Schmitt et. al, 1997). Evidence has accumulated that support the
contention that invasion and metastasis of solid tumours requires the action of tumourassociated proteases. These proteases are responsible for the degradation of extracellular
matrices that must be breached by the migrating cell to achieve colonisation of a distant
tissue.
Components of the plasminogen activation proteolytic cascade are also linked to the
pathology of breast cancer growth and metastasis (Duffy, 1993) and have been termed
metastatic factors. Differentiated, E R positive breast cancer cells express low levels of u P A
and u P A R (Long and Rose, 1996; Connolly and Rose, 1997). In contrast, E G F R stimulation
or c-erbB-1 over-expression in aggressive human breast cancer cells enhances the expression
and secretion of u P A and expression of u P A R (Long and Rose, 1996; Connolly and Rose,
1997). It is apparent that breast cancer cell lines such as M D A - M B - 2 3 1 cells, that are highly
tumourogenic and metastasise in nude mouse models and/or are invasive in in vitro models of
metastases (Thompson et al, 1992), tend to be EGFR(+)/erbB-l protein(+) and ER(-) (Lee et
al, 1990), as well as uPA/uPAR(+) (Holst-Hansen et al, 1996). Combined over-expression of
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uPA, u P A R and PAI-1 is associated with decreased disease-free periods and reduced patient

survival times (Janike et. al. 1993; Christensen et. al, 1996; Costantini et. al, 1996; Neils
et. al, 1996), whilst elevated levels of PAI-2 are associated with a favourable prognosis in
primary breast cancer (Foekens et. al, 1995). As well as plasminogen activator antigen levels
Yamashita et. al, (1993) examined plasminogen activator activities associated breast cancer
metastasis from patients presenting with primary metastases in the bone only, bone and lung,
lung only or disease-free subjects in terms of lymph node status. The authors found that tPA
activity and antigen levels are low in patients with bone-only metastasis from node-negative

breast cancers (Yamashita et. al, 1993). In contrast, uPA activity, as opposed to tPA activity
is expressed by node-positive breast cancer, which may progress into lung metastases

(Yamashita et. al, 1993). The in vitro invasive capacities of human breast cancer cell lines i
dependent on both uPA and plasmin activity (Hoist-Hanson et. al, 1996).
Cell-surface localised plasminogen may also be involved with breast cancer
metastasis. Plasminogen binds in a lysine-dependent manner to infiltrating grade II or III
ductal carcinomas (Burtin et. al, 1993). However, the plasminogen receptors of these breast
cancer cells are not saturated in vivo and bind additional amounts of plasminogen in vitro

(Burtin et. al, 1993). The above studies all present evidence that aggressive, invasive breast
cancer is associated with the expression of high levels of the plasminogen activation cascade
components. These studies indirectly support the contention that metastasising breast cancer
cells acquire active plasmin at their surfaces that can be used by the cells to degrade
physiological barriers. However, the precise mechanism of glu-plasminogen acquisition and
activation by these cells remains poorly defined.
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1.4 Rationale and Aims
The fibrin clot acts to focus proteolytic activity at its surface by binding the proteases
of the plasminogen activation cascade in a ternary complex. Similarly, the cell-surface can
bind plasminogen activators and glu-plasminogen in a ternary complex. Thus, the process of
glu-plasminogen activation at the cell-surface may be analogous to glu-plasminogen
activation during fibrinolysis and requires the cell-surface-association of both plasminogen
activators and glu-plasminogen. The activity of both inhibitors of plasminogen activation and
modifying agents help regulate the activation of glu-plasminogen at the cell surface. Thus,
plasminogen activation at the cell-surface is a balance between activators, inhibitors and
modifying agents.
Cellular plasminogen receptors are not as well characterised as the other components
of the plasminogen activation cascade. To date nine cellular plasminogen receptor candidate
proteins have been identified (table 1.4). However, detailed mechanistic knowledge about the

interaction of glu-plasminogen with this class of protein is rudimentary. Therefore, the overa
objective of this thesis was to define a mechanism for the binding of glu-plasminogen to its
plasminogen receptors that accounted for the observed increase in the activation rate of
receptor-bound glu-plasminogen.
It is hypothesised that the lysine-dependent binding of glu-plasminogen to its receptor
is mediated by a competition reaction between the internal lysine residues of glu-plasminogen
and the lysine residues of a receptor for the LBS motifs of glu-plasminogen. The result of
such reactions would disrupt the intramolecular lysine-binding network of glu-plasminogen
facilitating the open, activation-susceptible conformation of the zymogen. a-Enolase was
selected as the plasminogen receptor molecule of choice since it had previously been shown
to bind glu-plasminogen in a lysine-dependent manner that increases the activation rate of the
zymogen. Another reason for the selection of a-enolase as a model plasminogen receptor
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candidate to study the mechanism of plasminogen binding was that it possesses a C-terminal
lysine residue.
The specific aims of this thesis were to:
[1] Determine if the human gene product of ENOl (namely recombinant a-enolase) did
encode an authentic plasminogen receptor protein and to produce antibodies against this
protein.
[2] Use a-enolase as a model plasminogen receptor protein to determine a physiologically
relevant mechanism for its interaction with glu-plasminogen.
[3] Examine the cell surface glu-plasminogen binding events in three human breast cancer
cell lines in relation to their metastatic potentials.
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Chapter 2

The human EN01 gene product (recombinant human alphaenolase) displays many characteristics required for an
authentic plasminogen binding protein.
2.1 Introduction
Glu-plasminogen interacts with cells via both proteinaceous and non-proteinaceous

(e.g. gangliosides) cell-surface moieties (Miles et. al, 1989) in a lysine-dependent manner

date, nine candidate cell-surface plasminogen binding proteins have been identified and six

other proteins (apparent Mr 40-60 kDa) have been reported but remain essentially unidentifi
and uncharacterised (Lopez-Alemany et. al, 1995). One of these plasminogen receptor
candidates, a 54 kDa protein has been isolated from the plasma membrane of monocytoid cell
line U-937 and identified as human a-enolase by partial amino-acid-sequence homology
(Miles et. al, 1991) and is known as a-enolase-related molecule (ERM; Section 1.3.5).
The 54 kDa ERM has all the properties required for classification as a cell-surface

plasminogen binding protein, in that it is able to bind glu-plasminogen in a saturable, spe
and lysine-dependent manner with a Kd of approximately 1.4 JJM and once bound to this
molecule, the activation rate of glu-plasminogen is significantly increased. The ERM bound

glu-plasminogen is also partially shielded from inactivation by a2-antiplasmin by competing
with a2-antiplasmin for the lysine binding sites of plasminogen (Redlitz et. al, 1995).
The molecular weight of cytoplasmic a-enolase is 47 kDa, whereas the molecular
weight of ERM is estimated at 54 kDa. Thus, ERM may be encoded by a separate gene. The
purpose of this chapter was to assess whether the human ENOl gene encoded a glu-
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plasminogen binding protein. Data within this chapter indicated that recombinant human a-

enolase (r-a-enolase), as encoded by the ENOl cDNA, was an authentic plasminogen bindin

protein. Furthermore, the plasminogen binding capacity of human a-enolase is not due to
post-translational modification of the protein.

2.2 Material and Methods

2.2.1 Materials
Plasminogen, a2-antiplasmin, the plasminogen specific substrate Spectrozyme-PL and

monoclonal antibody #3641 and #3642 which specifically recognise epitopes within the NT

and Kl-3 domains of glu-plasminogen were all kindly donated by Dr Richard Hart (America
Diagnostica Inc., Greenwich, CT., U.S.A.). Plasmid HHCME18, which encoded the human
ENOl gene, was purchased from ATCC. Plasmid pQE-30 and Ni2+-NTA-Agarose were from
QIAGEN Inc. Hilden, Germany. Lysine Sepharose 4B, G75-Superdex and PD-10 columns
were obtained from Pharmacia, Uppsala, Sweden. RPMI 1640, L-glutamine were purchased
from Trace Biosciences Castle Hill, NSW, Australia. Fetal calf serum was obtained from
Parkville, Vic, Australia. Active human tc-uPA was from Serono, Sydney NSW, Australia.

Plastic tissue culture flasks were purchased from Corning, Corning, NY, USA. Microtitre

well plates were from Titre-Tek Flow Laboratories, The Netherlands. Trasylol was bought
from Bayer, Leverkusen, Germany. Carboxypeptidase B was obtained from Boehringer
Mannheim, Mannheim Germany. Horse radish peroxidase conjugated avidin (avidin-HRP),
alkaline phosphatase conjugated avidin (avidin-AP). Molecular weight protein standards

obtained from Novex (Sydney, Australia). All other reagents were of the highest quality

commercially available and all reagents were made using double de-ionised water purifie
a Millipore water purification system.
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2.2.2 Purification and biotinylation of human glu-plasminogen
Human glu-plasminogen was also purified from human plasma using lysine
Sepharose-4B affinity chromatography as described below.

Briefly, 400 ml of plasma

containing 1 m M P M S F , 5 m M E D T A and 0.02% NaN 3 , was loaded onto a lysine Sepharose4B column (60 ml) for 24 h at 4°C at a flow rate of 30 ml/h. The column was washed
overnight with P B S (pH 7.4) supplemented with 1 m M P M S F , 5 m M E D T A and 0.02% N a N 3

at 4°C at a flow rate of 30 ml/h until baseline was achieved. The column was washed w
wash buffer (50 m M Na-phosphate (pH 7.4), 500 m M NaCl, 1 m M P M S F , 5 m M E D T A and
0.02% NaN 3 ) at a flow rate of 30 ml/h until baseline was achieved. The plasminogen was

competitively eluted with PBS (pH 7.4) containing 200 mM of the lysine analogue E-ACA
a flow rate of 30 ml/h. The fractions were analysed by non-reducing 1 2 % S D S - P A G E and
western blotting using monoclonal antibodies #3641 and #3642 which are specific for the
N T P and Kl-3 domains of plasminogen, respectively. The plasminogen was dialysed against
PBS (pH 7.4) for 24 h at 4°C with 3 changes of buffer.
2.2.3 Modification of glu-plasminogen.
H u m a n glu-plasminogen was biotinylated by first increasing the p H above 8 by the
addition of 1 0 % (v/v) 1 M N a H C 0 3 (pH 9.0). A 40 molar excess of biotin-X-NHS was added

and the reaction mixture incubated overnight at 4°C with rocking. Human glu-plasminoge
in P B S was conjugated with fluorescein isothiocyanate isomer I (FITC) as described by
Goding (1976). Both unconjugated biotin-X-NHS and FITC were separated from the
conjugated protein by gel filtration using a PD-10 gel filtration column equilibrated with
PBS/0.1% azide. The lysine-dependent binding capacity of modified glu-plasminogen was
determined by batch lysine-Sepharose-4B affinity chromatography.
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6xHis- a-enolase protein

The human a-enolase [Human ENOl (HHCME18) ATCC] coding domain within a
1.23-kb Sac l-Xho 1 cDNA fragment was ligated downstream and in-frame to the 6-His
affinity tag in the QIAexpress pQE-30 expression vector (QIAGEN Inc.). The resulting

construct pQE-ENOl was transformed into JM109 E.coli host cells. The expression of the

resultant pQE-ENOl construct creates an enolase fusion protein with a 6-His N-terminal

affinity tag and a predicted protein size of approximately 42 kDa. This recombinant h
enolase protein will be referred to throughout this thesis as r-a-enolase.

2.2.5 Non-denaturing purification of r-a-enolase
The procedure for the large scale purification of r-a-enolase under non-denaturing

conditions was followed as outlined by the QIAexpress protocol with minor modification

Briefly, transformed JM109 cells were pelleted and resuspended in sonication buffer (
Na-phosphate (pH 8.0), 300 mM NaCl, ImM PMSF, 4 mM MgCl2 and 0.2% Tween-20).

After 2 freeze-thaw cycles in liquid nitrogen, the cells were treated with 1 mg/ml ly

for 30 min on ice followed by treatment with RNase (lOug/ml) and DNase (5 ug/ml) for 1
min at 4°C and sonicated (Branson Sonifier 250) for three 1 min bursts on ice. The

preparation was centrifuged at 14,000g for 15 min at 4°C and the supernatant batch loa

onto Ni2+-NTA-agarose resin for 1 h at 4°C. This was then poured into a column and was

with 10 column volumes of sonication buffer and 10 column volumes of wash buffer (50 m
Na-phosphate, pH 6.0, 300 mM NaCl, 10% glycerol, ImM PMSF). Bound r-a-enolase was
eluted from the column with 250 mM imidazole-HCl in 50mM Na-phosphate (pH 6.0), 300
mM NaCl a flow rate of 15 ml/h. The eluted samples were analysed by SDS-PAGE and

fractions containing a 42 kDa component were pooled and further purified by gel filtr
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using a G 7 5 Superdex column (Pharmacia) with column buffer (25 m M Na-phosphate, 2.5
mM MgS04, 0.05% NaN3) at a flow rate of 30 ml/h. The samples were analysed by SDSPAGE, enolase enzyme activity, and plasminogen binding capacity. Fractions containing

kDa or a 42kDa component with pig binding capacity and/or enolase enzyme activity wer

dialysed overnight against the G75 Superdex column buffer containing 50% glycerol and
stored at -20°C until required.
2.2.6 Enolase Glycolytic Activity Assay
Enolase glycolytic activity in each of the G75 Superdex fractions was assayed by
measuring the rate of phosphoenolpyruvate (PEP) production as described by Christian
Wold (1942). Briefly, a sample of each fraction (lOOjil) was incubated with 1 mM 2-

phospho-D-glycerate (2-PGA) in 1 ml of reaction buffer (50 mM imidazole-HCl, (pH 6.8),
400 mM KC1, 3 mM MgSO^ at 25°C. The appearance of PEP with time was monitored at
240nm. A standard curve was constructed by measuring the A240nm of 0 to 100 jiM PEP.

2.2.7 Denatured purification of r-a-enolase.
Cells were solubilised by incubating with buffer A (10 mM Tris-HCl (pH 8.0), 6M

guanidine-HCl, 0.1 M Na-phosphate) for 1 h at room temperature and the lysate centrifu

at 10,000g for 15 min at 4°C. The supernatant was incubated with 4 ml of Ni2+-NTA-agar

previously equilibrated with buffer A at room temperature for 1 h. The column was pou

and the resin washed with 10 column volumes of buffer A at a flow rate of 15 ml/h. Th
column was then washed with 10 column volumes of buffer B (0.01 M Tris-HCl (pH 8.0),

M urea, 0.1 M Na-phosphate) and 10 column volumes of buffer C (0.01 M Tris-HCl (pH 6.3

8 M urea, 0.1 M Na-phosphate). The final wash using buffer D (Tris-HCl (pH 5.9), 8 M u

0.1 M NaCl) effectively removed all the contaminating proteins. Elution of r-a-enolas
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performed using buffer E (Tris-HCl (pH 4.5), 8 M urea, 0.1 M Na-phosphate) and 3 ml
fractions were collected and analysed by non-reducing 1 2 % S D S - P A G E (under reducing
conditions).
2.2.8 Plasminogen ligand blotting.
R-a-enolase was fractionated on 12 % SDS-PAGE gels and transferred to PVDF
membranes overnight at 30 V at 48C. The membranes were washed once with T N C M (TrisHCl (pH 7.5), 150 m M NaCl, 2 m M CaCl 2 , 3 m M M g C l 2 ) and blocked with T N C M / 0 . 0 5 %
Tween-20/BLOTTO for 1 h at room temperature followed by three 5 min washes with
TNCM/0.05% Tween-20. The blots were then probed with 2u\g/ml biotinylated plasminogen
in T N C M / 0 . 0 5 % Tween-20/BLOTTO for 1 h at room temperature and washed for 1 h with
TNCM/0.05% Tween-20. A 1:2000 dilution of avidin-AP (Calbiochem) in T N C M / 0 . 0 5 %
Tween-20/BLOTTO was added and incubated with the membrane for 1 h. This was followed
by three 5 min washes with T N C M / 0 . 0 5 % Tween-20 and one wash with T N C M . The blot was
developed using the NBT/BCIP colour development system at room temperature.
2.2.9 96-well microtitre plasminogen binding assay.
R-a-enolase (500 p M ) was coated onto 96-well microtitre plates in 50 m M N a H C 0 3

buffer (pH 8.5) overnight at 4°C. Biotinylated plasminogen standards 0-50 nM in 50 m
N a H C 0 3 (pH 8.5) were also coated onto the same microtitre plates overnight at 4°C, thereby

enabling quantification of biotinylated plasminogen bound to r-a-enolase. The plate
then washed twice with PiNT (100 m M Na-phosphate (pH 7.5), 150 m M NaCl 0.05% Tween-

80) and blocked with 50 ul of PiNT containing BLOTTO at 37°C for at least 1 h. The p
were washed as above and varying concentrations of biotinylated plasminogen with or

without competitors in PiNT/BLOTTO were added and incubated for 1 h at 37°C then rin
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three times with PiNT. A 1:2000 dilution of avidin-HRP in P i N T / B L O T T O was added and
incubated for 1 h at 37°C. This was followed by 4 washes with PiNT. The plates were
developed using the OPD colour development system and read at 490 nm.

2.2.10 Carboxpeptidase B digestion of r-a-enolase and plasminogen binding assay.
To examine whether or not the C-terminal lysine residues of r-a-enolase were

important for plasminogen binding, r-a-enolase (1 ng/ml) was coated onto microtitre pl
overnight at 4°C in 50 mM NaHC03 (pH 8.5). Once again biotinylated plasminogen
standards (0-50 nM) were also coated onto the plates in 50 mM NaHC03 overnight at 4°C.
The plates were then washed with PiNT three times and blocked with PiNT/1% BSA in wash

buffer for 1 h at 37°C followed by one wash. Bound r-a-enolase was treated with various
concentrations of carboxypeptidase B (CBP) for 10 min at 37°C in PiNT, after which the

plates were washed three times and probed with ljiM biotinylated plasminogen in PiNT/1%
BSA for 1 h at 37°C. The plates were washed and probed with avidin-HRP conjugate in
PiNT/1% BSA and colour developed using OPD substrate as described above.
2.2.11 Protein Analysis.
All protein concentrations were determined using the Bio-Rad DC Protein Assay. The
apparent molecular weight of purified r-a-enolase after fractionation by 12% SDS-PAGE

determined using scanning laser densitometry (Bio-Rad) relative to the mobility of pro
standards and these averaged between 42 and 54 kDa.
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2.3 Results

2.3.1 Plasminogen purification and characterisation
Representative data showing the purification of plasminogen using lysine sepharose
chromatography are shown. Plasminogen was eluted from the lysine-sepharose column
(figure 2.1 A ) with 200 m M E - A C A as illustrated by 1 2 % non-reducing S D S - P A G E (figure
2. IB). This band had an apparent molecular weight of 92 k D a and was immunologically
reactive against both anti-NTP (#3641) and anti-Kl-3 (#3642) monoclonal antibodies. This
suggested that glu-plasminogen was successfully purified from plasma. The lysine-dependent
activation of purified glu-plasminogen was examined by incubating lOjxg of glu-plasminogen
with a 25:1 molar ratio of tc-uPA for 10 min at 37°C in the presence of various concentrations
of e-ACA. The reactions were terminated with reducing sample buffer, boiled and the samples
fractionated by 1 2 % S D S - P A G E

(figure 2.1C). Incubation of glu-plasminogen and tc-uPA

with 5 m M e - A C A resulted in a 2.4 fold increase in the amount of plasmin A-chain formed
compared to glu-plasminogen that was not treated with E - A C A (figure 2.1C). This suggested
that glu-plasminogen was isolated in a closed conformation that was capable of an E - A C A dependent conformational change which facilitated an increase in the activation rate of the
zymogen.
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Figure 2.1: The purification of glu-plasminogen from human plasma.
A typical chromatogram of the purification of glu-plasminogen from plasma. (B) Non-reducing 1 2 % SDS-PAGE and
western blots of the elutant from the lysine-sepharose column. The western blots were probed with anti-plasminogen
N T P (#3641) and anti-Kl-3 (#3642) plasminogen monoclonal antibodies. (C) Reducing 1 2 % SDS-PAGE of a uPAdependent activation of glu-plasminogen in the presence of increasing concentrations of e-ACA.
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2.3.2 Modifications of glu-plasminogen
Glu-plasminogen was either biotinylated or FITC conjugated for use as probes in
various glu-plasminogen binding assays (chapters 2 and 5). However, the modification of gluplasminogen with either NHS-X-biotin or F I T C m a y ablate the ability of the protein to
interact in a lysine-dependent manner with a potential receptor. Thus, the lysine binding
capacity of modified glu-plasminogen was assessed by batch affinity chromatography using
lysine-sepharose.
After either biotinylation or F I T C conjugation, a sample of the modified gluplasminogen was loaded onto lysine-sepharose at 4°C for 30 min, the resin was washed, and
the bound modified glu-plasminogen was batch eluted with 200 m M E-ACA. The fractions
from the batch lysine-sepharose chromatography were fractionated by 1 2 % non-reducing
S D S - P A G E and either stained with Coomassie blue (figure 2.2A; biotinylated gluplasminogen) or exposed to U V light and photographed (figure 2.2B; FITC conjugated gluplasminogen). The absence of modified glu-plasminogen in the flow throughs and
wash buffers suggested that both biotinylated and FITC conjugated glu-plasminogen were
able to interact with lysine-sepharose. Moreover, the elution of biotinylated and FITC
conjugated glu-plasminogen with E - A C A demonstrated that the interactions of the modified
glu-plasminogen with lysine-sepharose was both lysine-dependent and reversible. This
suggested that both biotinylated and F I T C conjugated glu-plasminogen had retained their
lysine-dependent binding characteristics and thus m a y be used as in vitro probes in gluplasminogen binding assays.
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Figure 2.2: Reversible lysine-dependent binding of biotinylated and F I T C conjugated glu-plasminogen to
lysine sepharose.
Non-reducing 1 2 % S D S - P A G E of biotinylated glu-plasminogen after lysine Sepharose-4B batch
chromatography. Biotinylated glu-plasminogen (10 ug; lane 1) was incubated with lysine Sepharose-4B for 30
min. The resin was washed with P B S (lanes 2 and 3) and incubated with P B S containing 200 m M e-ACA (lanes
4-6). (B) Non-reducing 1 2 % S D S - P A G E of FITC conjugated glu-plasminogen after lysine Sepharose-4B batch
chromatography. FITC conjugated glu-plasminogen (20 ug; lane 1) was incubated with lysine Sepharose-4B for
30 min. The resin was washed with P B S (lanes 2 and 3) and incubated with P B S containing 200 m M e-ACA
(lanes 4-6).
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a-enolase purification.

Purification of r-a-enolase by Ni2+-NTA chromatography under non-denaturing
conditions yielded a preparation containing dimeric (94 kDa), monomeric (52 kDa) and

proteolytic fragments of r-a-enolase (figure 2.3A). Ligand blot analysis indicated that the
length monomeric and dimeric forms of r-a-enolase were able to bind plasminogen (figure
2.3B). After gel filtration on a G-75 Superdex column (figure 2.4A) the crude r-a-enolase

preparation was separated into an SDS-stable dimeric r-a-enolase (93 kDa) enriched fractio
and a monomeric r-a-enolase (42 kDa) enriched fraction as shown by non-reducing SDSPAGE (figure 2.4B). Enolase glycolytic activity corresponded to the dimeric r-a-enolase
enriched fraction (fractions 14-16) isolated from the gel filtration column (figure 2.4A).
2+

r-a-enolase was purified using Ni - N T A chromatography under denaturing conditions (figure

2.5A) no glycolytic activity was present. SDS gel electrophoresis of the denatured purifie

a-enolase showed a single band at 48 kDa (figure 2.5B). Ligand blotting analysis of purifi
r-a-enolase using biotinylated plasminogen revealed a single 48 kDa band (figure 2.5B).

Taken together, these data suggested that plasminogen could only bind full length r-a-enol

and that the tertiary structure of r-a-enolase was not essential for its plasminogen bindi
activity.
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3: Proteins eluted from the Ni2+-NTA column with 250 mM imidazole-HCl. LANE 4: Ligand blot: elutant from la
was probed with 2 ug/ml biotinylated plasminogen and avidin-AP (1:2000 dilution).
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12% SDS-PAGE (non-reducing) of the fractions eluted from the gel filtration column.
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Figure 2.5: R-a-enolase purified under denaturing conditions.
(A) Ni2+-NTA agarose chromatograph of the purification of denatured r-a-enolase (refer to material and methods
(Section 2.2.6) for explanation of buffers A to E). (B) Silver stained 1 2 % S D S - P A G E (reducing conditions) and ligand
blot of the buffer E elution peak probed with 2 ug/ml biotinylated plasminogen.

2.3.4 Plasminogen binding properties of r-a-enolase.
Non-denatured dimeric enriched fraction of r-a-enolase (fraction 14) was immobilised
onto microtitre plates and incubated with varying concentrations of biotinylated gluplasminogen (0-20 |xM). Glu-plasminogen binding to r-a-enolase was dose-dependent and
approached saturation above 10 uM (figure 2.6). The non-specific binding of glu-plasminogen
to BLOTTO was low, typically 0.07% at a plasminogen input concentration of 2 JJM, and
thus wells coated with only BLOTTO and probed with biotinylated glu-plasminogen were

used as controls in the microtitre plate plasminogen binding assay. Glu-plasminogen bound ra-enolase with an apparent Kd of 1.9 JJM (figure 2.6). The mechanism of the plasminogenrra-enolase binding was characterised using plasminogen concentrations that corresponded to

the linear portion of the saturation curve (figure 2.6) in the absence or presence of lysin
arginine analogues (figure 2.7). The lysine analogues were the best
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Figure 2.6: T h e r-a-enolase:biotiny!ated plasminogen saturation binding curve.

R-a-enolase (500 pM) was coated onto a 96 well microtitre plate and probed with biotinylated plasminogen (•). Nonspecific binding was determined by probing with biotinylated plasminogen in the presence of a 50 fold excess of n
biotinylated plasminogen (O). Specific binding was calculated by subtracting total binding from non-specific bind
(•)•

inhibitors of glu-plasminogen binding (e-ACA (94%) > T A (80%)), whilst benzamidine had
minimal inhibitory capacity on glu-plasminogen binding (14%).

2.3.5 Carboxypeptidase digestion of r-a-enolase.
To examine whether the C-terminal lysine residue of r-a-enolase mediated its glu-

plasminogen binding capacity, r-a-enolase was immobilised onto the wells of the microt
plate and incubated with CPB to remove the its C-terminal lysine residue. Digestion of
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Figure 2.7: Glu-plasminogen binding inhibition curves.
R-a-enolase (500 pM) was coated to the plates and probed with varying concentrations of biotinylated gluplasminogen (0-2U.M) in the absence ( ) or presence ( O ) of 100 m M inhibitors. Inhibitor-dependent glu-plasminogen
binding was calculated as the difference between the inhibitor + glu-plasminogen binding data and the total gluplasminogen binding data (•).

r-a-enolase with C P B (0-20 IU) inhibited plasminogen binding to the non-denatured dimeric
enriched fraction of r-a-enolase in a concentration dependent manner. This inverse

relationship suggested that the presence of the C-terminal lysine residue from r-a-enolase

important for glu-plasminogen binding (figure 2.8A). The non-specific binding of biotinylat
glu-plasminogen to BSA or CPB was negligible (data not shown). Similarly, removal of the
C-terminal lysine residue from denatured r-a-enolase (figure 2.8B) by treatment with CPB
(20 IU) neutralised its glu-plasminogen binding capacity, indicating that the presence of

terminal lysine residue was critical for the glu-plasminogen binding capacities of both the

non-denatured and denatured forms of r-a-enolase. Both the pharmacological inhibitor resul

(figure 2.7) and CPB digestion data suggested that the mechanism of glu-plasminogen binding
to r-a-enolase was a lysine-dependent process mediated in part by the C-terminal lysine
residue of r-a-enolase.
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Figure 2.8: The effect of carboxypeptidase B digestion on the plasminogen binding capacity of r-a-enolase.
(A) R-a-enolase (1 Ug/ml) was coated onto the microtitre plate and digested with increasing concentrations of
carboxypeptidase B (0-20 IU) for 10 min at 37°C. The carboxypeptidase was removed and the wells probed with 1 u M
biotinylated plasminogen. (B) Non-reducing 1 2 % S D S - P A G E and ligand blot showing the effect of carboxypepidase B
digestion of denatured r-a-enolase and the subsequent ability of biotinylated plasminogen to bind digested r-a-enolase.
Denatured r-a-enolase was incubated with either carboxypeptidase B (20 IU) or with P B S buffer for 15 min at 37°C.
The samples were then fractionated under non-reducing conditions by 1 2 % S D S - P A G E .

2.3.6 Plasminogen Activation Assay.
The efficiency of r-a-enolase-bound glu-plasminogen activation by uPA was
compared between r-a-enolase bound glu-plasminogen and unbound glu-plasminogen using

the Spectrozyme-PL assay. As illustrated by figure 2.9 the activation rate for glu-plasminog
bound to immobilised r-a-enolase was 36-times greater than that for unbound gluplasminogen after 20 minutes.
2.3.7 a2-Antiplasmin Competition Assay

The ability of r-a-enolase to compete with a2-antiplasmin for the lysine binding sites of gl
plasminogen was examined by coating microtitre plates with a2-antiplasmin (10 pM) and
probing with biotinylated glu-plasminogen (100 nM) in the presence or absence of varying
concentrations of r-a-enolase (0-3jiM). R-a-enolase was able to specifically inhibit gluplasminogen binding to a2-antiplasmin in a concentration-dependent manner (figure 2.10),
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Figure 2.10: R-a-enolase/a2-antiplasmin plasminogen binding competition assay.

a2-antiplasmin (10 pM) was coated to the microtitre plate and then probed with 100 nM biotinylated glu-pl
in the presence of increasing concentrations of r-a-enolase (0-3 uM) plus (O) or minus (•) of 100 mM e-AC
at 37°C. The wells were subsequently incubated with avidin-HRP (1:2000 dilution) for 1 h at 37°C and colou
developed.
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with an IC5o= 1.4 |iM. At a concentration of 3 |iM, r-a-enolase completely inhibited gluplasminogen from binding a2-antiplasmin. Moreover, £-ACA (100 mM) was able to
completely inhibit glu-plasminogen binding a2-antiplasmin, suggesting that the interaction of
oc2-antiplasmin with glu-plasminogen was mediated by the lysine binding sites of gluplasminogen. Thus, r-a-enolase prevents the lysine-dependent binding of a2-antiplasmin of
binding to glu-plasminogen.

2.3.8 Refolding r-a-enolase
R-a-enolase was purified under denaturing conditions as previously described was
refolded on the N i - N T A column using an FPLC-mediated binary gradient to slowly dilute the
concentration of urea in solution (figure 2.11 A ) . The most prominent band that was eluted
from the N i - N T A column was a 42 k D a band that corresponded with the predicted molecular
weight of r-a-enolase. The refolded r-a-enolase that eluted from the column was devoid of
glycolytic activity however, it did retain its glu-plasminogen binding capacity (figure 2.1 IB).
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Figure 2.11: Purification of refolded r-a-enolase.
(A) 1 2 % S D S - P A G E of r-a-enolase purified under denaturing conditions and refolded while remaining bound to
the Ni-NTA column. R-a-enolase was refolded on the column by gradually decreasing the urea concentration
from 6 M d o w n to 1 M urea. The r-a-enolase was eluted from the column with P B S containing 250 m M
imidazole-HCl. (B) Biotinylated glu-plasminogen ligand dot blot. Refolded r-a-enolase (5 (xg/ml) was adsorbed
to P V D F membrane for 1 hour. The membrane was washed three times and probed with various concentrations
of biotinylated glu-plasminogen for 1 hour, washed, probed with avidin-HRP for 1 hour and washed. The
membrane was finally developed by E C L .

2.4 Discussion
Several key components of the plasminogen activation cascade, including urokinase
plasminogen activator (uPA) have been localised to the surface of numerous non-malignant
and malignant cell types. Urokinase binds to its cell-surface receptor (uPAR) with high
affinity (Ellis and Dano, 1991). In contrast, glu-plasminogen binds with low affinity to
cell-surface, although there are large numbers of plasminogen binding sites per cell. Several
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cell-surface plasminogen binding protein candidates have been identified, one of which is a 54
kDa ERM (Miles et. al, 1991; Redlitz et. al, 1995).
This chapter describes the expression of the human ENOl gene product (r-a-enolase)
and characterises its glu-plasminogen binding properties (table 2.1). Comparison of the

relevant physiochemical properties of r-a-enolase and the 54 kDa ERM plasminogen binding
protein (Redlitz et. al, 1995) suggested that they are homologous with respect to their
terminal glu-plasminogen binding properties. Therefore, the human ENOl gene encoded an
authentic human a-enolase plasminogen binding protein.
Table 2.1: A comparison of the physio-chemical binding properties of r-a-enolase and the 54 kDa a-enolaselike plasminogen binding protein (Redlitz et. at., 1995).
a-Enolase:Plasminogen Binding Parameters
Molecular Weight
V
d{plasrainogen)

e-ACA-dependent binding
Benzamidine-dependent binding
C-Terminal Lysine-dependent binding
Increased Activation Rate
a-Enolase IC,„
of a2-antiplasmin
Pig
Binding
k
IU
1
,
mi
u
1—
Taken from Redlitz etal. 1995. N / D Not Determined.

i

R-a-Enolase

Enolase-like molecule

42 kDa
1.9 uM
94%
14%
Yes
Yes (uPA)
1.4 uM

54 kDa
1.4 uM
95%
N/D3
Yes
Yes (tPA)
1.2-2.4 u M

R-a-enolase had a predicted molecular weight of 42 kDa, whereas the molecular

weight of wild-type human a-enolase is 46 kDa (Shimizu et. al., 1983). The difference of 4
kDa was due to the N-terminal truncation of the human ENOl cDNA during construction of

the pQE-30ENOl expression plasmid. This was done so as to increase the efficiency of ENO

expression by the QIAexpress system. The absence of this N-terminal fragment of a-enolas

did not significantly affect the plasminogen binding capacity of r-a-enolase, suggesting
amino acid sequence Ser; to Glu47 was not involved in plasminogen binding interaction with
a-enolase. The glycolytic activity of r-a-enolase was poor. One possible reason for the
glycolytic activity of r-a-enolase is that the sequence Ser, to Glu47 is involved with the
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glycolytic activity of the a-enolase enzyme, or alternatively, the r-a-enolase m a y be folded
incorrectly around its active site.
Dimeric, non-denatured r-a-enolase was SDS stable in contrast to wild-type a2+

enolase. The 6xHis N-terminal Ni affinity tag m a y have induced the SDS-stable dimerisation
of r-a-enolase. Alternatively, N-terminal truncation of r-a-enolase may have altered the

tertiary structure of r-a-enolase and hence the dimerisation properties of the molecule, the
inducing an SDS-stable complex. Finally, the E.coli may have folded r-a-enolase incorrectly
thereby inducing an SDS-stable dimer. Nevertheless, both dimeric and monomeric nondenatured r-a-enolase were able to bind glu-plasminogen. Moreover, 6M guanidine-HCl and
8M urea denatured r-a-enolase (monomeric only) were able to bind glu-plasminogen. These

data suggest that neither the quaternary nor tertiary structures of r-a-enolase were importan
for the glu-plasminogen binding capacity of the molecule. Glu-plasminogen binds to
monomeric wild-type a-enolase as determined by SDS-PAGE (Redlitz et. al, 1995) hence,
the glu-plasminogen binding capacity of wild-type a-enolase may also be independent of the

tertiary structure of wild-type a-enolase. Removal of the C-terminal lysine residue from both
r-a-enolase and wild-type a-enolase reduced the glu-plasminogen binding capacities of these
molecules. Based on these structural data the glu-plasminogen binding capacity of a-enolase

is dependent upon the primary structure of a-enolase. That is, while the presence of lysine a

the C-terminal end of the molecule is important the tertiary and quaternary structures of the

molecule is not. Finally the fact that r-a-enolase, expressed in bacteria, had glu-plasminoge
binding properties comparable to wild-type a-enolase suggests that eukaryotic cell posttranslational modification of a-enolase is not required for its glu-plasminogen binding
activity.
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In summary, this chapter demonstrated that h u m a n E N O l gene encoded an authentic
human a-enolase plasminogen binding protein. A major advantage of utilising r-a-enolase in

the further characterisation of a-enolase as a cellular plasminogen binding protein is tha
quantities of purified r-a-enolase can be produced in a reproducible and cost effective
manner. Furthermore, r-a-enolase has an N-terminal 6-His affinity tag and thus directed
binding assays could be performed in which the orientation of r-a-enolase is known.
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Chapter 3

Deconstructing the interaction of glu-plasminogen with its
receptor a-enolase.
3.1 Introduction
As reviewed in sections 1.1.1.2 and 1.1.1.5 glu-plasminogen exhibits a lysine-dependent,
closed, right-handed, spiral conformation (Tranqui et. al, 1979). Removal of N T P from gluplasminogen results in the formation of lys-plasminogen (86 kDa) which has a more open, Ushaped conformation than glu-plasminogen (Marshall et. al, 1994; Weisel et. al, 1994). Sitedirected mutagenesis studies, which removed the lysine binding function of individual kringle
domains, have demonstrated that the closed conformation of glu-plasminogen is maintained

by the binding of multiple kringle LBS motifs with internal lysine residues (M Cance et. a
1995; Cockell et. al, 1998) such as Lys 5 0 and Lys 6 2 located in the N T P of glu-plasminogen

(Cockell et. al, 1998). The presence of this intramolecular lysine binding network suggest
the L B S motifs of glu-plasminogen are occupied by the internal lysine residues of the protein.
Disruptions to the intramolecular lysine binding network of glu-plasminogen by exogenous
lysine analogues induces an open conformation of glu-plasminogen. The interactions of lysine
analogues at multiple sites within glu-plasminogen change the conformation of the protein
from its closed to open state (Markus et. al, 1978; Marcus et. al, 1979). Marshall et al.
(1994) suggested that glu-plasminogen can actually exist in three distinct conformations in
vitro; a (closed), (3 (partially open), and y (fully open).
End-point assays have been used (e.g. Chapter 2 and 5) to study the interaction of gluplasminogen with both cells and cellular plasminogen receptor molecules and have
determined binding parameters such as low affinity and high binding capacity (in the case of
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intact cells). However, detailed kinetic analysis of the binding of glu-plasminogen to its
receptor has not been determined. Thus, BIACORE technology was used to characterise, in

real-time, the relationship between binding and conformational switching of glu-plasmino
using the r-a-enolase as a plasminogen receptor model. Furthermore, fluorescence
spectroscopy was used to confirm a-enolase-induced conformational changes in gluplasminogen observed by BIACORE analysis. Kinetic analysis of the binding of lysplasminogen to a-enolase was also examined since lys-plasminogen has a more open
conformation than glu-plasminogen (Marshall et. al, 1994; Weisel et. al, 1994). Thus, by
comparing the binding kinetics between the two plasminogen forms additional insights may
be gained into the binding mechanism of glu-plasminogen.

The results presented in this chapter provide for the first time direct evidence that the

binding of glu-plasminogen to a-enolase involves a multivalent, competition binding reac
that is associated with a conformational change in glu-plasminogen. The implications of
data will be discussed in terms of the activation of glu-plasminogen.

3.2 Material and Methods
3.2.1 BIACORE Analysis
All BIACORE experiments were performed by M. Lackmann at the Ludwig Institute
for medical research (Melbourne). The binding of glu-plasminogen to r-a-enolase was
analysed on the BIACORE optical biosensor (Pharmacia Biosensor, Sweden) using either aenolase-(His)6-derivatised CM 5 or NTA-modified sensor chips. Covalent immobilisation of
a-enolase onto N-hydroxysuccinimide (NHS, 0.05 M)/N-hydroxysuccinimide-N-ethyl-N'(diethylaminopropyl)carbodiimide (0.2 M) - activated sensor chips. Prior to analysis,
plasminogen was buffer exchanged (Phast-desalting column, 100 x 3.2 mM, Amersham-
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Pharmacia) into B I A C O R E running buffer (10 m M Hepes, 150 m M NaCl, 1.4 m M E D T A ,
0.005% Tween-20, pH 7.4) and adjusted to a concentration of 10 uM. From this stock
solution dilutions were prepared for BIACORE experiments. The affinity surface was

regenerated between subsequent sample injections of plasminogen with 35ul of a desorpti
buffer (3M MgCl2, 0.075 M Hepes/NaOH, 25% ethylene glycol, pH 7.2) followed by two

washes with BIACORE running buffer. Alpha-enolase (His)6 (15 ul, 200 nM) was also bound
onto a NTA-modified sensor chip (BIACORE AB, Sweden) which had been charged with an
injection of 25 ul NiCl2 (0.5 mM) in modified running buffer containing 50 uM EDTA. In

these experiments the chip surface was regenerated after sample application by sequenti

ul-injections of 6M guanidine-hydrochloride, 50 mM EDTA, 20 mM Tris, pH 8.6 and of 0.35
M EDTA, 0.15M NaCl, 0.005% Tween 20, pH 8.2. To minimise differences in the a-enolase

concentration on the chip surface, injection of both NiCl2 and a-enolase (His)g from th
NiCl2 and a-enolase stock solutions were used for all experiments.

3.2.2 Analysis of BIACORE sensorgram data.
A minimum of six data sets corresponding to glu-plasminogen binding reactions at

concentrations between 4 uM and 63.5 nM were analysed. Fitting the sensorgram data to t

algorithms of reaction schemes 3.1 and 3.2 involved analysing the individual associatio
dissociation phases of each binding reaction using the BIAevaluation software, version
The global fit modeling of reaction schemes 3.3-3.5 involved the simultaneous fitting
association and dissociation phases of the individual binding reactions.
The ^-statistics test was used to determine whether a particular reaction scheme (i.e.
expected outcome) was a good mathematical representation of the plasminogen binding
sensorgram data (observed binding data).
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Models that displayed small %2 values and which did not vary by a large magnitude
over the range of plasminogen concentrations examined, were deemed to be a good
mathematical representation of the sensorgram data. Furthermore, deviations of the

sensorgram data from the expected reaction scheme model had to be small and random si
Reaction scheme 3.1: A+BoAB : a simple 1:1 Langmuir kinetic.
Reaction scheme 3.2: Ai+BjoAiBi : a two or more component kinetic, without
knowledge of the concentrations of individual
components, only dissociation rates can be estimated
Reaction scheme 3.3: A+B<->AB<->A B : the two-state reaction/conformational change
model: Analyte (A = plasminogen) binds to ligand (B
= a-enolase). Complex AB changes to A*B which
cannot dissociate directly to A+B.
Reaction scheme 3.4: A+B 1 <->AB 1;
A+B2oAB2 : heterogeneous ligand (B = a-enolase), parallel
interactions: one analyte (A = plasminogen) binds
independently to two binding sites (Bl, B2). Two
independent sets of rate constants, kal, kdl and ka2,
kd2
Reaction scheme 3.5: A+B^AB;
AB+BoAB2 : Bivalent analyte A (plasminogen) binds to a
monovalent ligand B (a-enolase)
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the magnitude of these residuals demonstrates the quality of the sensorgram data and are
another measure of how well the expected reaction scheme fits the observed binding data
(O'Shannessy et. al, 1993).
3.2.3 Intrinsic Fluorescence Spectroscopy
All fluorescence experiments were performed using a F4500 Fluorimeter (Hitachi)
with a slit width of 5 nm at room temperature. Plasminogen species (1 uM) in 50 mM TrisHCl (pH 7.0), 100 mM NaCl were excited at 280 nm and the intrinsic fluorescence emission
spectra were measured from 300-450 nm.

3.3 Results
3.3.1 Dissociation kinetics of glu- and lys-plasminogen from immobilised a-enolase.
This study describes for the first time the dissociation kinetics of glu- and lysplasminogen from sensor chip-immobilised a-enolase. The BIACORE sensorgrams (binding

curves) obtained from the binding of increasing concentrations of glu- and lys-plasmino
NHS-immobilised a-enolase are shown in figure 3.1. A qualitative assessment of the

250

T
500
time (s)

1000

250
500
time (s)

1000

Figure 3.1: B I A C O R E analysis of glu- and lys-plasminogen binding to NHS-immobilised a-enolase.
(A) Samples containing increasing concentrations of glu-plasminogen in B I A C O R E running buffer were
injected onto a sensor chip which had been derivatised with immobilised a-enolase using N H S / E D C chemistry.
The decreasing responses reflect samples containing 4, 3, 2, 1, 0.5, 0.25, 0.125, 0.0625 u M glu-plasminogen.
Arrows marked with I and II indicate the start and end of the sample injection (start of association and
dissociation phases), respectively. (B) T h e response curves for the interaction of varying concentrations of lysplasminogen with the sensorchip-immobilised a-enolase are shown. Coupling of a-enolase and concentration of
lys-plasminogen were according to the conditions described in A.
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sensorgrams reveals obvious differences in the interaction of glu-plasminogen (figure 3.1 A )
and lys-plasminogen (figure 3.IB) binding with a- enolase. This was most evident in the
contours of their steady-state phases (between arrow I and II) which did not result in
equilibrium binding under these experimental conditions, importantly, the contour of the
sensorgrams suggested a heterogeneous interaction for both glu-and lys-plasminogen with aenolase.
By comparing the fit of the experimental data to different kinetic algorithms available

in the BIAevaluation software we set out to establish a suitable kinetic model for the obser

binding data (Table 1). The linear one-to-one pseudo-first order model (Reaction scheme 3.1)
2
did not fit the data, as indicated by a pronounced decrease in the "goodness of fit", %

(increase of %2 above the "signal noise" of 3 - 6 RU) with increasing analyte concentrations

(Table 3.1) and by a marked deviation of the "offset values" (deviation of the fitted respon
2
at t = oo) from zero (not shown). Similarly, the concentration-dependent increase of % values
in the fit of association data to the single component model confirms that the interaction
cannot be described adequately by this model. In contrast, the multiple component
dissociation model (Reaction scheme 3.2), which does not require knowledge of the analyte
concentration, produced an accurate fit to the dissociation data and yielded % values close
zero at all concentrations of glu- and lys-plasminogen analysed (Table 3.1). Statistical
comparison of the fits (%2 values) to the two models by F-test confirmed that the multiple
component model is a better mathematical representation of our data, since F-test values of
1.0 were obtained for both glu- and lys-plasminogen binding. Both glu- and lys-plasminogen
had similar, apparently rapid (low affinity)
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dissociation rates (k d l = 4.7xl0"2 s1 and4.0xl0" 2 s"1, respectively) from NHS-immobilised aenolase (Table 3.1). While the slow dissociation rate (high-affinity) component of lysplasminogen (kd2= 6.3xl0"4 s"1) was two-fold lower compared to that of glu-plasminogen
o 1

(kd2= 1.6x10" s" ) (Table 3.1), it was clear that both glu- and lys-plasminogen interacted w

a-enolase via at least two distinct binding sites. In addition, e-ACA competitively disrup
the binding of glu- and lys-plasminogen to NHS-immobilised a-enolase (M. Lackmann pers.

communication), confirming the role of lysine in these interactions (Chapter 2; Redlitz et
1995). Similar binding experiments were also performed using a sensor chip with
substantially less NHS-immobilised a-enolase (1.3 ng/mm2 versus 4.3 ng/mm2 immobilised).

Whilst the overall responses were reduced, very similar binding characteristics were obser
(M. Lackmann pers. communication). This indicated that the kinetics were not effected by
mass-transfer limitations during the interactions of glu- and lys-plasminogen on the more

densely derivatised sensor chip. Furthermore, to confirm that the heterogeneous kinetics w

characteristic of the interaction between glu- and lys-plasminogen and a-enolase and/or its
components, and not due to the random orientation of a-enolase on the chip, a-enolase was
also immobilised in a defined orientation via its N-terminal 6-Histidine tag. Under these
experimental conditions, very similar binding characteristics were observed for both glulys-plasminogen binding, and a representative set of glu-plasminogen sensorgrams are shown
in figure 3.2. Again, the multiple component reaction model best approximated the

dissociation phase of this interaction (Table 3.1) and the estimated dissociation rate con
2 -1 -3 -1
(kdl = 6.1x10

s

and kd2 = 1x10

s ) were comparable to those obtained for the binding

of glu-plasminogen to NHS-immobilised a-enolase (Table 3.1).

Ill
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Figure 3.2: B I A C O R E analysis of glu-plasminogen binding to Ni 2+ -NTA immobilised a-enolase.

oc-Enolase was immobilised onto a Ni2+-NTA chip by its N-terminal 6-his affinity tag. The decrea
reflect samples containing 4, 3, 2, 1, 0.5, 0.25, 0.125 and 0.0625 uM glu-plasminogen. Followin

of glu-plasminogen, bound ligand, Ni and a-enolase were stripped from the NI -NTA-chip and the a

surface regenerated by the injection of Ni + and a-enolase prior to the injection of glu-plasmin
methods). The sensorgrams presented only show the progress data for the injection of glu-plasmin
and its dissociation (arrow II) from the a-enolase surface.

3.3.2 Two-state conformational change reaction model
We performed global fitting of the BIACORE binding data to further define the
interaction mechanisms. Firstly, a global fitting program was used to identify a suitable
kinetic model which would provide a convincing representation of the BIACORE data. In
this process, the entire binding data describing the plasminogen/a-enolase interaction at

different plasminogen concentrations were fitted to a number of kinetic algorithms, includ

linear one-to-one interaction and several complex interaction models. The selected kinetic

model(s) was then used to simultaneously analyse the kinetic parameters of the association

and dissociation phases of the individual plasminogen/a-enolase binding curves (Tables 3.2

and 3.3). The probability of an appropriate fit of the experimental data to the selected m
are also shown in Tables 3.2 and 3.3. The two-state reaction/conformational change model
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(Reaction scheme 3.3) yielded a good fit within the range of glu-plasminogen concentrations
2
examined (% : 0.9 - 2.2; Table 3.2). As suggested by the contour of the binding curves, the
interaction of glu-plasminogen with a-enolase was characterised by an initial apparent fast
2 1
dissociation rate (k*ji = 2.64 ± 0.6 x 10 s ) and an association rate which was increasing
with decreasing glu-plasminogen concentrations (kal = 4.3 - 19.3 x 103M"1s"1). In contrast,
the second phase of the interaction appeared to proceed in a largely concentration3 1 1
independent manner with markedly lower on and off rates (k a 2 = 3.8 x 10 M s

and k d 2 =

-4-1
7.4 ±0.27 x 10 s ). Overall, the dissociation rate constants derived by fitting the binding
data to this model are within close range of the rate constants estimated by the non-linear
regression analysis discussed earlier (Table 3.1). An alternative model, assuming a
heterogeneous population of sensor chip-immobilised a-enolase binding glu-plasminogen in
2
parallel reactions (Reaction scheme 3.4) yielded a markedly decreased fit with %

values

between 1.9-141 (Table 3.2) and does not adequately represent the data. Similarly, global
analysis with an algorithm which adjusts for mass transfer limitations of the analyte

(plasminogen) binding to a sensor surface of high ligand (i.e. a-enolase) concentration gav
poor fit to the data (data not shown), confirming that these effects did not influence the
kinetics of the interaction. Analysis indicates that the binding of glu-plasminogen to aenolase involves a conformational change in glu-plasminogen, which in itself effects the

binding in a second phase of the interaction. In contrast, the generally large % values obt

for the lys-plasminogen binding data indicated that none of the global fitting models curre

available fitted the data over the entire lys-plasminogen concentration range used (Table 3
As stated above, the two-component model is determined independently of the association
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phases and provided a strong fit of the lys-plasminogen dissociation data (Table 3.1). Since
the dissociation rate constants shown in Table 3.3
Table 3.2: Kinetic parameters of the glu-plasminogen/a-enolase interaction.
Concentration

Kd

uM

uM

M-V

1.5
1.4

103
4.3
5.0
6.3
8.6

4
3
2
1
0.5
0.25

1.05

0.6
1.5
0.2

kal

11.9
19.3

kdl
1

ka2

v2

10" 3

Reaction

Ligand

4.5
4.3
4.1
4.2
2.8
2.6

8.0
9.3
9.7
9.6
2.6
5

2.0
2.2
2.0
1.1
0.9
0.9

22.1
26.5
23.9
4.94

3.5
2.8
2.2
2.0
2.1

v2

-1
s
IO" 4

M-V

3.26

kd2

X
Two-State-

-1
s
IO" 2

1

X
Heterogeneous

141

1.9

2.64
1.0
3.8
7.4
Mean
1) The binding data were fitted to the two kinetic algorithms of the BIAevaluation 3.0 software (see methods)
which yielded the closest match of experimental data with the chosen model. The listed kinetic constants are
2
derived in each case only from the candidate model with the closest fit (lowest % value).
2) Mean values were estimated only for those parameters which did not indicate a concentration-dependent
change.

Table 3.3: Kinetic parameters of the lys-plasminogen/a-enolase interaction.
Concentration

\M
4
3
2
1
0.5
0.25
0.125

Kd
UM
3.2
2.6
0.8
0.9
:3.5
K D I .1.9
K D 1 :0.8
KQ!

kai
M-'s"1

kai
s"1

IO4
2.0
2.4
2.6
3.8
1.9
2.7
5.9

IO'2

7.6
7.6
6.6
5.5
6.6
5.3
4.5

ka2
M-'s"'

kd2

s"'
10"3

3.3 xlO"3
3.2 xlO"3
2.6 xlO"3
1.8 xlO"3
6.6 xlO"7
7.8 xlO"7
19.5 xlO"7

2.7
2.6
0.9
1.2
1.1
1.0
1.2

x2

x2

Two-StateReaction'
48.3
24.7
15.8
41.1

Bivalent
Analyte'

363
320
193

121
475
112
1240
8.79
3.42
1.96

1.5
6.2
Mean 2
1.0
on 3.0 softwar 3 (see methoc
BIAevaluati
rithms
of
the
1) The binding cata were fitt
;d to the two kinetic algo
which yielded the closest match of experimental data with the chosen model. The listed kinetic constants are
derived in each case only from the candidate model with the closest fit (lowest % value).
2) M e a n values were estimated only for those parameters which did not indicate a concentration-dependent
change.

were similar to those obtained by the two-component model for the same range of lysplasminogen concentrations (Table 3.1), it is possible that the association phase is the

component of the binding interaction that cannot be deconvoluted by any of the global fittin
algorithms currently available, at least under the physiological-like conditions used in these
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experiments. In any case, it is clear that the binding mechanisms between glu- and lysplasminogen are distinct.

3.3.3 Intrinsic fluorescence spectroscopy
To confirm that binding with a-enolase induces a conformational change in gluplasminogen, the intrinsic fluorescence spectra of glu-plasminogen in the presence and
absence of a-enolase were determined (figure 3.3). These were compared to the intrinsic

fluorescence spectra of glu-plasminogen in the presence and absence of the lysine analogue
ACA, previously shown to "open" glu-plasminogen resulting in an increase in its intrinsic
fluorescence Christensen and Molgaard, 1992). In addition, the spectra of plasmin and lysplasminogen, having a more open conformation than glu-plasminogen (Marshall et. al, 1994;
Weisel et. al, 1994), are shown for comparison.

B
6000
Lys-plasminogen

Lys-plasminogen

Glu-plasminogen:r-rx-enolase

-Glu-plasminogen + e-ACA
Glu-plasminogen

Glu-plasminogen
e-ACA
r-a-enolase

300

350
400
Wavelength (nm)

300

350
400
Wavelength (nm)

450

Figure 3.3: C o m p a r i s o n of the intrinsic fluorescence spectra of glu-plasminogen in the absence a n d
presence of e - A C A or a-enolase to those of plasmin a n d lys-plasminogen.
(A) T h e fluorescence spectra of 1 u M plasmin, glu- and lys-plasminogen, glu-plasminogen + 100 m M e - A C A
and 100 m M e - A C A control were obtained after excitation at 2 8 0 n m . (B) T h e fluorescence spectra of 1 u M
plasmin, glu- and lys-plasminogen, glu-plasminogen + 190 n M a-enolase and 190 n M a-enolase control were
obtained after excitation at 2 8 0 n m . T h e intrinsic fluorescence of both e - A C A (117) and a-enolase (146) at the
concentrations used for these experiments were negligible. Higher concentrations of a-enolase were not be used
as this alone w a s associated with increased intrinsic fluorescence.
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Plasmin and lys-plasminogen had comparable relative intrinsic fluorescence emission
maxima at 330 n m (4850 and 4694, respectively). In contrast, the relative intrinsic
fluorescence m a x i m u m for glu-plasminogen was significantly lower (3480). Addition of 8A C A to glu-plasminogen (figure 3.3A) resulted in a significant increase in the relative
intrinsic fluorescence of glu-plasminogen (AF=1019) to one which was comparable to the
relative fluorescence obtained for the same concentration of either lys-plasminogen or
plasmin. The addition of a-enolase to glu-plasminogen (figure 3.3B) also induced a
significant increase in the relative intrinsic fluorescence of glu-plasminogen (AF= 785) which
was suggestive of a conformational change.

3.4 Discussion
This study aimed to define the binding kinetics and associated conformational changes
glu-plasminogen undergoes during an interaction with its cellular receptor, a-enolase.
Experiments were performed

using B I A C O R E

technology under physiological-like

conditions and analysed using BIAevaluation software (version 3.0). Identical experiments
were performed with lys-plasminogen for direct comparison with glu-plasminogen on the
basis that lys-plasminogen has a more open conformation and is more readily activated. This
feature of lys-plasminogen that has been exploited by numerous studies that have examined
conformational status and activation rate of the different plasminogens, both in solution and
in the presence of binding moieties (reviewed in Markus, 1996).
The simplest reaction model that described the lysine-dependent dissociation phases of
both the glu- and lys-plasminogen sensorgrams is the non-linear multiple component
dissociation model (Reaction scheme 3.2). Glu-plasminogen has also been shown to bind to a
lysine-derivitised sensor chip surface with multiple dissociation reactions (Warkentin et. al,
1998). Such multiple dissociation reactions were not surprising since both plasminogen
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species have up to four L B S potentially available for binding. The contours of the
sensograms, being obviously different, were suggestive of different binding mechanisms, as
might also have been expected from the different initial conformations of glu- and lysplasminogen. While global fitting of the glu-plasminogen binding data could be accurately
described by the two state reaction/conformational change model (Reaction scheme 3.3) over
the entire concentration range of glu-plasminogen used (which spanned its physiological

concentration of 2 LiM), the lys-plasminogen binding data could not. In fact, lys-plasminoge

could not be adequately described by any of the currently available global fitting algorithm
at least under the physiological conditions we used to compare glu- and lys-plasminogen

binding. Since lys-plasminogen is not detectable in vivo (Holvoet et. al, 1985; and certainl
not at the micromolar concentrations of lys-plasminogen used in these experiments) it is
concluded, that under the conditions used in this study, that lys-plasminogen may not be as

useful as initially anticipated for comparing to the binding kinetics of glu-plasminogen. Fo
these reasons the remainder of this discussion deals with the mechanism of glu-plasminogen
binding.
The two-state reaction/conformational change model that describes the binding of glu-

plasminogen to a-enolase suggests that the initial conformation of glu-plasminogen is altere
after it has been bound by a-enolase. Furthermore, both a-enolase and e-ACA produced an
increase in the intrinsic fluorescence of glu-plasminogen. This reflected a conformational
change to a more open form and validates the two-state reaction/conformational change
model as a description of the binding of glu-plasminogen to a-enolase.
The association phase kinetics of glu-plasminogen binding to a-enolase suggested by
the two-state conformational change model are complex. The relative magnitudes of kal and
ka2 for this interaction differ by approximately 6 orders of magnitude, indicating that the
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majority of the observed binding of glu-plasminogen to a-enolase is due to k a i. However,

kai, unlike ka2> is not constant, but increases with decreasing glu-plasminogen concentrati
A decreasing concentration of glu-plasminogen can also be viewed as a relative increase in
the a-enolase abundance which is paralleled by an increase in kal. The acceleration in the

initial glu-plasminogen to a-enolase binding rate as the relative concentration of a-enolas
increases would indicate a competition reaction. This suggests that during the initial

interaction an a-enolase lysine residue competes with and displaces a lysine residue of glu
plasminogen from one of its LBS motifs. This would disrupt the closed, lysine-dependent
conformation of glu-plasminogen and induce a conformational change in the zymogen
revealing a second LBS (figure 3.4). The second binding event (ka2) may stabilise this new
conformation of glu-plasminogen. Hence, the interaction of glu-plasminogen with a-enolase

would be mediated by at least two binding events; an initial competition reaction that resu
in a lysine-dependent conformational change to glu-plasminogen, followed by a second

binding event that stabilises the new conformation (figure 3.4). In agreement with this no
the lysine-dependent binding of a2-antiplasmin may also involve two or more LBS motifs of

plasmin(ogen) (Christensen et. al, 1995). The actual lysine residues of a-enolase(s) involv

in the interaction with glu-plasminogen remain to be determined. There are several possible

candidates, of which the C-terminal lysine is likely to play a role (Chapter 2; Redlitz et.
1995)
Taken together, these data suggest that at circulating levels of 2 (iM, glu-plasminogen
will bind to cell surface receptors (such as a-enolase) and be converted to an open

Chapter 3: Kinetics of plasminogen binding to a-enolase.

Lys

118

(Gli>Plg)

residues

^al

M1

reversible
conformation
change

J-**k

<3^
VJ2_

•>d2

Figure 3.4: A model of glu-plasminogen interaction with a-enolase.
A lysine residue from an a-enolase molecule ( O ) competes with and dissociates an internal lysine residue of
glu-plasminogen that initially occupied a L B S («) of glu-plasminogen (kai/k<ii). This induces a lysinedependent conformational change in glu-plasminogen making another L B S (•) available which can interact with
a second lysine residue from a-enolase (ka2/kd2)- This stabilises an open conformation of glu-plasminogen that
may be more susceptible to activation. Note, the second binding interaction of glu-plasminogen m a y be mediated
either by lysine residues within a single a-enolase molecule, or by lysine residues on separate a-enolase
molecules. However, for clarity only the former possibility is shown here.

conformation. This finding agrees with the well documented observation that the binding of
small lysine analogues to glu-plasminogen changes its conformation which in turn enhances
its activation rate by the plasminogen activators (see Section 1.1.1.6). In addition, it has
shown that the lysine-dependent binding of glu-plasminogen to fibrin, cell and isolated
receptors including a-enolase (Table 1.2; Chapter 2; Redlitz et. al, 1995), facilitates an
increase in the rate of glu-plasminogen activation. Since the interaction between gluplasminogen and a-enolase is associated with a change to a more open conformation of gluplasminogen, this suggests that the physiologically important role of cell surfaces

plasminogen binding proteins is to present glu-plasminogen in a form that is essential for it
efficient activation by the plasminogen activators.
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Chapter 4

The production and characterisation of polyclonal and
monoclonal antibodies against the plasminogen
binding protein human a-enolase.
4.1 Introduction
The expression and characterisation of the h u m a n E N O l gene product
confirmed that h u m a n a-enolase is an authentic glu-plasminogen binding protein
(Chapter 2). In m a m m a l s there are three dimeric glycolytic enolase isoforms: neuronspecific y-enolase, muscle specific (3-enolase and the ubiquitous a-enolase (Shimizu

et. al, 1983). Since a-enolase is a glycolytic enzyme it is hypothesised that it will b
highly conserved. As such human a-enolase may have high sequence similarity to
mouse a-enolase. Several groups have successfully generated monospecific rabbit
polyclonal antibodies against human a-enolase (Redlitz et. al, 1995; Shimizu et. al,
1983; Suzuki et. al, 1980). However, monoclonal antibodies that have been raised
against a-enolase using classical techniques display low reactivity against a-enolase
(Redlitz et. al, 1995).
Several h u m a n pathological conditions such as discoid lupus erythematosus
result in the production of autoantibodies specific for a-enolase (Adamus et. al,
1998; Orth et. al, 1998; Gitlits et. al, 1997; Akisawa et. al, 1997; Moodie et. al,
1993; Walter et. al, 1995) suggesting that these anti-a-enolase autoantibodies m a y
have a broad disease association (Gitlits et. al, 1997).
The N e w Zealand Black ( N Z B ) mouse strain, which develops a lupus-like
pathology, appear to be genetically predisposed to the spontaneous development of a
wide range of autoantibodies (Payelle-Brogard et. al, 1998; Theophilopoulos and
Dixon, 1985). The reasons for the production of autoantibodies by the mice are
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complex and remain ambiguous, however the NZB immune system changes its
characteristics over time. For example, B lymphocytes from aging N Z B mice replace
their normal IgM and IgG cell surface receptors with monoclonal IgM cell surface
receptors (Bhoopalam et. al, 1973). Furthermore, N Z B mice bone marrow becomes
increasing deficient in small pre-B and pro-B/early pre-B cell subpopulations possibly
due to the production of anti-IL-7 monoclonal autoantibodies which interfere with the
development of the B-cell lineage (Merchant et. al, 1996). Nevertheless, the N Z B
mouse system has been used for the successful production of monoclonal antibodies
against several weak antigens (Frosch et. al, 1985; A d a m u s et. al, 1991; Jacquemart
et. al, 1988; Ballard et. al, 1983; Sanai et. al, 1988; Doberson et. al, 1985) and m a y
represent a suitable system for the production of monoclonal antibodies against
human a-enolase.
The aim of this chapter was to generate anti-a-enolase antibodies that could
neutralise the plasminogen binding capacity of a-enolase and to determine the
fraction of plasminogen binding a-enolase that was due to cell-surface a-enolase.

This chapter describes the successful production and limited characterisation of bo
rabbit polyclonal antibody sera and a panel of mouse monoclonal antibodies that
recognise human a-enolase.

4.2 Materials and Methods
4.2.7 Animals and Materials
N e w Zealand Black ( N Z B ) mice were purchased from Walter and Eliza Hall
Institute of Medical Research (Melbourne, Australia). The Balb/C mice were bred in
house at the University of Wollongong. N e w Zealand White rabbits were purchased
from the University of New South Wales (Sydney, Australia).
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Polyethylene glycol (4000), Hybrigrow, HAT, HT media and complete
protease inhibitor tablets were all purchased from Boehringer Mannheim (Heidleberg,
Germany). Iscoves modified Delbeccos medium (DVIDM) was purchased from Life
Technologies (Sydney, Australia). Monoclonal antibody isotyping (Isostrip) kit,
Freunds complete and incomplete adjuvants were purchased from Sigma. Goat antimouse alkaline phosphatase ( G A M - A P ) , goat anti-rabbit-HRP (GAR-HRP), goat antirabbit alkaline phosphatase ( G A R - A P ) Goat anti-mouse I g M - H R P conjugate were all
purchased from Calbiochem/Novabiochem Sydney, N S W Australia. The D A K O
L S A B + Kit was from D A K O Corporation (CA, U S A ) .
4.2.2 Preparation of Antigen
H u m a n r-a-enolase was expressed and purified as described previously in
chapter 2.
4.2.3 Preparation of R-a-enolase inclusion bodies.
The r-a-enolase inclusion bodies were prepared according to the method of
Harlow

and

Lane

(1988) and

stored

at -20°C

until required. Briefly,

E.C0//JM1O9ENO1 cells were centrifuged at 10,000g for 10 min at 4°C. The pellet
(10% w/v) was resuspended in ice cold lysis buffer (50 m M Tris-HCl (pH 8.0), 150
m M NaCl, 5 m M E D T A , protease inhibitor cocktail [Boehringer Meinheim]) and
incubated with lysozyme (1 mg/ml) for 20 min at room temperature with gentle
agitation. The lysate was centrifuged for 10 min at 10,000g at 4°C and the pelleted
spheroplasts resuspended in 50 m M Tris-HCl (pH 8.0), 150 m M NaCl, 5 m M E D T A
and 1 % Na-deoxycholate for 10 min on ice. The lysate was supplemented with 8 m M
M g C l 2 incubated with 10 ug/ml DNasel for 20 min at room temperature with

occasional agitation of until the viscosity of the solution decreased. The lysate wa
pelleted at 7000 g for 10 min at 4°C and washed once with 50 m M Tris-HCl (pH 8.0),
150 m M NaCl, 5 m M E D T A and 0.1% nonidet (NP-40). The inclusion bodies were
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centrifuged at 14,000 g for 10 min at 4°C and washed twice with ice cold PBS. The
purity of r-a-enolase in the inclusion body preparation was determined by SDSPAGE.
4.2.4 Preparation of Fibroblast Conditioned Medium (FCM).
The mouse fibrosarcoma cell line L929 was cultured for 48 hours in 50 ml
EVIDM medium supplemented with 10% heat inactivated FCS, 100 fig/ml
streptomycin and 100 IU/ml penicillin G at 378C in a 10% CO2, 85% humidified
incubator. At confluence the L929 cell culture supernatant was centrifuged at 200g
and sterile filtered. The F C M was stored at -20°C until required.
4.2.5 Preparation of Hybridomas
Both female N Z B

and B A L B / C mice (6-8 weeks old) were injected

intraperitoneally with 100 |ig of r-a-enolase inclusion bodies emulsified 1:1 with
Freunds complete adjuvant (250 ul/mouse). Four weeks later the mice were given a
second intraperitoneal injection of 50 ug of r-a-enolase inclusion bodies emulsified
with 1:1 Freunds incomplete adjuvant (250 ul/mouse). Sera were examined for r-aenolase antibodies by ELISA (see below). Two weeks later all mice were
hyperimmunised by intraperitoneal injection with 50 ug of r-a-enolase inclusion
bodies in sterile PBS (250 ul/mouse) a total of three times in seven days. The sera
were examined for r-a-enolase antibodies by ELISA (see below). Four weeks after

the final hyperimmunisation injection the best responder were injected i.v. with 50 u
of soluble r-a-enolase in 200 ul of sterile PBS for three consecutive days prior to
splenectomy. Splenocytes were fused to the non-Ig producing Sp2/Ag8 mouse
myeloma cell line according to the method described in Harlow and Lane (1988). Ra-enolase antibody secreting hybrids were identified using the ELISA assay described
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below and cloned out by limiting dilution. The resulting monoclonal antibodies were
isotyped using the Isostrip isotyping kit (Sigma).
4.2.6 Antibody Screening ELISA
Hybridomas and subsequent clones were screened for antibody production by
ELISA. Briefly, 5 ug/ml of r-a-enolase (100 ul/well) was coated onto 96 well plates
in 0.1 M Na-carbonate (pH 9.6) and incubated overnight at 4°C. The antigen solution
was removed and the wells washed three times with PiNT wash buffer (50 m M Naphosphate (pH 7.2), 150 m M NaCl, 0.05% Tween-80). Each well was blocked by
incubation with 100 ul of wash buffer supplemented with 1 % B S A (PiNT/BSA) for 1
hour at 37°C. The blocking buffer was removed and the wells washed once with
PiNT and either 100 ul aliquots of immune (1:100 dilution) or pre-irnmune (1:100
dilution) sera in PiNT/BSA or 100 |il of hybridoma tissue culture supernatant were
added to the wells and incubated for 1 hour at 37°C. The micro-titre plates were
washed three times with PiNT and then 100 ul of either G A R - H R P or G A M - H R P
solution diluted to 1:5000 with PiNT/BSA was added as the secondary antibody.
After incubation for 1 hour at 37°C the wells were washed four times with PiNT and
the plates were developed and processed as described above.
4.2.7 Monoclonal IgM storage and Western Blotting.
Hybridoma supernatant was centrifuged at 10,000g for 30 min and filtered
through 0.22 u m membrane. The p H was adjusted to 8.2. Glycerol ( 3 0 % v/v) and
thirmersal (0.02% w/v) were added. The supernatant was stored at 4°C until required.
Anti-r-a-enolase I g M monoclonal antibodies were concentrated and partially purified
by ultrafiltration using centriprep 500 concentrators. These supernatants were also
stored at 4°C until required.
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Denatured r-a-enolase or whole cell lysates were fractionated by 12% SDSPAGE under reducing conditions and transferred to PVDF membrane. The transferred
membranes containing r-a-enolase were washed for 5 min with T B S and then blocked
overnight at 4°C with T B S supplemented with 1 % B S A (TBS/BSA). The blots were
incubated for 1 hour at room temperature with neat hybridoma supernatants
containing 0.05% Tween-20 (pH 7.5; 10 ml). The blots were washed three times for 5
rnin each with T B S supplemented with 0.05% Tween-20 (TBST) and re-blocked for
15 min with T B S T / B S A . The blots were incubated with a 1:2000 dilution of G A M H R P (IgM-specific), washed twice for 5 min with T B S T and once with T B S and
developed using E C L .

4.2.8 Anti-human a-enolase rabbit polyclonal antibody production.
A male N e w Zealand White ( N Z W ) rabbit (14 weeks old) was immunised s.c.
with 1 m g of antigen in sterile P B S emulsified 1:1 with complete Freunds adjuvant (1
ml) between the scapulae (100 ul/site). Twenty one days post-immunisation the rabbit
was boosted with another subcutaneous injection of 1 m g of antigen in sterile P B S
emulsified 1:1 with incomplete Freunds adjuvant (1 ml) (100 jj.l/site). I m m u n e serum
from the rabbit was taken, 28 days after the initial immunisation. The rabbit was
boosted with 1 m g of antigen in 1 ml sterile physiological saline 49 days postimmunisation and one week later was bled and the serum collected and processed.
4.2.9 Polyclonal Antibody immunopurification.
A Ni-NTA-sepharose column was loaded with r-a-enolase as described for the

non-denaturing purification of r-a-enolase. However, the r-a-enolase was not elute
but rather the column was equilibrated with 10 column volumes of equilibration
buffer (50 m M Tris-HCl (pH 7.4), 150 m M NaCl) and the r-a-enolase anti-serum (2
ml) was applied to the column by gravity flow. The column was then washed with 5
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column volumes of equilibration buffer, followed by 5 column volumes of wash
buffer (50 mM Tris-HCl (pH 7.4), 2M NaCl). The anti-r-a-enolase polyclonal
antibody was eluted by incubating the column with 1 column volume of 4M MgCl2

(pH 7.2) for 15 minutes, and the column was allowed to flow under gravity. The ant

r-a-enolase polyclonal antibody was collected and dialysed against ddH20 for 1 ho
and then against PBS for 24 hours with three changes of buffer.
4.2.10 Human cancer cell culture.
The human breast cancer cell lines (MCF-7, M D A - M B - 2 3 1 , T-47D) were
gifts from Prof. R. Sutherland (Garvan Institute of Medical Research, Sydney, N S W ,
Australia). The human colon cancer cell lines (HCT116, K M 1 2 - S M ) were obtained
from the John Curtin School of Medical Research. U937 cells were purchased from
A T C C . The human breast and colon cancer cell lines were all routinely cultured in
RPMI-1640 supplemented with 1 0 % (v/v) heat-inactivated fetal calf serum. The
insulin-dependent T-47D cell line was cultured in the above media containing insulin
(0.2 IU/ml). U 9 3 7 cells were routinely grown and passaged in D M E M supplemented
with 1 0 % heat inactivated fetal calf serum. All the cells were incubated in a
humidified incubator at 37°C with a 5% CO2: 95% air atmosphere.

4.2.11 Whole cell lysate preparation
Confluent cells were washed with sterile ice-cold phosphate-buffered saline
(PBS) and harvested by scraping with a rubber policeman. The cells were incubated
with cell lysis buffer [50 m M Tris-HCl (pH 8.0), 150 m M NaCl, 4 m M MgCl2, 10 %
glycerol, 5 mM EDTA, 1 mM PMSF, 0.1% (v/v) Triton X-100, 0.5% (w/v) Na-

deoxycholate] at 4°C for 20 min. The resulting lysates were collected and centrif
at 14000 g for 15 min at 4°C and the supernatant stored at -20°C until required.

Chapter 4:Anti-a-enolase antibody production.

yyc.

4.2.12 Immunohistochemistry
Cells were grown on glass coverslips for 48 without changing the growth
media. The cells were washed three times with PBS at room temperature. The cells
were then fixed by incubation with PBS supplemented with 1% gluteraldehyde for 1
hour at room temperature and then washed once with PBS. The fixed cells were
permeabilised by incubation with PBS supplemented with 0.2% TX-100 for two
minutes and then washed with PBS. Endogenous peroxidases were inactivated with
3% H202 for 5 minutes. The cells were incubated with 10% human serum for 30
minutes and washed with PBS. Rabbit anti-r-a-enolase polyclonal antibody diluted
1:50 with PBS/10 % human serum (200 ul) for 1 hour at room temperature. The cells
were washed twice with PBS and incubated with the secondary reagents from the
DAKO LSAB+ Kit according to the manufactures instructions. After rinsing with
PBS the cells were viewed using a video camera (National Panasonic) attached to an
inverted compound microscope (Leica, Germany). Colour images of the cells
(original magnification x400 unless otherwise stated) were captured by a Power PC
(Macintosh 8500/20) using Apple Video Player software (Macintosh).
4.2.13 Flow Cytometry
Subconfluent, adherent cells that had been in culture for 48 h without a change
of media, were harvested by rinsing flasks twice with cold PBS (pH 7.2) and then
detaching with 5 mM EDTA/PBS at 37°C for 5 min. Cells were incubated with

various concentrations of either an irrelevant isotype control (i.e. rabbit anti-DNP
with rabbit anti-a-enolase polyclonal antibodies for 30 min in ice-cold RPMI/0.1%
BSA, washed three times with 200 ul ice-cold RPMI/0.1% BSA. The cells were then
incubated with FITC-conjugated anti-rabbit IgG (1:50 dilution of stock in ice-cold
RPMI/0.1% BSA) for 30 min on ice in the dark. The cells were washed again,
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resuspended in 200 ul of binding buffer containing 5 ug/ml PI and the cells
immediately analysed by dual-colour flow cytometry

4.3 Results
4.3.1 Antigen Preparation
Recombinant-a-enolase inclusion bodies were used as the antigen for all
immunisations. Figure 4.1 A the SDS-PAGE gel of the E.colUMl09 inclusion body
preparation shows two bands at approximately 45 kDa (full length r-a-enolase) and at
approximately 33 kDa. Only the 42 kDa r-a-enolase band possessed glu-plasminogen
binding activity as detected by a biotinylated glu-plasminogen ligand blot (figure
4. IB). The 42 kDa r-a-enolase band accounted for approximately 80% of the total
protein concentration of the inclusion body preparation. Thus the effective dose r-aenolase was approximately 40 ug/mouse and 800 ug/rabbit.
B
IB

M

IB

110.3 —• ' mmmm

97.4
66.2

•*.-.*

Mi* 45.0 gilit wmm A r-a-enolase
(45 kDa)

14.4
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12% SDS-PAGE Biotinylated Plasminogen
Ligand Blot

Figure 4.1: a-Enolase inclusion bodies.
(A) 12% reducing SDS-PAGE of r-a-enolase inclusion bodies isolated from £.co//.JM109pQE30ENOl. (B)
Glu-plasminogen ligand blot of the inclusion body preparation probed with biotinylated glu-plasminogen.
M : Molecular weight markers, IB: inclusion bodies.

Chapter 4:Anti-a-enolase antibody production.

128

Sequence alignment of human (SWISS-PROT: P06733) and mouse (SWISSPROT: P17182) a-enolase demonstrated that these enzymes have 94% amino acid
sequence identity and 98% amino acid sequence similarity (figure 4.2). Since human
and mouse a-enolase have high sequence identity mice pre-disposed to the production
of autoantibodies (i.e. the NZB mouse system) may generate a good humoral immune
response after immunisation with recombinant human a-enolase.
Human: 1 SILKIHAREIFDSRGNPTVEVDLFTSKGLFRAAVPSGASTGIYEALELRDNDKTRYMGKG 60
SIL+IHAREIFDSRGNPTVEVDL+T+KGLFRAAVPSGASTGIYEALELRDNDKTR+MGKG
Mouse: 1
SILRIHAREIFDSRGNPTVEVDLYTAKGLFRAAVPSGASTGIYEALELRDNDKTRFMGKG 60
Human: 61 VSKAVEHINKTIAPALVSKKLNVTEQEKIDKLMIEMDGTENKSKFGANAILGVSLAVCKA 12 0
VS+AVEHINKTIAPALVSKK+NV EQEKIDKLMIEMDGTENKSKFGANAILGVSLAVCKA
Mouse: 61 VSQAVEHINKTIAPALVSKKVNWEQEKIDKLMIEMDGTENKSKFGANAILGVSLAVCKA 12 0
Human: 121 GAVEKGVPLYRHIADLAGNSEVILPVPAFNVINGGSHAGNKLAMQEFMILPVGAANFREA 180
GAVEKGVPLYRHIADLAGN EVILPVPAFNVINGGSHAGNKLAMQEFMILPVGA++FREA
Mouse: 121 GAVEKGVPLYRHIADLAGNPEVILPVPAFNVINGGSHAGNKLAMQEFMILPVGASSFREA 180
Human: 181 MRIGAEVYHNLKNVIKEKYGKDATNVGDEGGFAPNILENKEGLELLKTAIGKAGYTDKW 2 40
MRIGAEVYHNLKNVIKEKYGKDATNVGDEGGFAPNILENKE LELLKTAI KAGYTD+W
Mouse: 181 MRIGAEVYHNLKNVIKEKYGKDATNVGDEGGFAPNILENKEALELLKTAIAKAGYTDQW 240
Human: 241 IGMDVAASEFFRSGKYDLDFKSPDDPSRYISPDQLADLYKSFIKDYPWSIEDPFDQDDW 300
IGMDVAASEF+RSGKYDLDFKSPDDPSRYI+PDQLADLYKSF+++YPWSIEDPFDQDDW
Mouse: 241 IGMDVAASEFYRSGKYDLDFKSPDDPSRY1TPDQLADLYKSFVQNYPWSIEDPFDQDDW 300
Human: 301 GAWQKFTASAGIQWGDDLTVTNPKRIAKAVNEKSCNCLLLKVNQIGSVTESLQACKLAQ 360
GAWQKFTASAGIQWGDDLTVTNPKRIAKA +EKSCNCLLLKVNQIGSVTESLQACK AQ
Mouse: 301 GAWQKFTASAGIQWGDDLTVTNPKRIAKAASEKSCNCLLLKVNQIGSVTESLQACKPAQ 360
Human: 361 ANGWGVMVSHRSGETEDTFIADLWGLCTGQIKTGAPCRSERLAKYNQLLRIEEELGSKA 420
+NGWGVMVSHRSGETEDTFIADLWGLCTGQIKTGAPCRSERLAKYNQ+LRIEEELGSKA
Mouse: 361 SNGWGVMVSHRSGETEDTFIADLWGLCTGQIKTGAPCRSERLAKYNQILRIEEELGSKA 420
Human: 421 KFAGRNFRNPLAK 433
KFAGR+FRNPLAK
Mouse: 421 KFAGRSFRNPLAK 433
Figure 4.2: Sequence alignment of human and mouse cc-enolases.
Sequence alignments were performed by the online automated alignment program BLAST2. (A) The
sequence alignment of human (SWISS-PROT: P06733) and mouse (SWISS-PROT: P17182) ocenolase.

4.3.2 Immune Responsiveness
Two species of mice (NZB and Balb/C), with different pre-dispositions for the
development autoimmune diseases, were immunised with r-a-enolase inclusion
bodies to determine which mouse strain displayed the best immune response against
the antigen after hyper-immunisation. As shown by figure 4.3A, the anti-r-a-enolase
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Figure 4.3: The i m m u n e response to r-a-enolase in B A L B / C and N Z B mice.
ELISA assays were used to measure the (A) IgM and (B) IgG immune responses on day 21 (D) and day 49
(•) from the B A L B / C and N Z B mice after intraperitoneal immunisation with r-a-enolase inclusion
bodies. The plates were coated with 5 Ug/ml of r-a-enolase and probed with different sera from the
different strains of mice.

IgM sera raised in the N Z B strain displayed a 4.8 fold higher titre for r-a-enolase than
the BALB/C strain on day 21. The NZB anti-r-a-enolase IgM titre was 9 fold greater
than the BALB/C titre on day 49. The anti-r-a-enolase IgG response was absent in
both the NZB and BALB/C strains on day 21, however on day 49 the anti-r-a-enolase
IgG titre from the NZB strain was 83 fold higher than the BALB/C anti-r-a-enolase
titre (figure 4.3B). Thus, the monoclonal antibodies described below were produced
using the splenocytes from a hyperimmunised NZB mouse.
A panel of three hybridomas that secrete anti-r-a-enolase monoclonal
antibodies were derived from the splenocytes of a hyperimmunised NZB mouse. All
of these antibodies had an IgM K, U isotype. The concentrations of monoclonal
antibodies secreted into the supernatant by their respective hybridomas were
estimated using a combination of 2-12% SDS-PAGE gradient gels and total protein
concentrations of the supernatants and were approximately 100, 220, and 160 ug/ml
for #1A6, # 1 A 8 and # 1 C 8 respectively.
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4.3.3.Characterisation of the mouse anti-r-a-enolase IgM monoclonal antibodies.
Concentrated hybridoma supernatants containing the monoclonal antibodies
#1A6, #1A8 and #1C8 were examined for cross-reactivity to different enolase
antigens by ELISA (figure 4.4). All monoclonal antibodies were reactive against
denatured r-a-enolase, refolded r-a-enolase and rabbit muscle enolase. However,
monoclonal antibodies #1A6 and #1A8 and #1C8 displayed better reactivity against
both rabbit muscle and denatured r-a-enolase compared to refolded r-a-enolase.
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Figure 4.4: Cross reactivity of anti-r-a-enolase monoclonal antibodies against different samples
of enolase.
Comparison of the cross reactivity of anti-r-a-enolase hybridoma supernatants containing monoclonal
antibodies # 1 A 6 , # 1 A 8 and #1C8. Increasing dilutions of supernatants were assayed by E L I S A on
denatured r-a-enolase ( A ) , rabbit muscle |3-enolase (•) and refold r-a-enolase (•) adsorbed to the
wells of microtitre plates.

Hybridoma supernatants were also examined for their reactivity against r-aenolase by western blot analysis. In all cases the reactivity of the anti-a-enolase
monoclonal antibodies against r-a-enolase by western blot was poor (figure 4.5).
Nevertheless, neat hybridoma supernatant containing MAb #1A8 was the most
efficient at detecting r-a-enolase by western blotting. In contrast to MAb #1A8, MAb
#1C8 did not detect r-a-enolase by western blotting. Thus, these anti-a-enolase
monoclonal antibodies may not represent sensitive probes for the detection of aenolase antigen using a western blot format.
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Figure 4.5: Western blot analysis of hybridoma supernatants reactivity against r-a-enolase.
Various amounts of r-a-enolase (2 ug, 1 ug and 0.5 ug) were fractionated by 12% SDS-PAGE
(reducing conditions) transferred to P V D F membrane and probed with neat supernatant with the
hybridoma supernatants. The blots were developed by E C L and all three blots were exposed
simultaneously on the same autoradiography film.

4.3.4 Characterisation of the rabbit anti-r-a-enolase polyclonal antibodies.
Rabbit (3-enolase has less sequence identity (85%) and similarity (91%) to
human a-enolase than does mouse a-enolase (figure 4.6). Thus, the rabbit may
represent a better system for the production of anti-a-enolase antibodies than the
mouse.
The cross-reactivity of the anti-r-a-enolase rabbit day 28 post immunisation
polyclonal sera raised against r-a-enolase inclusion bodies was examined by ELISA
both before and after adsorption of the sera onto a Ni-NTA-r-a-enolase antigen
column. The non-adsorbed anti-r-a-enolase rabbit polyclonal serum displayed high
reactivity for r-a-enolase whilst not detecting rabbit muscle enolase at dilutions
greater than 103 (figure 4.7A). For the adsorbed polyclonal serum, microtitre plates
wells were coated with either non-denatured r-a-enolase, denatured r-a-enolase,
rabbit muscle enolase or BSA (figure 4.7B). At dilutions greater than 103 the adsorbed
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anti-r-a-enolase polyclonal serum w a s specific for non-denatured r-a-enolase only
(figure 4.7B). The r-a-enolase adsorbed polyclonal sera was unreactive against nondenatured r-a-enolase after dilutions of greater than approximately IO6. Thus, the NiNTA-r-a-enolase adsorbed anti-r-a-enolase polyclonal rabbit serum displayed high
reactivity for r-a-enolase, and was also dilution specific for non-denatured human ra-enolase.

Human: 4
Rabbit:4

KIHAREIFDSRGNPTVEVDLFTSKGLFRAAVPSGASTGIYEALELRDNDKTRYMGKGVSK 63
KI AREI DSRGNPTVEVDL T+KG FRAAVPSGASTGIYEALELRD DK+RY+GKGV K
KIFAREILDSRGNPTVEVDLHTAKGRFRAAVPSGASTGIYEALELRDGDKSRYLGKGVLK 63

Human: 64 AVEHINKTIAPALVSKKLNVTEQEKIDKLMIEMDGTENKSKFGANAILGVSLAVCKAGAV 123
AVEHINKT+ PAL+ KKL+V +QEK+DK MIE+DGTENKSKFGANAILGVSLAVCKAGA
Rabbit:64 AVEHINKTLGPALLEKKLSWDQEKVDKFMIELDGTENKSKFGANAILGVSLAVCKAGAA 123
Human: 124 EKGVPLYRHIADLAGNSEVILPVPAFNVINGGSHAGNKLAMQEFMILPVGAANFREAMRI 183
EKGVPLYRHIADLAGN +++LPVPAFNVINGGSHAGNKLAMQEFMILPVGA++FREAMRI
Rabbit:124 EKGVPLYRHIADLAGNHDLVLPVPAFNVINGGSHAGNKLAMQEFMILPVGASSFREAMRI 183
Human: 184 GAEVYHNLKNVIKEKYGKDATNVGDEGGFAPNILENKEGLELLKTAIGKAGYTDKWIGM 243
GAEVYH+LK VIK KYGKDATNVGDEGGFAPNILEN E LELLKTAI AGY DKWIGM
Rabbit:184 GAEVYHHLKGVIKAKYGKDATNVGDEGGFAPNILENNEALELLKTAIQAAGYPDKWIGM 243
Human: 244 DVAASEFFRSGKYDLDFKSPDDPSRYISPDQLADLYKSFIKDYPWSIEDPFDQDDWGAW 303
DVAASEF R GKYDLDFKSPDDP+R+I+ +L +LYKSFIK+YPWSIEDPFDQ DWGAW
Rabbit:244 DVAASEFHRDGKYDLDFKSPDDPARHITGQKLGELYKSFIKNYPWSIEDPFDQGDWGAW 3 03
Human: 304 QKFTASAGIQVVGDDLTVTNPKRIAKAVNEKSCNCLLLKVNQ1GSVTESLQACKLAQANG 363
+F A
IQWGDDLTVTNPKRIA+AV +K+CNCLLLKVNQIGSVTES+QACKLAQ+NG
Rabbit:304 SRFLAGVDIQWGDDLTVTNPKRIAQAVEKKACNCLLLKVNQIGSVTESIQACKLAQSNG 363
Human: 364 WGVMVSHRSGETEDTFIADLWGLCTGQIKTGAPCRSERLAKYNQLLRIEEELGSKAKFA 423
WGVMVSHRSGETEDTFIADLWGLCTGQIKTGAPCRSERLAKYNQL+RIEE LG KA FA
Rabbit:364 WGVMVSHRSGETEDTFIADLWGLCTGQIKTGAPCRSERLAKYNQLMR1EEALGDKAVFA 423
Human: 424 GRNFRNPLAK 433
GR FRNP AK
Rabbit:424 GRKFRNPKAK 433

Figure 4.6: Sequence alignment of human a-enolase and rabbit B-enolase.
Sequence alignments were performed by the online automated alignment program BLAST2. The
sequence alignment of human a-enolase (SWISS-PROT: P06733) and rabbit |3-enolase (SWISSPROT: P25704).
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Figure 4.7: Cross reactivity of anti-r-a-enolase polyclonal sera against different samples of enolases.
(A) Comparison of the cross reactivity of rabbit anti-r-a-enolase polyclonal antiserum raised against r-aenolase inclusion bodies. Increasing dilutions of antiserum were assayed by E L I S A on non-denatured
(fraction 14) r-a-enolase (•), denatured r-a-enolase (•), rabbit muscle enolase ( O ) and B S A (A) adsorbed
to the wells of microtitre plates. (B) Comparison of the cross-reactivity of immunopurified rabbit anti-r-aenolase polyclonal antibodies against r-a-enolase (•) and rabbit muscle [3-enolase ( O ) adsorbed to the wells
of the microtitre plate.

The affinity purified rabbit anti-r-a-enolase polyclonal antibody was able to
detect a 47 kDa protein present in the whole cell lysate extracts of several human
cancer cell lines that co-migrated with purified denatured r-a-enolase (figure 4.8).
Moreover, the affinity purified rabbit anti-r-a-enolase polyclonal detected a single
band from the mammalian cell line whole cell lysates, thereby suggesting that the
polyclonal antibody was monospecific. All of the cell lines examined expressed
similar levels of a-enolase. The higher molecular weight band in the r-a-enolase lane
(lane 6) may represent aggregated r-a-enolase, possibly due to long term storage of
the recombinant protein.
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Figure 4.8: Western blot analysis of a-enolase from human breast and colon cancer cell lines.
Whole cell lysates (40 |Xg/lane) were fractionated by 1 2 % SDS-PAGE under non-reducing conditions and
stained with Coomassie brilliant blue R-250. (B) The Western blot was probed with immunopurified anti-aenolase antibody (0.5 iig/ml) and G A R - H R P (1:2000) for 1 hour each and developed using ECL. Lane 6
contains purified denatured r-a-enolase (276 ng).

Anti-a-enolase polyclonal antibodies were also examined for their reactivity

against gluteraldehyde fixed cells that were known to express a-enolase (figure 4.9)
Both the permeabilised MDA-MB-231 and MCF-7 cells were stained when incubated
with anti-a-enolase polyclonal antibodies. In contrast, the staining of the nonpermeabilised cells with anti-a-enolase polyclonal antibodies was comparable to the

anti-DNP isotype control antibody (figure 4.9). This suggested that a-enolase was no
present on the surfaces of these human breast cancer cell lines where it can bind
extracellular glu-plasminogen.
Flow cytometric analysis (figure 4.10) of unfixed MDA-MB-231 cells that had
been incubated with either anti-a-enolase or anti-DNP polyclonal antibodies did not
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Figure 4.9: a-Enolase immunohistochemistry on permeabilised and non-permeabilised breast
cancer cells.
(A) Immunohistochemistry of gluteraldehyde fixed, TX-100 permeabilised M C F - 7 cells (I and II) and
non-permeabilised M C F - 7 cells (III and IV). Panels I and III probed with rabbit anti-DNP (isotype
control) antibody and panels II and IV were probed with the rabbit anti-a-enolase polyclonal
antibodies. (B) Immunohistochemistry of gluteraldehydefixed,TX-100 permeabilised M D A - M B - 2 3 1
cells (V and VI) and non-permeabilised M D A - M B - 2 3 1 cells (VII and Vffl). Panels V and VII probed
with rabbit anti-DNP (isotype control) antibody and panels V I and VIII were probed with the rabbit
anti-a-enolase polyclonal antibodies.
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Figure 4.10: Anti-a-enolase flow cytometry using M D A - M B - 2 3 1 breast cancer cells.
Density plots of MDA-MB-231 cells incubated with various concentrations of either rabbit anti-aenolase polyclonal or rabbit anti-DNP polyclonal (isotype) antibodies. The cells were incubated just
prior to flow cytometry analysis with the non-vital stain propidium iodide (PI).
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result in an anti-a-enolase shift in fluorescence relative to the control antibody
fluorescence. This suggested that a-enolase antigen was not present on the surfaces
the M D A - M B - 2 3 1 cells, thereby confirming the immunohistochemical data obtained
using the gluteraldehyde fixed cells.

4.4 Discussion
a-Enolase is a h u m a n autoantigen associated with several diseases such as
discoid lupus erythematosus, primary sclerosing cholangitis and cancer-associated
retinopathy syndrome (Orth et. al, 1998; Gitlits et. al, 1997; A d a m u s et. al, 1996;
Adamus et. al, 1993; A d a m u s et. al, 1998). Thus, the high sequence similarity
between h u m a n a-enolase and mouse a-enolase as well as the fact that a-enolase is a
lupus-associated autoantigen suggested that mice which are susceptible to lupus-like
autoimmune diseases, such as the N Z B strain, might represent a good system for the
production of anti-a-enolase monoclonal antibodies.
High level expression of r-a-enolase in transformed £.co//JM109 cells
resulted in the formation of intracellular insoluble r-a-enolase inclusion bodies. These
inclusion bodies were isolated and found to be a good source of immunogenic r-aenolase probably because the insoluble inclusion bodies facilitated the slow release of
the antigen (Harlow and Lane, 1988). Immunisation of N Z B mice with r-a-enolase
inclusion bodies resulted in the production of anti-a-enolase sera containing I g M and
IgG of moderate reactivity in contrast to the immunisation of B A L B / C mice with the
same antigen.
The I g M isotype of the anti-a-enolase monoclonal antibodies was not
unexpected since several studies that have used N Z B or N Z B x N Z W F, crosses for the
production of monoclonal antibodies have isolated monoclonal antibodies with an
I g M isotype (Dobersen et. al, 1985; Sanai et. al, 1988, Ballard et. al, 1983;
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Jacquemart et. al, 1988;). However, a study has isolated an IgG monoclonal
antibody against a weakly immunogenic bacterial antigen using the NZB mouse
system (Frosch et. al, 1985).
The anti-a-enolase monoclonal antibodies were able to recognise both r-aenolase and rabbit muscle enolase by ELISA, however these antibodies did not
efficiently recognise r-a-enolase by western blotting. In contrast, the rabbit anti-aenolase polyclonal antibody sera displayed a dilution-specific, high reactivity
response for r-a-enolase as compared to rabbit muscle enolase. Moreover, this
polyclonal sera recognised wild-type human a-enolase as detected by western
blotting. Finally, a-enolase antigen was detected in the breast cancer cell lines MDAMB-231 and MCF-7 cells thereby confirming that this glycolytic enzyme is expressed
in breast cancer tissue (Hennipman et. al, 1987). However, a-enolase was not
detected on the surfaces of these cells.
In conclusion, anti-a-enolase monoclonal and polyclonal antibodies were
successfully produced. The complete characterisation of the anti-a-enolase
monoclonal antibodies requires the immunopurification of these antibodies from the
hybridoma supernatants using either a r-a-enolase antigen column or antigenindependent chromatography methods. Since the a-enolase polyclonal antibodies did
not detect this antigen on the surfaces of these human breast cancer cell lines, it was
unnecessary to determine the plasminogen binding inhibitory capacity of the anti-aenolase monoclonal antibodies in this study. However, future studies using these antia-enolase monoclonal antibodies would require the purification and further
characterisation of these anti-a-enolase antibodies.
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Chapter 5

Increased plasminogen binding is associated with
metastatic breast cancer cells: Differential expression
of plasminogen binding proteins.
5.1 Introduction
The acquisition of the malignant phenotype requires a multitude of complex
processes including a loss of control of cell proliferation (e.g., via oncogene
activation), higher metabolic requirements and the ability of cells to invade and
metastasise throughout the body (reviewed in Evans, 1991). The processes of tumour
cell invasion and metastasis are likely to involve the inappropriate expression of
proteinases (reviewed in Mignatti and Rifkin, 1993). The serine proteinases of the
plasminogen activation proteolytic cascade appear to play an important role in this
process (reviewed in Duffy, 1993; Mignatti and Rifkin, 1993). Overexpression u P A
and PAI-1 are associated with poor prognosis, shorter disease-free periods and
reduced survival in breast cancer patients (Janicke et al, 1991; Christensen et al,
1996; Constantini et al, 1996; Nielsen et al,. 1996). The u P A : u P A R interaction on
cancer cell surfaces is a key event that results in increased in vitro matrix degradation
and migration (Duffy, 1993; Mignatti and Rifkin, 1993). For example, inhibition of
u P A and plasmin by specific inhibitors or antibodies, or antisense inhibition of u P A R
resulted in decreased plasminogen activation and hence decreased extracellular
matrix degradation in vitro or decreased metastasis in nude mouse models with
various cancer cell lines (Baker et. al, 1990; K o o k et. al, 1994), including h u m a n
breast cancer cell lines (Holst-Hansen et. al, 1996; Stonelake et. al, 1997). In vitro
invasiveness has been correlated with u P A and plasmin activity as well as high
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uPAR and plasminogen activator inhibitor type 1 (PAI-1) protein levels in human
breast cancer cell lines (Holst-Hansen et. al, 1996).
Plasminogen antigen has been localised to cell surfaces in sections of human
mammary carcinoma tissue (Burtin et. al, 1993), and to the invasive front of
cutaneous melanoma lesions (De Vries et. al, 1996). Cell-surface localisation of
plasminogen is advantageous for cell migration since the activation of receptor-bound
plasminogen to plasmin is enhanced while cell-bound plasmin is protected from
circulating inhibitors (e.g.: a2-antiplasmin) (Plow and Miles, 1990). Glu-plasminogen
binds to numerous different cell types in a lysine-dependent manner with low affinity
and a high number of receptor sites/cell (see section 1.2.3 ; table 1.5).
Breast cancer is an example of a hormone-dependent cancer. Breast cancer
cell lines that are oestrogen receptor (ER) positive and do not express the receptor
tyrosine kinase epidermal growth factor receptor (EGFR) have a fundamentally nonmetastatic phenotype (Lee et, al, 1990). In contrast to the non-metastatic ER positive
phenotype approximately 20-30% of all human breast cancers overexpress two
closely related receptor tyrosine kinases, EGFR and/or v\%5HERllneu (C-erbB-l),
and this phenotype is associated with more aggressive tumour growth and reduced
patient survival (Singleton and Strickler, 1992). The presence of ER is also inversely
related to uPA and uPAR levels in breast carcinomas and cell lines (Mignatti and
Rifkin, 1993; Long and Rose, 1996). In addition, it is apparent that breast cancer cell
lines that readily form tumours and metastasise in nude mouse models and/or are
invasive in in vitro models of metastases, (e.g.., MDA-MB-231 cells) (Thompson et.
al, 1992), tend to be EGFR(+)/erbB-2 protein(+) and ER(-) (Lee et. al, 1990), as
well as uPA/uPAR(+) (Holst-Hansen et. al, 1996). EGFR stimulation or c-erbQ-2
overexpression in human breast cancer cells enhances the expression and secretion of
uPA and expression of uPAR (Long and Rose, 1996; Connolly and Rose, 1997).
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The purpose of this chapter was to characterise the cell surface gluplasminogen binding events in three human breast cancer cell lines. In the cell lines
used in this study, elevated cell-surface lysine-dependent plasminogen binding and
plasmin formation is associated with metastatic capacity and other parameters
(EGFRJerbB-2 status, ER status, uPA/uPAR status) commonly associated with
human breast cancer malignancy. Furthermore, non-viable cells breast cancer cells
bound 100-fold more glu-plasminogen than viable cells and that the presence of nonviable cells must be considered when determining cell-surface binding parameters. In
addition, a distinct plasminogen receptor profile was evident in the plasma
membranes of the breast cancer cell lines, suggesting heterogeneity of plasminogen
binding proteins in these cell lines.
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5.2 Materials and methods
5.2.1 Materials
R P M I 1640, L-glutamine, and Hanks Buffered Salt Solution were purchased
from Trace Biosciences (Castle Hill, N S W , Australia). Fetal calf serum was obtained
from C S L (Parkville, Vic, Australia). T A , e-ACA, aprotinin, polyvinyl pyrrolidine
(PVP-40), bovine serum albumin (fraction V ) (BSA) and fluorescein isothiocyanate
(isomer 1) (FITC) were purchased from Sigma Chemical C o (St Louis, M O , U S A ) .
Biotin-X-NHS was from Calbiochem (San Diego, C A , U S A ) , z-lysine thiobenzylester
was from Peninsula Laboratories (CA, U S A ) . Enhanced Chemiluminescence (ECL)
detection kit was purchased from Amersham International (Buckinghamshire, U K ) .
Molecular weight protein standards were obtained from N O V E X (San Diego, C A ,
USA). The D A K O L S A B + Kit was from D A K O Corporation (CA, U S A ) .
5.2.2 Specific proteins and antibodies
H u m a n recombinant a-enolase was prepared as previously described (Chapter
2). Active human u P A was from Serono (Sydney, N S W , Australia). Plasmin, the
plasmin specific substrate Spectrozyme-PL, mouse anti-human u P A R monoclonal
antibody (#3696) and rabbit anti-human u P A R polyclonal antibody (#399R) were
provided by American Diagnostica Inc (Greenwich, C T , U S A ) . Rabbit anti-human
plasminogen polyclonal antibody and horseradish peroxidase-conjugated goat antirabbit polyclonal antibody were purchased from Calbiochem (San Diego, C A , U S A ) .
Mouse anti-human E G F R monoclonal antibody (clone L A I ) was obtained from
Upstate Biotechnology, Inc. (Lake Placid, N Y , U S A ) , while mouse anti-human c-neu
(9G6) monoclonal antibody was obtained from Santa Cruz Biotechnology, Inc. (Santa
Cruz, C A , U S A ) . Anti-DNP IgGL was kindly donated by Dr Mark Wilson and FITCconjugated anti-mouse IgG was from Silenus (Sydney, N S W , Australia). Aprotinin

Chapter 5:Plasminogen binding and activation on human breast cancer cells

143

(Roche Biochemicals) was FITC conjugated in PBS according to the method
described by Goding (1976).
5.2.3 Cell Culture
Routine cell culture for this study was performed as described in chapter 4.
5.2.5 Membrane Preparations
5.2.5.1 Total cellular membrane
Confluent cells were washed and harvested by scraping in ice-cold P B S and
subjected to hypotonic shock in a small volume of ice-cold hypotonic buffer (3 mM
NaP04 (pH 7.4), 5 mM EDTA, 1 mM PMSF phenylmethylsulfonylfluoride). The
suspensions were then sonicated with several 20 second bursts at high power with a

Branson Sonifier 250 (CT, USA), checked under a microscope for effective disruption

of the cells, then centrifuged at 500 g for 5 min. The supernatant was centrifuged a

46000 g for 30 min and the resultant supernatant was frozen in aliquots at -70°C. Th
crude membrane pellet was resuspended in 5 ml ice-cold 5 mM EDTA/PBS, briefly
resonicated, diluted to 50 ml with EDTA/PBS and centrifuged at 46000 g for 30 min.
The resulting membrane pellet was resuspended in 1 ml EDTA/PBS with brief
sonication, then aliquoted and stored at -70°C.
5.2.5.2 Plasma membrane
Confluent cells were washed, harvested, subjected to hypotonic shock as
above then homogenised in a Dounce homogeniser. Plasma membranes were then
isolated using the aqueous two-phase PEG polymer/dextran system as described by
Rana and Majumder (1987).
5.2.6 Western blotting and plasminogen ligand blotting
Whole cell lysates and membrane preparations were boiled in sample buffer,
fractionated on 10 or 12 % SDS-PAGE gels and parallel gels were either stained with
Coomassie blue or transferred to PVDF membranes at 100 V for 1 h or 30 V
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overnight at 4°C. For Western blotting the membranes were washed in TBST [50 mM
Tris-HCl (pH 8.0), 150 m M NaCl, 0.05% (v/v) Tween-20], blocked in 1 0 % milk
powder/TBST at room temperature for 1-2 h, rinsed in T B S T , then incubated with the
primary antibody in 2 % milk/TBST for 1 h at room temperature. After extensive
washing the membrane was reblocked for 20 min with 6 % milk/TBST, and incubated
with the appropriate secondary antibody diluted 1:2000 in 2 % milk/TBST. After three
washes with T B S T and one wash with T B S the immune complexes were detected by
ECL.
For ligand blotting, membranes were washed once with T N C M [50 m M TrisHCl (pH 7.5), 150 m M NaCl, 2 m M CaCl2, 3 m M MgCl2] and blocked with
TNCM/2% PVP-40 overnight at room temperature. The membranes were then probed
with 5 n M glu-plasminogen in the absence or presence of 100 m M E A C A in
TNCM/PVP-40 containing 0.05% (v/v) Tween 20 ( T N C M T ) for 45 min and washed
for 1 h with three changes of T N C M T . After re-blocking for 30 min, a 1:2000 dilution
of rabbit anti-plasminogen polyclonal antibody in T N C M T / P V P - 4 0 was added and
incubated with the membrane for 1 h. This was followed by three 5 minute washes,
re-blocking for 10 min and probing with a 1:1000 dilution of horseradish peroxidaseconjugated goat anti-rabbit-polyclonal antibody in T N C M T / P V P - 4 0 for 1 h. This was
followed by three washes with T N C M T and one wash with T N C M . The blots were
then developed by E C L .
5.2.7 Urokinase plasminogen activator activity and plasmin activity assays
The activity of u P A in the membrane preparations was measured as described
by Coleman and Green (1981). Briefly, membrane preparations (10 ug protein/well)
were preincubated with glu-plasminogen (1 uM) for 45 min at 37°C, followed by a
further 45 min incubation with the chromogenic plasmin substrate, Z-lysine
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thiobenzylester (170 uM). Colour development was read at 414 nm. Standard curves
were constructed using uPA. Plasmin activity was measured using the SpectrozymePL assay (American Diagnostica Inc., conditions are described in the figure legend).
Standard curves for the u P A and plasmin assays were constructed using either u P A or
plasmin, respectively.
5.2.8 Flow cytometry and fluorimetry
Subconfluent, adherent cells that had been in culture for 48 h without a change
of media, were harvested by rinsing flasks twice with cold P B S (pH 7.2) and then
detaching with 5 m M E D T A / P B S at 37°C for 5 min. For FITC-glu-plasminogen
binding assays cells were washed twice and resuspended in freshly made and chilled
binding buffer (Hanks Buffered Salt Solution containing I m M CaCl2, 1 m M MgCl2,
20 mM HEPES (pH 7.4), and 0.1% BSA) at a concentration of 1 x 106 cells/ml. A
200 ul aliquot of the cell suspension was pelleted by centrifugation at 200g and
resuspended in 200 ul binding buffer containing FITC-glu-plasminogen in the
presence or absence of the lysine analogue, T A . After incubation for 1 h on ice in the
dark, the cells were washed and resuspended in 250 ul binding buffer containing the
non-vital dye propidium iodide (PI; 5 Ug/ml). Cell-associated fluorescence was then
measured by dual-colour flow cytometry (FACSort, Becton-Dickinson). B y using
dual-colour flow cytometry it was possible to distinguish between two parameters
based on the different fluorochromes; i.e., ligand binding (FITC produces a strong
green fluorescence) and cell viability (PI binds to D N A and d s R N A and produces a
strong red colour; Chucholowski et. al, 1992; Darzynkiewicz et. al, 1994). This
technique was used to establish 'gates' - the exclusion of PI for a viable 'gate', the
inclusion of PI for a non-viable 'gate'.
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Flow cytometry is a semi-quantitative technique and ligand binding, measured
in fluorescence units, cannot be related to input protein concentration. Therefore, in
order to analyse specific binding isotherms by Scatchard transformation, the binding
experiments described above were analysed by fluorimetry. Briefly, after the final
wash step the cells were resuspended in 2 ml binding buffer without PI and the
extrinsic fluorescence of FITC-glu-plasminogen measured using a fluorimeter (F4500, Hitachi) with a slit width of 0.5 mm. Excitation and emission wavelengths were
set at 488 nm and 521 nm, respectively. A FITC-glu-plasminogen standard curve was
constructed in order to relate fluorescence units to glu-plasminogen concentration
taking into account the ratio of FITC per molecule of glu-plasminogen. To determine
the proportion of non-viable cells, parallel dual-colour flow cytometry experiments
were performed and consistently indicated that 10-15% of the cell samples were nonviable according to PI uptake.
Cell-surface plasmin was detected using dual-colour flow cytometry as
described above with the following modifications. Cells were preincubated in the
absence or presence of unlabelled glu-plasminogen (0.5 uM) for 30 min at room
temperature followed by incubation on ice for 1 h with FITC-aprotinin (1 uM) in the
absence or presence of a 50-fold excess of unlabelled aprotinin. The cells were then
washed, resuspended in buffer containing PI and measured as described above.
For the detection of cell-surface uPAR, uPA and c-neu indirect
immunofluorescence staining was performed. Cells were incubated with either an
irrelevant isotype control (i.e. anti-DNP), or one the above specific monoclonal
antibodies for 30 min on ice (20 ug/ml in ice-cold RPMI/0.1% BSA), washed three
times with 200 ul ice-cold RPMI/0.1% BSA, and incubated with FITC-conjugated
anti-mouse IgG (1:50 dilution of stock in ice-cold RPMI/0.1% BSA) for 30 min on
ice in the dark. The cells were washed again, resuspended in 200 ul of binding buffer
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containing 5 ug/ml PI and the cells immediately analysed by dual-colour flow
cytometry as described above.
In all the fluorescence based experiments autofluorescence was subtracted. All
data was analysed using CELLQuest software (Becton-Dickinson).
5.2.9 Plasminogen ligand histochemistry
Cells were passaged onto sterile glass coverslips in their appropriate media
and allowed to adhere and spread for at least 48 h. The cells were then washed three
times with PBS and fixed with glutaraldehyde (1% v/v in PBS) for 1 h at room
temperature. Fixation was necessary since unfixed cells consistently rounded up and
floated off the coverslips with the following procedure. After washing twice with PBS
the cells were either permeabilised by incubation with 0.2% v/v Triton X-100 for 2

min at room temperature (to allow ligand to reach intracellular binding moieties in t
glutaraldehyde fixed cells; Harlow and Lane, 1988) or left in PBS. Following two
washes with PBS the permeabilised and non-permeabilised cells were incubated with
3 % H 2 0 2 for 5 min, rinsed with P B S , and incubated in PBS/0.1% B S A containing
either 0.2 uM biotinylated BSA or glu-plasminogen in the absence or presence of 5
mM tranexamic acid for 30 min at room temperature. The cells were washed three
times with PBS, incubated with streptavidin-peroxidase and finally with the
diaminobenzidine chromogen substrate solution provided with the DAKO LSAB+
Kit. The cell histochemical images were captured as described in section 4.2.12.

5.2.10 Immunohistochemistry
Immunohistochemistry of breast cancer cells grown on coverslips was
performed according to the method described in section 4.2.12.
5.2.11 Invasive and metastatic characteristics of human breast cancer cell lines
Local tissue invasion and metastatic ability of the M D A - M B - 2 3 1 , M C F - 7 , and
T-47D cell lines in nude mice has been characterised in detail by Thompson et. al,
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(1992). Only the MDA-MB-231 cell line was found to be invasive and metastatic
(Thompson et. al, 1992). To confirm the metastatic characteristics of the MDA-MB-

231 cell line 1-2 x IO6 cells/site were injected into the flank region (s.c.) of mal
week old Swiss nu/nu nude mice. The mice were sacrificed and the lymph nodes
adjacent to the primary tumours were excised and examined histologically.

5.3 Results
5.3.1 Metastatic phenotypes of human breast cancer cell lines
5.3.1.1 Expression of c-neu oncogenic product, epidermal growth factor and
oestrogen receptors in human breast cancer cell lines.
Aggressive/invasive human breast cancer express high levels of EGFR/cerbBl (Singleton and Strickler, 1992) and have been associated with expression of

low levels of oestrogen receptor (Lee et al, 1990). The cell lines used in this stud
were phenotyped with respect to these parameters. Expression of EGFR by the breast
cancer cell lines MDA-MB-231 and MCF-7 were examined by SDS-PAGE and
western blot. Figure 5.1 A shows a western blot probed with an anti-EGFR
monoclonal antibody. MDA-MB-231 cells expressed a band corresponding to the
molecular weight of EGFR. This band was absent in the MCF-7 whole cell lysate
lane.
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Figure 5.1: The E G F R and c-neu status of the h u m a n breast cancer cell lines.
Whole cell lysates of M D A - M B - 2 3 1 and M C F - 7 were fractionated by 1 2 % S D S - P A G E under nonreducing conditions and transferred to P V D F membrane. The membranes were probed with antihuman E G F R monoclonal antibody. (B) A representative density plot of fluorescence intensities due to
the indirect labeling of M D A - M B - 2 3 1 cells with an anti-c-neu monoclonal antibody (FL-1 FITC) versus
PI uptake (FL2-PI). Viable (low PI fluorescence) and non-viable (high PI fluorescence) cell gates were set
around populations of cells that either excluded or included PI, respectively. (C) Flow cytometry of viable
(PI negative) breast cancer cell lines M D A - M B - 2 3 1 and M C F - 7 (2xl05 cells) probed with 20 ug/ml
anti-c-neu monoclonal antibody. These data are means (n = 4) ± S E M .
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All flow cytometry data presented within this dissertation is dual-colour flow
cytometry (cell-surface antigen associated green fluorescence (FL-1) and the nonviable, water soluble, DNA intercalating stain Pi-red fluorescence (FL-2)). This
technique was able to distinguish antigens or binding moieties on the surfaces of
viable cells from non-viable cells. Density plots of fluorescence intensity due to
FITC-antibody binding (FL-1) versus nuclear PI staining (FL-2) were used to
establish 'gates' based on PI uptake by the cells. Cells which excluded the water
soluble PI were gated as viable, whereas cells staining with PI were gated as non-

viable (figure 5. IB). The expression of the oncogenic product c-neu at the cell surf

of viable (i.e. PI negative) breast cancer cell lines were determined by flow cytomet
using an anti-c-neu monoclonal antibody (figure 5.1C). Both viable MCF-7 and
MDA-MB-231 cells were positive for cell surface c-neu antigen with MCF-7 cells
expressing approximately 1.5 fold more c-neu than MDA-MB-231 cells (figure 5.1C).
Immunohistochemical staining of the human breast cancer cells with a
monoclonal antibody specific for oestrogen receptor resulted in positive staining of
the T-47D and MCF-7 cell lines and negative staining of the MDA-MB-231 cell line

compared to the positive control tissue section (figure 5.2). This suggests that both
T-47D and MCF-7 cell lines were oestrogen receptor positive. In contrast, the MDAMB-231 cell line was oestrogen receptor negative (figure 5.2D). These data confirm

the previous observations with respect to the oestrogen receptor status of these cell
(deFazio et. al., 1992). Taken together, these data suggest that the MDA-MB-231 cell
line is EGFR positive and oestrogen receptor negative, whereas, the MCF-7 cell line
is EGFR negative and oestrogen receptor positive. However, both the metastatic and

non-metastatic breast cancer cell lines were positive for cell-surface c-neu antigen.
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Figure 5.2: T h e oestrogen receptor status of three h u m a n breast cancer cell lines.
Cells were cytocentrifuged onto glass slides at 200g and probed with anti-oestrogen receptor monoclonal
antibody (1:30) followed by biotinylated anti-mouse IgG and streptavidin conjugated H R P . The immune
complex was detected by diaminobenzidine chromogen precipitate ( D A B ) and counter-stained with
haemotoxylin. (A) malignant breast cancer fine needle biopsy positive control 03) M C F - 7 , (C) T47-D and
(D) M D A - M B - 2 3 1 breast cancer cell lines. Magnification x400. Performed inhouse by Southern Pathology.

5.3.1.2 Tumourgenecity and metastatic potential of the MDA-MB-231 cell line.
The human breast cancer cell line MDA-MB-231 have previously been
characterised as a metastatic cell line (Singleton and Strickler, 1992). In contrast,
human breast cancer cell lines MCF-7 and T-47D have been shown to be only mildly
tumourgenic and do not metastasise in vivo (Thompson et. al, 1992). The
tumourgenicity and metastatic potential of the MDA-MB-231 cell line were
confirmed by subcutaneously inoculating the flank of five Swiss Nu/Nu mice with
lxlO6 cells in RPMI. Three out of the five mice (60%) developed subcutaneous
primary tumours ranging from 1.1% to 16.5% their total body mass (figure 5.3A).
Gross examination of the tumours dissected from these mice revealed the presence of
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Figure 5.3: Tumourigenesis of M D A - M B - 2 3 1 h u m a n breast cancer cell lines in the swiss nu/nu
model.
(A) A swiss nu/nu mouse with an M D A - M B - 2 3 1 tumour xenograph. The arrow indicates where the
tumour xenograph has invaded the skin of the mouse. (B) A n M D A - M B - 2 3 1 tumour dissected from a
swiss nu/nu mouse. The arrow indicates a tumour surface-associated blood vessel (BV). (C) L y m p h
nodes isolated from either a control mouse or a tumour bearing mouse. (D) Lymph node section stained
with an isotype control antibody specific for D N P (400x magnification). (E) Lymph node section stained
with an anti-human milk fat globulin monoclonal antibody (400x magnification) The inset has a lOOOx
magnification.
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blood vessels associated with the surface of the tumour (figure 5.3B), suggesting tha
these tumours were vascularised. One of the tumour-bearing mice displayed local
invasion of the primary tumour into the skin of the flank (figure 5.3A). The lymph
nodes from the tumour-bearing mice were larger than a lymph node from the control
(RPMI-inoculated) mouse (figure 5.3C). This may indicate metastasis of the MDAMB-231 cells from the primary tumour, since breast tumour cells have been shown to
metastasis to lymph nodes (Singleton and Strickler, 1992). Immunohistological
examination of sections of lymph node material from the tumour bearing mice using a
monoclonal antibody specific for the breast carcinogen marker human milk fat
globulin (Taylor-Papadimitriou et. al, 1981), shows some slight staining in the
lymphatic tissue (figure 5.4). These data suggest that the human breast cancer cell
MDA-MB-231 is tumourgenic and may invade local tissue sites as well as
metastasising to the lymph nodes in Swiss nu/nu mice. However, the sample size of
the study was small. Taken together, the data from figures 5.1-5.3 suggest that the
MDA-MB-231 cell line is an aggressive cell line while the MCF-7 and T-47D cell
lines may be examples of more benign breast cancer cell lines.
5.3.1.2 uPAR and uPA antigen levels and uPA activity of the MDA-MB-231, MCF-7
and T47-D breast cancer cell lines.
Flow cytometry in conjunction with anti-uPAR and anti-uPA monoclonal
antibodies were used to determine the levels of uPAR and uPA expressed on the
surfaces of the breast cancer cell lines MDA-MB-231, MCF-7 (figure 5.4A). Viable
MDA-MB-231 cells (i.e. cells that were PI negative) expressed approximately 20 fold
more uPAR compared to viable MCF-7 cells. Urokinase receptor antigen had a
punctate distribution the surfaces of non-permeabilised MDA-MB-231 cells (figure
5.4B II). Immunohistrochemistry of non-permeabilised MCF-7 and T-47D cells
demonstrated that low levels of uPAR antigen were present on the surfaces of some
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Figure 5.4: u P A and u P A R status of the breast cancer cell lines.
(A) Cells were incubated with a uPA or a uPAR-specific M A b followed by a FITC-anti-mouse IgG and
resuspended in buffer containing PI. The labeled cells were analysed by dual-colour flow cytometry. Data
presented are mean fluorescences associated with the u P A R (•) and u P A (D) antigen levels on the
surfaces of PI negative M D A - M B - 2 3 1 and M C F - 7 cell lines after fluorescence of the isotype controls
have been subtracted. (B) Immunohistochemistry depicting the spatial distribution of u P A R (II and V )
and u P A (III and VI) on non-permeabilised M D A - M B - 2 3 1 (I-HI), M C F - 7 (IV-VI). (C) Western blot of
plasma membrane preparations of M D A - M B - 2 3 1 , M C F - 7 and T-47D breast cancer cell lines probed
with an anti-uPAR antibody and developed using ECL.
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cells of a colony (figure 5.4B V and VIII). Finally the levels of plasma membrane and
cell surface uPAR protein were markedly reduced in the MCF-7 (4-6 fold
respectively) and even more so in T-47D (10-15 fold respectively) compared to levels
in MDA-MB-231 cells (figure 5.4C). Thus, the aggressive human breast cancer cell
line, MDA-MB-231 used in this study over-expressed cell-surface uPAR.
Similarly the viable MDA-MB-231 cells expressed approximately 50 fold
more cell-surface uPA antigen than did the MCF-7 cell line as determined by flow
cytometry (figure 5.4A). The punctate distribution of uPA antigen on the nonpermeabilised MDA-MB-231 cells (figure 5.4B III) was similar to the distribution
pattern of uPAR. The plasma membrane uPA activity, in the presence of gluplasminogen, as determined by Spectrozyme UK chromagenic assay for the MDAMB-231 cell line was at least 3 fold and 18 fold greater than the MCF-7 and T-47D
cells lines (M. Ranson pers. communication). Thus, the level of uPA activity
correlated with uPA and uPAR antigen levels expressed on the surface of the MDAMB-231 cell line. This suggested that receptor-bound uPA was active at the cell
surface. Thus, the MDA-MB-231 breast cancer cell line, which has a more malignant
phenotype and is less differentiated than the MCF-7 and T-47D cell lines, express
more of both uPA and uPAR than these more differentiated and non-invasive cell
lines.
5.3.2 Cell-surface plasminogen binding on metastatic versus non-metastatic breast
cancer cells.
5.3.2.1 Fluorescence studies
FITC-labeled glu-plasminogen, which retained its lysine-sepharose binding
capacity (section 2.3.2), was used in flow cytometric glu-plasminogen binding assays
to determine the glu-plasminogen binding capacity of the three viable human breast
cancer cell lines. Histogram plots were used to calculate cell-surface, lysine-
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dependent glu-plasminogen binding (figure 5 . 5 A ) a n d indicated that while the M C F - 7
or

T-47D cell lines bound low but detectable amounts of FITC-glu-plasminogen (8.0

+ 0.8 and 9.5 + 2.3 fluorescence units, respectively), the MDA-MB-231 cell line
bound significantly more FITC-glu-plasminogen (21.2 + 3.6 fluorescence units) than
either the MCF-7 or T-47D cell lines.
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The amount of lysine-dependent FITC-glu-plasminogen binding to non-viable

cells was consistently 2 orders of magnitude higher than to viable cells (refer to fig
5.5A and B). Cell-surface glu-plasminogen binding to MDA-MB-231 cells was
lysine- and concentration-dependent indicating a specific interaction (figure 5.5A).
The viability of the MDA-MB-231 cells decreased as the FITC-glu-plasminogen
concentration increased (figure 5.6). Such that the concentrations of FITC-glu-

plasminogen required to saturate binding [e.g.., to saturate binding to r-a-enolase wa
approximately 10 |±M (~lmg/ml) of glu-plasminogen (figure 2.5)] were found to
render approximately 75% of the MDA-MB-231 cells non-viable (figure 5.6). Thus, it
was not possible to demonstrate saturable FITC-glu-plasminogen binding on these

viable cells. The reason for this apparent toxic effect is unclear, but it may be due t
loss of membrane integrity resulting from plasmin proteolysis even though the
binding experiments were performed on ice.
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Figure 5.6: Viability status of the MDA-MB-231 cells as the concentration of FITC-gluplasminogen.
Cells were incubated with various concentrations of FITC-glu-plasminogen for 1 hour on ice, washed,
resuspended in buffer containing PI and analysed by dual-colour flow cytometry. The percentage of viable
(PI negative) cells were determined and plotted against the concentration of FTTC-glu-plasminogen.

Despite the viability limitation, the dose-dependent binding of FITC-glu-

plasminogen was determined using fluorimetic analysis in an attempt to determine
Kd of this interaction (figure 5.7). This technique is similar in principle to a
radiolabelled glu-plasminogen binding assay and allows the determination of

parameters by Scatchard analysis. However, as with all these techniques the viabi
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Figure 5.7: Concentration curves and Scatchard analysis of glu-plasminogen binding to M D A MB-231 cells.

(A) MDA-MB-231 cells were incubated with increasing concentrations of FITC-glu-plasminogen up to
2 uM in the absence (x) or presence of 1 mM tranexamic acid (+) and analysed by dual-colour flow
cytometry. The lysine-dependent plasminogen binding of viable cells (A) was calculated as described
in the legend to figure 5.5. The values shown are means + SD (n = 3) from a representative experime
(B) Representative Scatchard plot of lysine-dependent FITC-glu-plasminogen binding. This plot was
derived from binding data generated by fluorimetry measurements and includes binding due to both
viable and non-viable cells.

status of the cells cannot be discriminated. Thus, glu-plasminogen binding to nonviable cells may result in an over-estimation of the magnitude of these binding
parameters since a small percentage of non-viable cells were invariably present in
most cell preparations, regardless of the care taken to prevent cell damage (figure
5.5). Nevertheless, when lysine-dependent FITC-glu-plasminogen binding curves

were transformed into Scatchard plots the best fit for the data was curvilinear (figure.
5.7B) indicating two classes of binding sites. The apparent equilibrium dissociation
-6

constants for glu-plasminogen binding to M D A - M B - 2 3 1 cells were 1.8 ± 0.6 x 10

M

for the higher affinity site and 2.0 + 0.9 x 10 M for the lower affinity site. The
number of binding sites per cell were 5.0 ± 1.6 x 10 and 3.9 + 1.8 x 10 for the higher
and lower affinity sites, respectively. This difference in number of binding sites/cell
(two orders of magnitude) is comparable to the difference in capacity seen on viable
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and non-viable cells by flow cytometry (figure 5.5B) and suggests that the lower
affinity sites are attributable to non-viable cells binding FITC-glu-plasminogen.
5.3.2.2 Ligand histochemistry studies
Ligand histochemistry allowed visualisation of the glu-plasminogen binding
capacity on viable cells that were attached and spread onto a substrata (figure 5.8 and
5.9). The differences seen by flow cytometry between the cell lines (figures 5.5, 5.7)
were reproduced by glu-plasminogen ligand histochemistry with non-permeabilised
cells (figure 5.8). The highest amount of positive brown staining was seen in the
M D A - M B - 2 3 1 cell line (figure 5.8A) compared to the M C F - 7 (figure 5.8D) or T-47D
(figure 5.8G) cell lines. In the presence of 5 m M T A glu-plasminogen binding was
greatly reduced in all three cell lines (figures 5.8B, 5.8E, 5.8H), confirming that the
cell lines bound glu-plasminogen in a lysine-dependent manner. The ligand
histochemistry technique also showed that staining was diffuse over the cell surfaces
(figure 5.8).
Deliberate permeabilisation of the cells with detergent resulted in an
enhancement of the amount of glu-plasminogen binding which could be substantially
reduced in the presence of 5 m M T A in all three breast cancer cell lines (figure 5.9).
The distribution of staining in these cells appeared to be diffuse in the cytoplasm and
on the cell surface, but was not associated with the nucleus. The results in figure 5.9
suggest that permeabilisation allows glu-plasminogen to bind to intracellular moieties
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Figure 5.8: Glu-plasminogen ligand histochemistry of non-permeabilised breast cancer cells.
Fixed and non-permeabilised M D A - M B - 2 3 1 (A-C), M C F - 7 0 > F ) , and T-47D (G-I) cells were incubated
with biotinylated glu-plasminogen (0.2 u M ) in the absence (A, D, G ) or presence (B, E, H ) of 5 m M
tranexamic acid, followed by incubation with streptavidin-HRP. Lower panels (C, F, I) show a lack of
streptavidin-HRP interaction and subsequent colour reaction with cells that had been incubated with
biotinylated B S A (0.2 u M ) . The arrow in panel (D) points to cellular debris.
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Figure 5.9: Glu-plasminogen ligand histochemistry of permeabilised breast cancer cells.
Same as for legend to figure 5.7 except that after fixation cells were permeabilised with Triton X-100 as
described in Materials and Methods (section 5.2.9).

Chapter 5.-Plasminogen binding and activation on human breast cancer cells

152

not otherwise available at the cell surface and that there are many more intracellular
glu-plasminogen binding moieties than cell surface ones in all these cell lines. This
was especially apparent in the MCF-7 and T-47D cell lines where some cells 5.8 D
and G). These ligand histochemistry data correlated well with the flow cytometry in
which glu-plasminogen binding was substantially greater in non-viable cells
compared to viable cells (refer to figure 5.5B). While the permeabilised MDA-MB231 cells (figure 5.9A) still appeared to bind more glu-plasminogen than the
permeabilised MCF-7 (figure 5.9D) and T-47D (figure 5.9F) cell lines, this difference
between the three cell lines was not as apparent as in the non-permeabilised cells
(figure 5.8). This may be due to the magnitude of glu-plasminogen binding in
permeabilised cells which has the effect of diminishing the differences in gluplasminogen binding capacity between the cell lines.
5.3.3 Total cellular and membrane-associated plasminogen binding proteins in the
three breast cancer cells.
Several bands were detected in ligand blots of whole cell lysates from the
breast cancer cell lines (figure 5.10). Of these, two were major glu-plasminogen
binding bands (apparent molecular masses 50 kDa and 30 kDa) and were present at

similar levels in all three cell lines (figure 5.10B). These bands corresponded to glu
plasminogen binding proteins because the lysine analogue, e-ACA, completely
abolished the binding of glu-plasminogen to these proteins (figure 5. IOC).
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Figure 5.10: Glu-plasminogen ligand blotting of breast cancer cell whole cell lysates.
Whole cell lysates (15 ug/lane) and human recombinant a-enolase (r-a-enolase, 5 ug/lane) were
separated by 1 2 % S D S - P A G E under reducing conditions and either stained with Coomassie Blue (A),
or transferred and subjected to ligand blotting using 5 n M glu-plasminogen in the absence (B) or
presence of 100 m M e - A C A (C). Blots (B) and (C) were derived from gels run, transferred and probed
in parallel and were exposed onto the same piece of autoradiograph film so that a direct comparison
could be made between them. Glu-plasminogen binding proteins were detected using an antiplasminogen polyclonal antibody. The arrows point to bands with apparent molecular masses of 50
kDa and 30 kDa.

Ligand blots of plasma membrane proteins indicated a distinct glu-

plasminogen binding protein profile on each of the three cell lines (figure 5.11).
MCF-7 plasma membranes contained three major bands with apparent molecular
masses of 57 kDa, 47 kDa, and 33 kDa, as well as two minor bands of 40 kDa and 36
kDa (figure 5.1 IB). The 47 kDa and the 33 kDa bands in the MCF-7 plasma
membranes (figure 5.1 IB) corresponded to the 50 kDa and 30 kDa bands
respectively, in the MCF-7 whole cell lysate (figure 5.10). While the MDA-MB-231

and T-47D plasma membranes did not contain detectable amounts of the 57 kDa or 47
- 50 kDa bands seen in the MCF-7 plasma membranes, the 30 - 33 kDa band was
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Figure 5.11: Glu-plasminogen ligand blotting of breast cancer cell plasma membranes.
Same as for legend to figure 5.9 except that plasma membrane fractions (15 ug/lane) were used instead
of whole cell lysates.

present in all plasma membranes as a major band (figure 5.1 IB). The MDA-MB-231
plasma membranes contained two other major bands with apparent molecular masses
of 36 kDa and 26 kDa (figure 5.10B). The T-47D plasma membranes also contained
the 36 kDa band but at a lower concentration than in the MDA-MB-231 plasma
membranes (figure 5.1 IB). In all ligand blots the glu-plasminogen binding protein ra-enolase (chapter 2) was used as a positive control. In each case the presence of eACA inhibited glu-plasminogen binding to this protein (figures 5. IOC and 5.11C).
5.3.4 Expression of identified plasminogen receptor candidates at the cell surface.
Commercially available antibodies against proteins identified as plasminogen
receptor molecules (table 1.4) were used in combination with immunohistochemistry
to determine if these proteins were present on the surfaces of selected breast cancer
cells lines. If present, the proteins may be responsible for localising glu-plasminogen
to these cells. Non-permeabilised MDA-MB-231 cells were positive for both annexin
II and actin expression but were negative for cytokeratin 8 and tetranectin expression
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(figure 5.12). Similarly, a proportion of non-permeabilised MCF-7 cells were positive
for annexin II, actin and cytokeratin 8 however, the M C F - 7 cells were negative for
tetranectin (figure 5.13). These data suggest that some of the proteins responsible for
binding glu-plasminogen on the surfaces of the M D A - M B - 2 3 1 cells were members of
the group 2 or latent plasminogen receptor candidates.
5.3.5 Plasminogen receptor purification.
Attempts were m a d e to purify the proteins responsible for localising gluplasminogen to the surface of the M D A - M B - 2 3 1 cell line using glu-plasminogen
affinity chromatography. Plasma membrane preparations, that contained plasminogen
binding activity (figure 5.14A), were solubilised in R I P A buffer and applied to the
glu-plasminogen affinity column. T w o major glu-plasminogen binding proteins were
eluted from the column with apparent molecular weights of 40 and 33 k D a (figure
5.14 C). The molecular weights of these bands are similar to the molecular weights of
the proteins that were detected by the glu-plasminogen ligand blot of the M D A - M B 231 plasma membrane preparation (figure 5.11). Furthermore, numerous less
abundant proteins were also eluted from the glu-plasminogen affinity column (figure
5.14C). The amount of protein isolated was not sufficient for N-terminal sequencing,
thus these plasminogen binding proteins remained unidentified.
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Figure 5.12: Non-permeabilised M D A - M B - 2 3 1 cell plasminogen receptor immunohistochemistry
Fixed and non-permeabilised M D A - M B - 2 3 1 cells were incubated with either control antibody preparations
(A, normal goat serum; D, mouse anti-DNP antibody; F, rabbit anti-DNP antibody) or antigen-specific
polyclonal antibodies (B, goat anti-actin; C, goat anti-annexin; E, mouse anti-cytokeratin 8; G rabbit antitetranectin).

B
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Figure 5.13: Non-permeabilised M C F - 7 cell plasminogen receptor immunohistochemistry.
Same as for legend tofigure5.9 except that M C F - 7 cells were used instead of M D A - M B - 2 3 1 cells.
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Figure 5.14: Plasminogen receptor purification from MDA-MB-231 cell line.

Plasma membranes of MDA-MB-231 cells were prepared using the two-phase polymer system
membranes were solubilised and the plasminogen binding proteins isolated using plasmi
chromatography. (A) Dot blot showing the plasminogen binding activity of the sample d
steps of the isolation process (B) Elution profile of the plasminogen affinity chroma
(C) Silver stained, non-reducing 12% SDS-PAGE of the flow through and elution fractio
plasminogen affinity column.
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5.3.6 Plasmin generation is associated with high glu-plasminogen binding capacity.
The ability to generate plasma membrane-associated plasmin activity was
compared between the three breast cancer cell lines. The M D A - M B - 2 3 1 cells, which
have the highest glu-plasminogen binding capacity (figure 5.6) and endogenous u P A
activity, were highly efficient at generating plasmin (figure 5.15A). This activity was
dependent on the presence of glu-plasminogen and was completely inhibited by
preincubation with the high affinity plasmin inhibitor aprotinin. At a glu-plasminogen
concentration of 0.5 (iM, there was no detectable plasmin specific activity in either
the M C F - 7 or T-47D plasma membranes compared with 110 pmol/min/mg in the
M D A - M B - 2 3 1 plasma membranes.
In order to demonstrate that plasmin was generated on the surfaces of viable
M D A - M B - 2 3 1 cells, dual-colour flow cytometry was used in conjunction with FITC
conjugated aprotinin (FITC-aprotinin) as the ligand. The ability of FITC-aprotinin to
inhibit plasmin-meditated proteolysis was compared to the plasmin inhibitory
capacity of unlabelled aprotinin. Figure 5.15B demonstrates that both FITC-aprotinin
and unlabelled aprotinin significantly reduced the plasmin-mediated degradation of
fibrinogen compared to the control (fibrinogen plus plasmin). Thus, FITC-aprotinin
was used as a specific detector of plasmin activity has been previously described
(Ellis et. al, 1987). The inset to figure 5.15A shows that FITC-aprotinin bound to
viable cells but only w h e n preincubated with glu-plasminogen, suggesting that M D A M B - 2 3 1 cells were capable of activating receptor-bound glu-plasminogen on the cell
surface.
M D A - M B - 2 3 1 cells, grown on coverslips, were preincubated with 0.5 u M
glu-plasminogen for 30 min at room temperature followed by incubation on ice for 1
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Figure 5.15: Plasmin formation by breast cancer cells.
(A) Breast cancer cell plasma membrane preparations (2 ug) were preincubated with 0.5 u M gluplasminogen for 30 min at room temperature, followed by a 5 min incubation in the absence (•) or presence
(D) of 1 m M aprotinin. Plasmin activity was then measured at 37°C over 20 min using the Spectrozyme P L
substrate (0.25 m M final concentration). Plasmin activity in the absence of glu-plasminogen and aprotinin
was also measured (H). The inset shows specific FITC-aprotinin binding to viable MDA-MB-231 cells as
assessed by dual-colour flow cytometry (refer to figure 5.5B). The specific binding was calculated by
subtracting binding in the presence of a 50-fold excess of unlabelled aprotinin from the total binding. The
values shown are means + S D (n = 3) from representative experiments. (B) A 1 2 % non-reducing SDSP A G E of the reaction of 1 mg/ml offibrinogenwith 25 ug/ml plasmin in the absence or presence of either
50 ug/ml aprotinin or 50 ug/ml FITC-aprotinin for 30 min at 37°C. (C) Fluorescence microscopy of 1 u M
FITC-aprotinin binding after the M D A - M B - 2 3 1 cells were incubated with 0.5 u M glu-plasminogen for 30
min at room temperature.
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h with 1 |xM FITC-aprotinin (green) and examined using fluorescence microscopy.
As illustrated by figure 5.15C, FITC-aprotinin was localised to the surface of these
cells, thereby confirming that glu-plasminogen was activated to plasmin at the
surfaces of the M D A - M B - 2 3 1 cells. It is also noteworthy that the majority of these
cells had a rounded morphology compared to the fixed and attached M D A - M B - 2 3 1
cells in figures 5.4, 5.8, 5.9 and 5.12. This suggests the presence of plasmin
proteolytic activity at the cell surface m a y be responsible for the change in
morphology of the M D A - M B - 2 3 1 cells by inducing the detachment of the cells from
the substrata..

5.4 Discussion
This chapter demonstrates that the spindle-shaped, EGER(+)/neu(+),

ER(-),

and metastatic M D A - M B - 2 3 1 cells were not only associated with high u P A antigen
and activity levels as well as u P A R overexpression but that they also had an increased
capacity to bind and activate cell-surface glu-plasminogen compared to the more
differentiated, non-metastatic cell lines, M C F - 7 and T-47D. These results suggest that
expression of cell surface plasminogen receptors play a part in regulating the
plasminogen activation cascade, and m a y contribute to the metastatic phenotype of
the M D A - M B - 2 3 1 cell line.
Dual-colour flow cytometry was initially used as a means to identify cellsurface specific glu-plasminogen binding. However, this technique also revealed that
both viable and non-viable cells could bind FITC-glu-plasminogen in a lysinedependent manner. Moreover, non-viable cells bound two orders of magnitude more
glu-plasminogen than viable cells. This was confirmed by ligand histochemistry
which showed that biotinylated glu-plasminogen binding capacity was substantially
increased in all cell lines after detergent permeabilisation. This is an important finding
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since it is very difficult to harvest adherent cells and maintain them throughout
experimental procedures at 100% viability (it was consistently found that between
10% and 30%, of the cells were non-viable as assessed by PI uptake by the time cells
were analysed by flow cytometry) and suggests that even a small proportion of nonviable cells could affect evaluation of authentic cell surface glu-plasminogen binding
capacity if viability status is not considered.
Scatchard plots of glu-plasminogen binding data to MDA-MB-231 cells using
a single-colour fluorescence technique resulted in curvilinear plots which are
suggestive of two classes of binding sites. Curvilinear Scatchard plots of gluplasminogen binding have been previously reported for endothelial cells using a
radiolabelled glu-plasminogen binding technique (Ganz et. al, 1991). The higher
affinity binding site in the MDA-MB-231 cells had an average K of 1.8 uM and
5.0xl0? binding sites per cell while the lower affinity one had an average K of 200
uM and 3.9xl09 binding sites per cell. The affinity and capacity of the higher affinity
site are similar to that reported for many cell types determined by radiolabelled gluplasminogen techniques (Plow and Miles, 1990; Hembrough et. al, 1995) and are
within physiological limits since glu-plasminogen is found in the circulation at
approximately 2 |iM. The capacity of the lower affinity site is two orders of
magnitude higher than the higher affinity site - exactly the difference seen in binding
capacity magnitude between viable and non-viable cells by dual-colour flow
cytometry. Since non-viable cells were present in all fluorimetry experiments, it is
likely that the lower affinity, very high capacity binding sites are due to non-viable
cells. The affinity and capacity of these non-viable cells implies that it would be hard
to saturate binding. Nevertheless, while binding to non-viable cells may not be
physiologically relevant, taken together, these results suggest that glu-plasminogen
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binding to non-viable cells is so large that subtle or even significant differences in
cell-surface specific glu-plasminogen binding capacity between cells can be
overestimated when measured by techniques that cannot distinguish between viable
and non-viable populations of cells.
The results also suggest that the abundance of intracellular glu-plasminogen
binding moieties is greater than the cell surface glu-plasminogen binding moieties
regardless of the cell-surface binding capacity. The 50 kDa plasminogen binding
protein present in the whole cell lysates of MDA-MB-231, MCF-7 and T-47D cells
may account for at least some of the increase in glu-plasminogen binding capacity of
both the MDA-MB-231 and T-47D cell lines upon permeabilisation. While all of the
cell lines expressed plasma-membrane associated glu-plasminogen binding proteins,
the glu-plasminogen ligand blots gave no information about the orientation of the
plasminogen binding proteins within the plasma membranes of intact cells. Therefore,
the presence of these proteins in the plasma membrane fraction does not necessarily
mean that they would be oriented on the cell surface in such a way that they could
bind pericellular glu-plasminogen. Since viable or non-permeabilised MCF-7 and T47D cells had minimal cell-surface glu-plasminogen binding capacity compared to
viable or non-permeabilised MDA-MB-231 cells, one possible explanation is that
only a small proportion of the MCF-7 and T-47D plasma-membrane associated
proteins are physiologically available to bind extracellular glu-plasminogen. Upon
permeabilisation a greater proportion of these proteins may also become available for
glu-plasminogen binding in the MCF-7 and T-47D cells. It is also possible that nonproteinaceous binding moieties such as gangliosides (Miles et. al, 1989) may account
for a significant proportion of the differences in cell-surface glu-plasminogen binding
between the cell lines.
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Nevertheless, the ligand blot data indicate that more than one protein moiety

contributes to total cellular glu-plasminogen binding capacity in these cell lines. T
intermediate filament protein cytokeratin 8 and the glycolytic enzyme a-enolase are

two potentially important receptors, which have a C-terminal lysine residue, and have
been isolated from the plasma membranes of rat hepatocytes (Hembrough et. al,
1995), the lymphoid monocytic cell line U-937 (Miles et. al, 1991) and embryonic rat
neurons (Nakajima et. al, 1994). Cytokeratin 8 has been localised to the cell surface
of human breast cancer cells (Hembrough et. al, 1995, 1996), and an a-enolase-like

protein with glu-plasminogen binding ability was isolated from the whole cell lysates
of two human breast cancer cell lines (Lopez-Alemany et. al, 1994). The glycolytic
enzyme, a-enolase (encoded by ENOl), is an authentic plasminogen binding protein
(Chapter 2) and it is expressed as a 47 kDa protein in whole cell lysates of these
human cancer cell lines (figure 4.8). Furthermore a-enolase antigen was detected
when the cells were permeabilised by TX-100 (figure 4.9).
Using a '* I-plasminogen overlay assay, Hembrough et. al, (1996) showed the
presence of several plasminogen binding proteins in the cytoplasm and plasma
membrane fractions of various breast cancer cells. Moreover, they showed the
presence of a major 55 kDa plasma membrane-associated glu-plasminogen binding
protein in MCF-7 cells which they identified as cytokeratin 8. In this study
cytokeratin 8 antigen was not detected on the surfaces of non-permeabilised MDAMB-231 cells by immunohistochemistry, however a small proportion of nonpermeabilised MCF-7 cells were positive for cytokeratin 8. Thus, it is possible that
the 57 kDa plasminogen binding proteins detected by the glu-plasminogen ligand blot
may be cytokeratin 8, which may contribute to the low levels of glu-plasminogen
binding observed on the MCF-7 cells. Neither a-enolase nor cytokeratin 8 antigen
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were not present on the surfaces MDA-MB-231 cells, suggesting that these group 1
plasminogen binding proteins do not contribute to the high glu-plasminogen binding
capacity of the MDA-MB-231 cells.
In contrast to cytokeratin 8 and a-enolase expression, the latent or group 2
plasminogen binding proteins actin and annexin II were expressed at the cell surface
of both the MDA-MB-231 and MCF-7 cell lines and thus may contribute the gluplasminogen binding capacity of these cells. However, if the presence of a C-terminal
lysine residue is important for plasminogen binding, then plasmin proteolysis of these
latent receptors might be critical for the glu-plasminogen binding capacity of these
cells. The MCF-7 cells only express low levels of uPA at their cell surface, whilst
MDA-MB-231 cells express relatively high levels of cell surface uPA. Thus, the high
plasminogen binding capacity of the MDA-MB-231 cell line may be due to creation
new cell surface C-terminal lysine residues via the activation glu-plasminogen which

is bound to the latent plasminogen receptors. In contrast, cells that express low levels
of uPA (e.g. MCF-7 cells) would need to express group 1 plasminogen receptors such
as cytokeratin 8 to bind glu-plasminogen.
It is clear from both the literature and this study that a number of
proteinaceous and possibly non-proteinaceous moieties are likely to contribute to cellsurface glu-plasminogen binding. It is therefore difficult to design specific
experiments aimed at establishing a direct relationship between glu-plasminogen
binding capacity and metastatic potential without identifying all of the gluplasminogen binding moieties on the breast cancer cell lines. However, Stonelake et.
al, (1997) recently demonstrated that in the presence of glu-plasminogen, MDA-MB-

231 and other metastatic breast cancer cell lines, unlike non-metastatic cell lines such
as MCF-7 and T-47D, had the ability to degrade human endothelial basement
membrane and that this activity was significantly inhibited by specific uPA or
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plasmin inhibitors. These authors also demonstrated a similar inhibitory effect by

lysine analogues and attributed this result to an inhibition of glu-plasminogen binding.
These studies strongly corroborate the data presented which indicates that the gluplasminogen binding capacity of breast cancer cells modulates plasmin activity in the
presence of uPA, and taken together, establishes a relationship between the gluplasminogen binding capacity of breast cancer cells and their migration and metastatic
potential in vitro and in vivo.
Another explanation for the apparent differences in cell-surface gluplasminogen binding capacity of the metastatic MDA-MB-231 cells versus the nonmetastatic MCF-7 and T-47D cells is possibly related to the ability of cells to target
some or all of their plasminogen binding proteins to the cell surface. One possible
mechanism may be linked to the difference in uPA/uPAR status between the cell
lines. Incubation of the WISH epithelial cell line, which expresses high levels of
uPAR but undetectable levels of uPA, with inactive uPA resulted in the
phosphorylation and redistribution of the cytoskeletal components cytokeratin 8 and
18 (Busso et. al, 1994). From this it was suggested that signal transduction pathways
via the uPAR GPI anchor are involved in cell migration (Busso et. al, 1994). Since
cytokeratin 8 has been shown to be a plasminogen receptor associated with the
external surfaces of human breast cancer cells (Hembrough et. al, 1995, 1996), signal
transduction events associated with uPAR expression may be one mechanism that
leads to an increased capacity of breast cancer cells, such as the MDA-MB-231 cells,
to bind cell-surface glu-plasminogen.
It is conceivable that variations in the activity of intracellular signaling
proteins due to EGFR and erbB-llneu expression may initiate events that lead to the
translocation of proteins within the cell (Milligan et. al, 1995), and may in some way

affect the localisation of proteins that can act as plasminogen receptors if placed in t
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correct orientation at the cell surface. Amino- or carboxy-terminal lysines appear to
be the only feature common and necessary to all candidate plasminogen binding
proteins. Any intracellular protein with an amino- or carboxy-terminal lysine that is
also subject to the above modifications could be translocated to the outer surface of
the plasma membrane and act as a plasminogen receptor.
Other markers whose cellular expression correlates with metastatic potential
have been identified in human breast cancer cell lines. These include matrix
metalloproteinase-2 (Azzam et. al, 1993), vimentin (Thompson et. al, 1992), and
surface glycoproteins such as CD44 (Culty et. al, 1994). However, a review of the
literature indicates that overexpression of components of the plasminogen activation
cascade play an important role in breast cancer invasion and metastasis (section 1.3).
While stromal cells adjacent to cancer cells in breast cancer tissue may contribute to
invasion, by expressing uPA and/or uPAR for example (Christensen et. al, 1996;
Costantini et. al, 1996; Nielsen et. al, 1996), data presented here and that of others
(Holst-Hansen et. al, 1996; Stonelake et. al, 1997), clearly shows that breast
epithelial cells with a metastatic phenotype have the capacity to efficiently convert
glu-plasminogen to plasmin. A combination of studies suggest that the concentration
and spatial distribution of the combination of uPA, uPAR, PAI-1, and PAI-2
expression in human breast carcinomas allows a better indication of degree of
malignancy (Foekens et. al, 1995; Christensen et. al, 1996; Costantini et. al, 1996).
The results presented in this chapter strongly suggest that another component of the
plasminogen activation cascade, the plasminogen receptors, are also important.
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Chapter 6

General discussion, summary and future directions.
The roles of most of the plasminogen activation cascade components in breast
cancer metastasis have been well documented (Foekens et. al, 1995; Christensen et.
al, 1996; Costantini et. al, 1996). Overexpression of many components of this
cascade have been associated with aggressive breast cancer and probably play an
important role in metastasis (Duffy, 1993). Glu-plasminogen has been demonstrated
on the cell-surface of human m a m m a r y carcinoma tissue (Burtin et. al, 1993).
However, data regarding the class of proteins that are responsible for localising gluplasminogen to the cell-surface and the mechanism of binding remains rudimentary.
The objective of this dissertation was to develop a physiologically relevant model for
the interaction of glu-plasminogen with the surface of metastatic human breast cancer
cells. Hence, an in vitro glu-plasminogen binding model was developed which m a y be
used to predict the mechanism of glu-plasminogen binding to the surfaces of cells
such as highly metastatic breast cancer cells which have a high glu-plasminogen
binding capacity.

6.1 a-Enolase as a plasminogen receptor molecule
A plasminogen receptor molecule has been isolated from the surface of U-937
monocytoid cells and identified by N-terminal amino acid sequencing as a human aenolase related molecule ( E R M ; Miles et. al, 1989). The apparent mass of E R M was
54 kDa, whereas cytoplasmic a-enolase has a molecular mass of 46 kDa. The
difference in mass between ERM and a-enolase suggested that these two proteins
may not be identical. The increased mass of ERM is not due to the differential
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splicing of the ENOl gene (Redlitz et. al, 1995). However, if ERM and a-enolase
are the same molecule then the apparent mass discrepancy may be due to a posttranslational modification of cytoplasmic a-enolase necessary for its translocation to
the cell surface. R-a-enolase, expressed in E.coli, had glu-plasminogen binding
activity that was homologous to the ERM (table 2.1; Redlitz et. al, 1995). This
suggested that the human ENOl gene product did encode an authentic gluplasminogen binding protein and that post-translational modification of a-enolase
was not necessary for its glu-plasminogen binding activity. Furthermore, differential
gene splicing of a-enolase was not necessary for the glu-plasminogen binding activity
of the protein, since the gene product of ENOl possesses a C-terminal lysine residue.
These data suggest that the amino acid sequence of a-enolase is sufficient for gluplasminogen binding in vitro.

6.2 A model describing the interaction of glu-plasminogen with cell
surface receptors.
A s reviewed in section 1.1.1.2, glu-plasminogen exists in a closed, lysinedependent, right-handed, spiral structure with an apparent maximum intramolecular
distance of 9.1 nm. Multiple LBS motifs of glu-plasminogen may be responsible for
interacting with internal lysine residues of the zymogen forming an intramolecular
lysine binding network which maintains the closed conformation of glu-plasminogen.
Using small lysine analogues it is well established that glu-plasminogen can undergo
a lysine-dependent conformational change to a more activation-susceptible
conformation (see section 1.1.1.5). Thus, the conformation of glu-plasminogen does
not remain constant during a lysine-dependent interaction.
Receptors usually display high affinity for their specific ligands, with the
notable exceptions of the integrin family of receptors and the cellular plasminogen
receptor family. Glu-plasminogen binds to a-enolase in a lysine-dependent manner
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with an apparent low affinity. Nevertheless, significant amounts of glu-plasminogen
bind in a lysine-dependent manner to the cell surface plasminogen receptors since the
apparent Kd for the interaction is similar to the concentration of glu-plasminogen in
the blood (Chapter 2; Chapter 5; Miles et. al, 1988). Thus, the low affinity binding of
glu-plasminogen to these cellular receptors is physiologically relevant. This low
affinity interaction dictates that glu-plasminogen would rapidly dissociate from its
receptor. However, this may not be the case, since the exogenous lysine-mediated
interactions of glu-plasminogen result in a conformational change, a slow on rate may
not equate to a rapid off rate. If this is correct then glu-plasminogen should remain
bound to the cell surface receptors for a significant period of time.
Kinetically, the binding of glu-plasminogen to a-enolase is explained using a
two-step competitive interaction model (Chapter 3). The initial phase involves a
competition reaction between an internal lysine residue of glu-plasminogen and an
exogenous lysine residue from a-enolase. This induces a conformational change in
glu-plasminogen. However once dissociated, the internal lysine residue of gluplasminogen may competitively dissociate the bound exogenous lysine residue of the
receptor from the kringle LBS unless a second interaction occurs. A second lysinedependent binding event between another kringle domain LBS of glu-plasminogen
and a second exogenous lysine residue from a-enolase stabilises the interaction such
that glu-plasminogen cannot dissociate directly from a-enolase without undergoing a
lysine-dependent conformational change that induces a more closed conformation.
Of the known plasminogen receptors only a-enolase and cytokeratin 8 possess
a C-terminal lysine residue (table 1.4), which has been identified as an epitope
involved in the plasminogen binding activity of a-enolase. The latent plasminogen
receptors (class 2 receptors; table 1.4), which do not posses a C-terminal lysine
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residue, may be modified at the cell surface by plasmin thereby creating a new Cterminal lysine residue on these receptors (see section 1.2.5). Since, a-enolase has a
C-terminal lysine residue, the glu-plasminogen kinetic binding data can be used as a
model for both group 1 and plasmin modified group 2 plasminogen receptors.
C-terminal lysine residues from class 1 plasminogen receptors or plasminmodified class 2 receptors may act to stabilise both the binding and conformation of
glu-plasminogen. The kringle domain LBS motifs of glu-plasminogen have different
affinities for the different classes of lysine residues with the internal lysine analogue
displaying the lowest affinity for all of the plasminogen LBS (table 1.1). Since the
closed conformation of glu-plasminogen is maintained by the low affinity interactions
of internal lysine residues with the LBS motifs of glu-plasminogen, the presence of a
C-terminal lysine residue would efficiently bind to the LBS thereby stabilising both
the binding and activation-susceptible conformation of receptor bound gluplasminogen.
However, the interaction of glu-plasminogen with the cell surface may not be
as simple as this two-step binding model suggests, since the majority of cell surface
plasminogen receptor candidates are group 2 receptors (e.g. actin and annexin II) and
require plasmin proteolysis for the acquisition of a C-terminal lysine residue. Indeed
the known class 1 plasminogen receptors (e.g. a-enolase) were not present on the
metastatic breast cancer cell surfaces. However, other unidentified class 1
plasminogen receptor molecules may be present at the surfaces of these cells. Since
known class 1 plasminogen receptors were not present on the MDA-MB-231 cell
surface the mechanism of glu-plasminogen binding to the cell surface may be linked
to an activation event. For example, the initial competitive binding of gluplasminogen to a class 2 plasminogen receptor may occur followed by plasminogen
activation. Once formed plasmin may create a new C-terminal lysine residue capable
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of the second lysine-dependent binding event that stabilises the interaction.
Alternatively, glu-plasminogen may cross-link several plasminogen receptors before
resulting in the open activation-susceptible conformation of glu-plasminogen. Despite
this uncertainty, the lysine-dependent binding of glu-plasminogen to the surfaces of
metastatic breast cancer cells involves a competition reaction between the internal

lysine residues of glu-plasminogen and the lysine residues of the receptors that results
in an increase in the activation rate of bound glu-plasminogen.
To understand the precise mechanism of glu-plasminogen binding to the cell

surface or fibrin the spatial relationships of the kringle domains in the closed, partia
open and open conformations of glu-plasminogen must be defined. Similarly, the
conformation(s) of glu-plasminogen at the cell surface as well as the kringles
responsible for localising glu-plasminogen to the cell surface must be defined.
However, experiments designed to answer these questions must not perturb the
intramolecular lysine binding network of glu-plasminogen.
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